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Chapter 1
Introduction
Introduction
Immune reconstitution in recipients of allogeneic stem cell transplants
After stem cell transplantation (SCT) preceded by a myeloablative-conditioning regimen
most haematological lineages regain their normal counts and function rapidly. This is not
the case for B and T cell lineages, resulting in a high incidence of opportunistic infections in
SCT recipients. Especially CD4+ T cell counts remain severely depressed during the first 6
months post-transplant, thereafter numbers gradually rise1.
By 3 months post-transplant, recovery of B cell counts is rapidly established, except for
patients with chronic graft-versus-host disease (GVHD)1-5. The in vitro response of B cells to
T cell independent B cell mitogens such as rabbit anti IgM and Staphylococcus aureus
Cowen strain, is significantly correlated to total B cell counts and normalizes within the
same time period2,3. However, the in vivo antibody response to capsular polysaccharide vac-
cines, which are also T cell independent antigens, is severely impaired in SCT recipients,
even when immunization is delayed until 12 months post-transplant. This decreased anti-
body response to polysaccharide antigens does exist in healthy children of 0-5 years as well6.
Small et al2 showed that immunoglobulin (Ig) M production normalized in conjunction with
the return of circulating B cells. However, IgG production did not occur until the second
year post-transplant, which is a pattern similar to that seen in healthy infants of 0-2 years.
Furthermore, during the first year post-transplant B cells showed a similar phenotype and
function as cord blood B cells and B cells from healthy neonates. These data support the
hypothesis that B cell differentiation post-transplant is recapitulating normal B cell
ontogeny2. In addition to recapitulation of normal B cell ontogeny, the recovery of B cell
function is dependent on T helper cell recovery. 
Reconstitution of T cells may result from two different pathways: 1) a thymus dependent
production of naive T cells and 2) peripheral expansion of mature T cells7,8. Due to thymic
involution in adults, the precise role of thymic dependent production of naive T cells in
immune reconstitution after SCT is still a matter of debate. T cell immune reconstitution,
especially the production of naive T cells, has been studied by different methods. When
CD4+ or CD8+ T cells emigrate the thymus they co-express a specific isotype of the CD45
family (CD45RA+). CD45RA+ CD4+ T cells are considered naive CD4+ T cells, however,
this marker is not reliable to evaluate naive CD8+ T cell production9. After challenge with
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an antigen in the periphery these CD4+ T cells convert to a CD45RA- phenotype and
become memory T cells10,11.
Among recipients of fully T cell depleted (TCD) grafts no CD45RA+ CD4+ T cells were
detected during the first 200 days post-transplant12,13. In these studies, T cell receptor (TCR)
diversity was studied by TCR spectratyping as well14. TCR diversity was only observed when
CD45RA+ CD4+ T cells appeared, which suggests that these cells are thymic emigrants.
Furthermore, reconstitution of the TCR repertoire was due solely to the appearance of donor
T cells with a random TCR diversity12,13. One thymectomized SCT recipient has been studied
and results were compared with those of thymus-bearing allogeneic SCT recipients. The
regeneration of CD4+ CD45RA+ T cells was strongly impaired in the thymectomized
patient compared to the other patients, while CD8+ CD45RA+ T cells regenerated
similarly15.
Whether the abovementioned cell surface marker is an accurate marker for thymic function,
has been debated, since research in nude rats showed that T cells may bi-directionally
switch between the two isotypes (CD45RA+ and CD45RA-)16,17. Furthermore, in HIV-
infected thymectomized patients, CD4+ CD45RA+ T cells rose after initiation of highly
active antiretroviral therapy, indicating that T cells with this phenotype are not exclusively
of recent thymic origin18. Recently, Douek et al19 developed a new method to measure the
production of naive T cells. During thymocyte development rearrangement of the TCR gene
leads to the excision of circular DNA fragments from genomic DNA20. An assay was devel-
oped to measure the number of TCR-rearrangement excision circles (TRECs) in peripheral
blood lymphocytes. These products are stable, unique to T cells and not duplicated during
mitosis19,20. Therefore, their concentration in peripheral blood can be used to estimate
thymic output19. 
TRECs have been measured in recipients of TCD and unmodified grafts and lower levels
were found to be associated with older age, the presence of extensive chronic GVHD and the
occurrence of opportunistic infections21-23. Earlier, also CD45RA+ CD4+ T cell counts were
shown to be related to age in a similar way13.
Apart from patient age and the occurrence of GVHD, other variables are considered adverse
risk factors for T cell recovery post-transplant, such as use of 1) TCD grafts, 2) immunosup-
pressive therapy, especially serotherapy with Antithymocyteglobulin, to prevent graft rejec-
tion or to prevent or treat GVHD, 3) grafts from matched unrelated (MUD) or partially
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matched related donors (PMRD) and 4) bone marrow grafts instead of peripheral blood
stem cell grafts.
Influence of TCD of grafts on immune recovery Only a few studies have com-
pared immune reconstitution in recipients of TCD grafts with immune reconstitution in
recipients of unmanipulated grafts2-4,24-26. These studies were largely performed among
recipients of related donor grafts and varying ex vivo TCD techniques were used. Recovery
of B cell counts and proliferative responses of B cells to B cell mitogens (rabbit anti IgM,
Staphylococcus aureus Cowen strain) were not influenced by TCD of grafts2-4. When T
helper and B cell function was measured in a mitogen-stimulated Ig production assay, Ig
production by B cells from recipients of non-manipulated grafts exceeded that of TCD SCT
recipients in one study3, however, no effect of TCD was found by others2. TCD did not influ-
ence recovery of EBV-specific cytotoxic T cell precursors nor their virus-specific cytotoxic
activity24. Recovery of total T cell and subset counts was not influenced by TCD either3,26,
although in some studies CD4+ and CD45+ CD4+ T cell subsets showed a slower reconsti-
tution in TCD SCT recipients4,25. Furthermore, the proliferative response of T cells to T cell
mitogens (phytohemagglutinin, pokeweed mitogen) was found to be significantly lower dur-
ing the first three months post-transplant in TCD SCT recipients3. Apart from one paper
describing a higher incidence of CMV reactivations after TCD SCT4, there is no increase in
infectious complications or fatal infections after TCD SCT3,25,27. Overall, from these studies it
can be concluded that ex vivo TCD of grafts from related donors does not have a major
impact on immune reconstitution. 
Influence of Antithymocyteglobulin on immune recovery Antithymocyte-
globulin (ATG) is often used before SCT with grafts from MUDs or PMRDs to prevent graft
rejection. Since ATG could be detected in sera at least during 2 months post-transplant with
25% of the initial peak concentration at day 28-48 28,29, it is hypothesized that ATG may
severely impair T cell recovery. Recently it was shown that total lymphocyte, CD3+ and
CD4+ cell reconstitution was significantly lower in transplant recipients of unrelated grafts
treated with high-dose ATG (15 mg/kg) as compared to low-dose ATG (7,5 mg/kg)30.
Furthermore, the rate of viral infectious complications was significantly higher in the high-
dose group. In adult recipients of MRD grafts, the use of ATG post-transplant to prevent
graft failure resulted in an impaired recovery of CD45RA+ CD4+ T cells, a prolonged inver-
sion of the CD4+/CD8+ T cell ratio, a delay in recovery of normal T cell mitogen responses
and an increased incidence of opportunistic infections as compared to patients not treated
4
 
with ATG31. Patients given ATG showed relatively increased numbers of CD8+ CD28-
CD57+ T cells. T cells with this phenotype respond poorly to T cell mitogens and can inhibit
the generation and function of virus-specific cytotoxic lymphocytes31, although this is con-
troversial since others showed these cells to be cytotoxic effector T cells9.
The results of both studies support the hypothesis that ATG interferes with T lymphocyte
recovery30,31, while B lymphocyte counts and immunoglobulin levels were not influenced by
ATG31.
Influence of donor type on immune recovery It is speculated that T and B cell
recovery is related to the degree of HLA matching between host and donor. HLA disparities
may alter the capacity of lymphoid progenitors of donor origin to mature within the host
thymus or bone marrow. On the other hand, HLA disparities stimulate the occurrence of
GVHD. Therefore, patients receiving grafts from unrelated or mismatched related donors
will always be treated with more intensive immunosuppression compared to recipients of
MRD grafts. A well known characteristic of GVHD itself is a defect in the development of
donor derived T cells, which leads to a long lasting T cell deficiency state32,33. Dulude et al33
have demonstrated that GVHD impairs the production of new T cells by the thymus and dis-
turbs the expansion of mature peripheral T cell pools in secondary lymphoid organs. This
defective expansion was due to a restriction in the number of functional T cell niches. It is
hypothesized that during the acute phase of GVHD, the thymus and secondary lymphoid
organs are damaged to such a degree that a prolonged impairment in the development of
donor derived T cells will occur. Furthermore, it has been demonstrated that patients with
acute GVHD show an increase in CD3+ cell apoptosis, which further impairs T cell depend-
ent immune reconstitution34. 
Altogether, this entanglement of factors makes it impossible to solely analyse the impact of
donor type on immune recovery. Despite this, efforts to analyse the influence of donor type
were made in several studies21,23,35-38. A more prolonged and profound CD3+, CD4+ and
CD8+ lymphopenia was seen in MUD recipients compared to MRD recipients. However, the
proliferative T cell response to PHA was comparable between the two groups. Furthermore,
interference of GVHD with the observed impaired T cell subset recovery in MUD recipients
could not be excluded35. Niehues et al38 showed, in the setting of paediatric cord blood
transplantation (CBT), that T cell recovery was favourable affected by use of a related
donor. In the other studies, no effect of donor type was observed21,23,36,37. Recently, immune
recovery in unrelated CBT recipients was analysed and compared to data from recipients of
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MRD grafts. TREC levels were comparable between the two groups, while TCR diversity was
normalized earlier in CBT recipients39. Two other studies described earlier12,13 did study the
patterns of CD4+ and CD4+ CD45RA+ T cell recovery and restoration of TCR diversity in
recipients of TCD grafts from MUDs and MRDs, respectively. The results were highly compa-
rable in these two reports. One might conclude from these results, that HLA disparities not
necessarily result in an altered maturation of lymphoid progenitors of donor origin in the
host thymus.
Influence of stem cell source on immune recovery Allogeneic unselected
peripheral blood stem cell (PBSC) grafts contain about 10 times more CD4+ naive and
memory T cells, CD8+ T cells and B cells40,41. Lymphocyte recovery has been shown faster
in PBSC recipients40-43, the difference being most striking for CD4+ naive and memory T
cells40,41,43. Furthermore, the rate of severe infections after engraftment was significantly
higher in bone marrow recipients43. However, when ex vivo TCD of grafts was performed
with Campath-1 antibodies, the recovery of B and T cells and subsets was comparable
among recipients of PBSC and BM grafts44.
In conclusion, patient age, the occurrence of GVHD and the use of immunosuppressive ther-
apy (especially ATG) are all adverse risk factors for T cell recovery post-transplant.
However, the contribution of ex vivo TCD, the use of unrelated or partially matched related
donors and the use of bone marrow instead of PBSC is less clear.
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The aim of this thesis was:
1 to analyse the impact of high- and low-dose ATG on immune recovery and GVHD
among MUD recipients (chapter 2, 3 and 9)
2 to study aspects of EBV and CMV reactivation/infection in recipients of allogeneic SCT:
a the predictive value of the EBV DNA viral load for the development of EBV-LPD
(chapter 4)
b the origin of the EBV strain giving active EBV infection post-transplant (chapter 5)
c the benefit of additional B cell depletion of T cell depleted grafts from matched unre-
lated donors regarding the incidence of EBV-LPD (chapter 6)
d the role of patient and/or donor CMV-seropositivity as an adverse risk factor for sur-
vival post-transplant (chapter 8 and 9)
3 to review:
a the prevention and treatment of EBV-LPD in recipients of bone marrow and solid
organ transplants (chapter 7)
b the prevention of Cytomegalovirus disease in recipients of allogeneic stem cell trans-
plants (chapter 10)
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Chapter 2
Effect of Antithymocyteglobulin on
quantitative immune recovery and graft-
versus-host disease after partially T cell
depleted bone marrow transplantation: 
a comparison between recipients of
matched related and matched unrelated
donor grafts
Ellen Meijer,
Andries C. Bloem,
Adriaan W. Dekker,
Leo F. Verdonck
Transplantation 2003; 75: 1910-1913
Abstract
The effect of Antithymocyteglobulin (ATG) on quantitative immune recovery and graft-ver-
sus-host-disease (GVHD) after partially T cell depleted (TCD) bone marrow transplantation
(BMT) was analysed in 59 and 32 recipients of grafts from matched related donors (MRD)
and matched unrelated donors (MUD), respectively. The conditioning regimen was similar
in all patients, except for ATG which was given only to MUD recipients. Thirteen MUD
patients were treated with high-dose (20 mg/kg) ATG and 19 with low-dose (8 mg/kg)
ATG. During the post-transplant period both CD3+, CD4+ and CD8+ T cell numbers and
the incidence of acute and chronic GVHD were significantly lower in MUD recipients com-
pared to MRD patients. MUD recipients treated with high-dose ATG showed the worst T cell
and subsets recovery. These data suggest that ATG, often used as part of conditioning regi-
mens in recipients of TCD grafts from MUDs, contributes to the very severe and prolonged T
cell deficiency that is typical of these patients. On the other hand, it effectively reduces inci-
dence and severity of GVHD.
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Introduction
Allogeneic bone marrow transplantation (BMT) is an established treatment modality for
adult patients with haematologic malignancies. However, 70% of patients who might benefit
from allogeneic BMT lack an HLA-identical sibling donor (matched related donor, MRD).
Therefore, there is an increasing use of HLA-matched unrelated donors (MUD).
Unfortunately, transplant-related mortality (TRM) after MUD-BMT is much higher than
after MRD-BMT, which is largely due to an increased incidence of opportunistic infections
and graft-versus-host disease (GVHD)1. The increased incidence of opportunistic infections
suggests that after MUD-BMT immune reconstitution is much more impaired, compared to
BMT from a matched sibling donor. Several factors may account for the impaired immune
reconstitution, such as HLA disparities, the increased incidence of GVHD and the use of
more intensive immunosuppression to prevent or treat GVHD.
Here, we set out to unravel the contribution of some of these immunodeficiency inducing
factors by studying the recovery of T cell subsets, NK cells and B cells after BMT in patients
treated with partially T cell depleted (TCD) grafts from either a MRD or MUD. Both patient
groups received a fixed low number of T cells in the graft and a similar conditioning regimen
except for Antithymocyteglobulin (ATG) that was only given to recipients of MUD trans-
plants.
Methods
Patients Between August 1997 and March 2001 allogeneic bone marrow transplanta-
tion was performed in 104 patients. Thirteen patients could not be analysed; 10 because of
early death (< 2 months post-transplant), 1 received donor lymphocytes < 2 months post-
transplant, 1 repopulated with blasts, 1 had a graft rejection. In total 91 patients, receiving
either bone marrow from a MRD (n=59) or from a MUD (n=32), were studied. Patients
with acute leukaemia in first complete remission, chronic myeloid leukaemia in first chronic
phase, untreated severe aplastic anaemia were considered low-risk. All patients with other
diseases were considered high-risk. The procedures were performed at the Department of
Haematology of the University Medical Centre Utrecht. Patients were treated according to
13
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clinical protocols approved by the local investigation review board after informed consent
was obtained.
Transplantation procedure Transplantation procedure, monitoring and pre-emp-
tive treatment of CMV reactivations, diagnosis and treatment of CMV disease, HLA typing
and partial TCD of grafts were performed as described2. In brief, the conditioning regimen
consisted of cyclophosphamide (60 mg/kg/day for 2 days), followed by total body irradia-
tion (600 cGy/day for 2 days) with partial shielding of the lungs. ATG (Thymoglobulin™,
Sangstat, Amstelveen, the Netherlands) was infused to MUD patients before cyclophos-
phamide was given. Thirteen patients received a dose of 4 mg/kg/day intravenously for 5
days. Due to a change in national treatment protocols ATG dose was lowered to 2
mg/kg/day for 4 days from April 1999. Nineteen patients received ATG low-dose.
Immunophenotyping Three colour FACS analysis (FACScan, Becton Dickinson
Immunocytometry Systems (BDIS), San Jose, CA) was performed on heparin-anticoagulated
venous blood. To 100 µL of undiluted blood a mixture of three antibodies was added con-
sisting of either CD3-Cy5 (Beckman Coulter, Mijdrecht, The Netherlands), CD4-FITC (BDIS)
and CD8-PE (BDIS); CD45-Cy5 (Beckman Coulter), CD3-FITC (BDIS) and CD19-PE (BDIS)
or CD45-Cy5, CD3-FITC and a mixture of CD16-PE and CD56-PE (BDIS). After a 20 minute
incubation at room temperature the erythrocytes were lysed using FACS lysing solution
(BDIS), washed once with wash solution consisting of PBS supplemented with 1% bovine
serum albumin and sodiumazide (0.01%), resuspended in 0.5 ml wash solution and
analysed by flow cytometry. In every sample a minimum number of 15,000 events were
acquired. List mode data were analysed using attractor software (BDIS). Percentages of T
(CD3+) , B (CD19+) and NK cells (CD3-, CD16+ and CD56+) in the CD45+ leukocyte
population were calculated. Based on the CD3/CD4/CD8 staining the distribution of CD4+
and CD8+ cells within the CD3+ T cell compartment was determined. Normal values were
derived from McNerlan et al3.
Statistics Data are expressed as mean ± SEM. Mean differences between patient char-
acteristics were assessed by Students t-test or Chi-square analysis. Mean differences con-
cerning T, B and NK cell recovery were tested using repeated-measures (RM) analysis and
analysis of variance (ANOVA) with group (MRD vs MUD), risk status, CMV serostatus, acute
GVHD (aGVHD) and chronic GVHD (cGVHD) as ‘between-subjects’ or ‘fixed’ factors, respec-
tively, and age as covariate. All cell counts were log-transformed in order to meet the basic
conditions on which the theory of RM-analysis and ANOVA is leaning. ANOVA was used
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next to RM analysis, since RM analysis excluded too many cases (due to missing values).
Both RM analysis and ANOVA gave comparable results. Levene’s test was performed to find
out whether the assumption of equality of variance could be maintained. Residuals were
checked for normality by means of the Kolmogorov-Smirnov (KS) statistic. The KS-statistic
in all cases showed values < 0.2 for the log-transformed cell count residuals. Calculations
were performed using SPSS/PC + 10.0 (SPSS Inc, Chicago Il, USA).
Results
Patient characteristics Patient characteristics are described in Table 1. MRD recipi-
ents were significantly older (42 ± 1.3 vs 32 ± 1.8; p<0.001), received less T cells (1.4 ±
0.1 vs 2.7 ± 0.3 x 105/kg; p<0.001) and suffered more acute (grade II-IV) and chronic
(extensive) GVHD (54% vs 19% and 30% vs 6%; p<0.01) compared to MUD recipients.
Immune recovery Analyses with group (MRD vs MUD), age, risk status, patient CMV
serostatus, aGVHD and cGVHD as factors revealed that only ‘group’ and ‘CMV serostatus’
significantly influenced T cell and subsets recovery during the 6 months post-transplant
period. In the MRD group markedly higher values were measured during this period, which
was significant by repeated-measures analysis (CD3+ and CD4+ T cells: p<0.01; CD8+ T
cells: p<0.05) and by analysis of variance (Figure 1). During the whole 6 months period no
normal values of CD4+ cells were reached in both patient groups and of CD3+ cells in MUD
recipients. Patient CMV serostatus also influenced T cell reconstitution. Patients with a posi-
tive CMV serostatus showed significantly higher T cell and subsets counts post-transplant
compared to CMV-seronegative recipients (p<0.01). No interaction between ‘group’ (MRD
and MUD) and ‘patient CMV serostatus’ was observed. B cell and NK cell recovery was not
influenced by any of the factors tested. The incidence of fatal infectious complications was
19% in MUD recipients compared to 12% in MRD recipients (ns).
A subgroup analysis among MUD recipients revealed that none of the aforementioned fac-
tors significantly influenced immune reconstitution. MUD recipients treated with high-dose
ATG showed a worse CD3+ and CD8+ T cell recovery compared to MUD recipients treated
with low-dose ATG, although not significant (Figure 2).
15
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Table 1 Patient characteristics
MRD MUD P
(n=59) (n=32)
Age, yr (range) 42 (18-56) 32 (18-52) p<0.001
Diagnosis
ALL 3 7
AML 6 7
CML 9 11
SAA 0 4
MM 16 0
NHL 11 1
MDS 0 2
CLL    1 0
CMV serostatus /
+/+ 20 6 ns
+/- 6 6
-/+ 11 4
-/- 22 16
Risk status (%)
Low 29 (49) 16 (50) ns
High 30 (51) 16 (50)
T cell count in graft 
(x 105/kg) 1.4 ± 0.1 2.7 ± 0.3 p<0.001
GVHD (%)
Acute          p=0.001
I/no 27 (46) 26 (81)
II-IV 32 (54) 6 (19)
III-IV 3 (5) 0
Chronic        p=0.008
Lim/no/ne 41 (70) 30 (94)
Ext 18 (30) 2 (6)
SAA = severe aplastic anaemia; MM = multiple myeloma; R/D = recipient/donor; Lim = limited; Ext = extensive; ne =
non evaluable.
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Figure 1
B, T and NK cell numbers during the post-transplant period in recipients of MRD transplants com-
pared to recipients of MUD transplants.
Shaded area represents normal values. 
**=p<0.01
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Figure 2
B, T and NK cell numbers during the post-transplant period in recipients of MUD transplants.
Patients pretreated with low-dose ATG (MUD/LD) compared to patients pretreated with high-
dose ATG (MUD/HD).
Shaded area represents normal values. 
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Discussion
The results of our study showed a markedly impaired quantitative T cell reconstitution dur-
ing the first 6 post-transplant months in the group receiving BMT from a MUD compared to
patients receiving transplants from an HLA-identical sibling. MUD recipients treated with
high-dose ATG had the worst T cell and subsets recovery. These differences between MRD
and MUD recipients might explain the well known increased incidence of infectious compli-
cations in MUD patients1.
Two factors may account for the disturbed immune reconstitution among our MUD recipi-
ents compared to MRD patients: use of ATG and HLA disparities.
Since ATG could be detected in sera at least during 2 months post-transplant with 25% of
the initial peak concentration at day 48 4, it is hypothesized that ATG may severely impair T
cell recovery, which was recently shown to be dose dependent5.
It is also speculated that T and B cell recovery is related to the degree of HLA matching
between host and donor. HLA disparities may alter the capacity of lymphoid progenitors of
donor origin to mature within the host bone marrow or thymus. On the other hand, HLA
disparities stimulate the occurrence of GVHD. Therefore, patients receiving grafts from unre-
lated or mismatched related donors will always be treated with more intensive immunosup-
pression compared to recipients of MRD grafts. A well known characteristic of GVHD itself is
a defect in the development of donor derived T cells, which leads to a long lasting T cell
deficiency state6,7. This entanglement of factors makes it impossible to solely analyse the
impact of donor type on immune recovery. Despite this, efforts to analyse the influence of
donor type were made in several studies8-10. In the first report a more prolonged and
profound CD3+, CD4+ and CD8+ lymphopenia was seen in MUD recipients compared to
MRD recipients. However, the proliferative T cell response to PHA was comparable between
the two groups. Furthermore, interference of GVHD with the observed impaired T cell sub-
set recovery in MUD recipients could not be excluded8. In the other studies, no effect of
donor type was observed9,10. Recently, immune recovery in unrelated cord blood transplant
(CBT) recipients was analysed and compared to data from recipients of MRD grafts. T cell
receptor (TCR)-rearrangement excision circles (TREC) levels were comparable between the
two groups, while TCR diversity was normalized earlier in CBT recipients11. Two other
reports12-13 did study the patterns of CD4+ and CD4+ CD45RA+ T cell recovery and
restoration of TCR diversity in recipients of TCD grafts from MUDs and MRDs, respectively.
The results in both groups were highly comparable in these two reports. One might conclude
from these results, that HLA disparities not necessarily result in an altered maturation of
lymphoid progenitors of donor origin in the host thymus.
Based on these data we consider ATG to be the most important negative factor in the recon-
stitution of T cells and there subsets in our MUD recipients. On the other hand, ATG resulted
in a lower incidence and severity of GVHD.
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depleted grafts from matched unrelated
donors: a dose finding study
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Abstract
In this study, we set out to evaluate the effect of 3 different Antithymocyteglobulin (ATG)
doses on graft failure and incidence of graft-versus-host disease (GVHD) among recipients of
partially T cell depleted (TCD) grafts from matched unrelated donors (MUDs). Data of 74
consecutively treated MUD recipients were analysed. Fifty-two, 13 and 9 MUD patients were
treated with ATG in a total dose of 8 mg/kg, 6 mg/kg and 4 mg/kg (given from days -8 until
-4), respectively. Granulocyte and platelet engraftment was not different between the
groups, while graft failure was observed in two patients only (receiving 8 mg/kg and
4 mg/kg ATG, respectively). The cumulative incidence of severe (grade III-IV) acute GVHD
and extensive chronic GVHD was 4%, 0%, 44% and 11%, 8%, 44% in groups receiving ATG
in a dose of 8 mg/kg, 6 mg/kg and 4 mg/kg, respectively (severe acute GVHD: p<0.001;
extensive chronic GVHD: p=0.05). Based on these findings, we recommend when ATG is
used in the setting of stem cell transplantation with (partially) TCD grafts from MUDs, to
give a total dose of 6-8 mg/kg. A further decrease in dosage resulted in a highly significant
increased incidence of severe acute and extensive chronic GVHD.
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Introduction
Despite improvements in HLA typing, graft-versus-host disease (GVHD) is still a major cause
of morbidity and mortality after stem cell transplantation (SCT) with grafts from matched
unrelated donors (MUDs). T cell depletion (TCD) of grafts is an effective method for preven-
tion of GVHD1-4. However, one of the limitations associated with this method is the occur-
rence of graft failure3,4. A large International Bone Marrow Transplant Registry (IBMTR)
analysis learned that the risk for graft failure was related to the type of TCD, being lowest
when T cell specific techniques were used3. Varying strategies are used to prevent graft fail-
ure, which is considered to be mediated by residual host T cells having survived the condi-
tioning regimen5,6. A method commonly used in the setting of SCT with TCD grafts from
MUDs, is the in vivo pre-transplant depletion of host immune cells using Antithymocyte-
globulin (ATG) or Campath-14. Several studies also showed effectiveness of in vivo TCD,
using ATG or Campath-1, as prophylaxis of GVHD after MUD transplantation7-18. The opti-
mal dose of ATG with respect to prevention of graft failure and severe GVHD is not known.
The immunosuppressive and direct toxic effects of ATG, however, necessitate the use of the
lowest possible dose.
Here, we set out to evaluate the effect of 3 different ATG (Thymoglobulin™, Sangstat) doses
on graft failure and incidence of acute and chronic GVHD among MUD recipients of partially
TCD grafts.
Methods
Patients For this study data of 74 patients receiving stem cells from MUDs were
analysed. Transplantations were performed between January 1999 and May 2002 at the
Department of Haematology of the University Medical Centre Utrecht and at the
Department of Haematology of the Erasmus Medical Centre Rotterdam, the Netherlands.
ATG (Thymoglobulin™, Sangstat, Amstelveen, the Netherlands) was given pre-transplant to
prevent graft failure. Because of the immunosuppressive and direct toxic effects of ATG it
was decided in November 2001 to decrease the total dose of ATG from 8 to 6 mg/kg in the
Utrecht centre and from 8 to 4 mg/kg in the Rotterdam centre. Thirty-three and 19 MUD
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recipients were treated with ATG in a total dose of 8 mg/kg, given in 4 days, and were
defined as MUD group 1 (treated in Utrecht) and 2 (treated in Rotterdam), respectively.
Thirteen and 9 patients received ATG in a total dose of 6 mg/kg and 4 mg/kg (also given in
4 days), respectively, and were defined as MUD group 3 (treated in Utrecht) and 4 (treated
in Rotterdam), respectively. Patients with acute leukaemia in first complete remission,
chronic myeloid leukaemia in first chronic phase and untreated severe aplastic anaemia
were considered low-risk. All patients with other diseases were considered high-risk.
Patients were treated according to clinical protocols approved by the local investigation
review boards after informed consent was obtained.
Transplantation procedure The transplantation procedure in both centres was
identical. The conditioning regimen consisted of cyclophosphamide (60 mg/kg/day for 2
days), followed by total body irradiation (600 cGy/day for 2 days) with partial shielding of
the lungs (total lung dose 850 cGy). The graft was infused after the second TBI fraction (day
0). ATG was given in 4 days, from day -8 until day -4, before cyclophosphamide was
infused. Post-transplant immunosuppression consisted of cyclosporin which was discontin-
ued within 3 months after transplantation, when no active GVHD was present. Infection pre-
vention for all patients consisted of ciprofloxacin, fluconazole and amphotericin B given
orally until granulocyte counts exceeded 500 cells/µl. Cephalothin was given intravenously
for 10 days from day +3. Furthermore co-trimoxazole and (val)acyclovir were given orally
from day +1 until 12 months post-BMT or longer in case of active GVHD, in a dose of 480
mg b.i.d. and 500 mg b.i.d., respectively. GVHD was classified according to the Seattle crite-
ria19 and graft failure according to criteria described by Kernan et al and McGlave et al1,2.
CMV monitoring Until April 2001 CMV monitoring was performed three times a week
using a pp65 assay as described20. Since then monitoring was performed once a week using
a real-time Taqman™ CMV DNA PCR. However, in patients with active GVHD and in
patients with a CMV reactivation, monitoring was performed twice a week. CMV reactiva-
tion was defined as CMV pp65 antigenemia of ≥ 1 positive staining granulocyte/150.000
cells or CMV DNA viral load (VL) of > 1000 copies/ml.
CMV disease Patients with symptoms of pneumonia, gastritis or enteritis underwent
bronchoscopy, gastroscopy or sigmoidoscopy, respectively. CMV pneumonia/gastritis/enteri-
tis was defined histologically by typical cytopathic effects and immunohistochemically by
immunofluorescence with use of monoclonal antibodies to immediate early CMV antigens in
biopsy specimens. When cultures of BAL fluid, saliva, urine and buffy coat were performed
26
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in case of infectious complications, these included always CMV cultures, irrespective of CMV
serostatus.
Ganciclovir therapy CMV-seropositive patients who demonstrated CMV reactivation
or who were treated with high-dose corticosteroids for acute GVHD grade II-IV received pre-
emptive or prophylactic therapy, respectively, with ganciclovir in a dose of 2.5 mg/kg intra-
venously twice a day for 14 days. When patients were symptomatic (unexplained fever or
symptoms compatible with CMV disease), CMV antigenemia/VL was rising or remained pos-
itive after 14 days of treatment, ganciclovir dose was doubled or foscarnet treatment was
started instead of ganciclovir in a dose of 60 mg/kg twice a day for 14 days. CMV disease
was treated with ganciclovir 5 mg/kg twice a day for at least 14 days and continued until
symptoms resolved and antigenemia/VL became negative. In case of disease progression or
rising antigenemia/VL foscarnet treatment was started instead of ganciclovir in a dose of 60
mg/kg twice a day. Furthermore, treatment with CMV specific immunoglobulins was added
to antiviral therapy in patients with CMV pneumonia.
HLA-matching Class I antigens were analysed by serological and low resolution molec-
ular typing with sequence specific primers (SSP). Since July 2000, high resolution molecular
typing (with SSP and/or sequence based typing (SBT)) of HLA-A and B antigens was per-
formed as well. Analyses of class II antigens were performed by high resolution molecular
typing with SSP and/or SBT throughout the whole study period. The aim was to obtain a
fully matched (for HLA-A, B, Cw, DRB1 and DQB1) or, if not available, an one HLA antigen
mismatched unrelated patient/donor pair.
BMT In vitro TCD of bone marrow (BM) was performed using the Sheep Red Blood Cell
technique (Rotterdam) or the immunorosette depletion technique (Utrecht) as described20.
Only 3 patients received a peripheral blood stem cell (PBSC) graft (one from group 1, one
from group 2 and one from group 3). TCD of these G-CSF stimulated PBSC grafts was per-
formed by positive selection of CD34+ cells (CliniMacs™, Miltenyi Biotec, Bergisch
Gladbach, Germany). After these maximal TCD procedures the residual number of T cells
was counted and nonmanipulated T cells (from a small BM/PBSC fraction that was set
apart) were added to obtain the desired fixed low number of T cells (1-2 x 105 T cells/kg
recipient weight).
Statistical analysis Differences between groups were compared using Pearson chi-
square analyses in case of discrete variables. In case of continuous variables univariate
analysis of variance (ANOVA) or Kruskal-Wallis test, whichever was appropriate, was per-
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formed. Overall survival (OS) was estimated by the Kaplan-Meier method. Probabilities of
transplant related mortality (TRM), relapse related mortality (RRM), acute GVHD and
chronic GVHD were calculated by the cumulative incidence procedure; death without TRM,
RRM, acute GVHD and chronic GVHD, respectively, being the competing risk. Univariate
analyses were performed using the log rank test. Calculations were performed using
SPSS/PC+ 10.0 (SPSS Inc, Chicago Il, USA).
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Results
Pre-transplant patient characteristics (Table 1). The percentage of HLA antigen
mismatched grafts and mean T cell and CD34+ cell counts of grafts were higher in recipi-
ents from MUD group 3 (treated with ATG 6 mg/kg) compared with the other groups,
29
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Table 1 Patient characteristics
MUD MUD MUD MUD P
group 1 group 2 group 3 group 4
(n=33) (n=19) (n=13) (n=9)
ATG dose 8 mg/kg 8 mg/kg 6 mg/kg 4 mg/kg
Age, yr 34 34 35 37 ns
(range) (17-55) (18-48) (18-53) (19-51)
Diagnosis, %
AML 18 26 46 13
ALL 30 11 15 13
CML 30 21 23 37
SAA 0 0 0 13
Other 21 42 15 25
CMV serostatus /, % ns
+/+ 24 16 15 0
+/- 15 26 54 38
-/+ 15 11 8 25
-/- 46 47 23 38
R/D sex, % ns
M/F 21 16 8 13
Others 79 84 92 87
Risk status, % ns
Low 18 26 15 0
High 82 74 85 100
Mean CD3+ cells& 2.2 1.6 2.4 1.9 0.008
(range) (2-4) (1-4) (2-5) (1-3)
Mean CD34+ cells&& 1.62 1.50 2.76 1.66 0.052
(range) (0.5-5.9) (0.55-3.24) (0.95-10.4) (0.81-2.96)
Mismatched graft, % 18 11 46 25 ns
/ = recipient/donor; & = in graft, x105/kg; && = in graft, x106/kg.
although this was only significant for mean T and CD34+ cell counts of grafts (p=0.008 and
p=0.052, respectively).
Effect of ATG dose on engraftment and GVHD (Tables 2 and 3, Figure 1).
Granulocyte and platelet engraftment was not different between the four MUD groups
(Table 2). Graft failure was observed in two patients, who were excluded from analyses, one
30
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Table 2 Platelet and granulocyte engraftment
MUD MUD MUD MUD P
group 1 group 2 group 3 group 4
(n=33) (n=19) (n=13) (n=9)
ATG dose 8 mg/kg 8 mg/kg 6 mg/kg 4 mg/kg
Platelets > 50 × 109/L
Recovery, % 94 84 100 78 ns
Median days, 26 32 20 41 ns
(range) (12-208) (15-112) (11-52) (20-158)
Granulocytes > 500 × 106/L
Recovery, % 100 100 100 100 ns
Median days, 19 23 19 20 ns
(range) (12-92) (11-35) (11-32) (14-38)
Table 3 Cumulative incidence of acute and chronic GVHD
MUD MUD MUD MUD P
group 1 group 2 group 3 group 4
(n=33) (n=19) (n=13) (n=9)
ATG dose 8 mg/kg 8 mg/kg 6 mg/kg 4 mg/kg
aGVHD, %
II-IV (SE) 18 (7) 16 (8) 23 (12) 56 (17) 0.057
III-IV (SE) 3 (3) 5 (5) 0 44 (17) <0.001
cGVHD, %
Any (SE) 24 (7) 26 (10) 23 (12) 44 (17) ns
Ext (SE) 12 (6) 10 (7) 8 (7) 44 (17) 0.052
Any = limited and extensive. 
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Figure 1
Cumulative incidence of acute GVHD according to ATG dose.
from MUD group 1 and one from MUD group 4. In recipients of 8 mg/kg ATG, treated in
Utrecht (MUD group 1) and Rotterdam (MUD group 2), the incidence of acute and chronic
GVHD was highly comparable. A further decrease in ATG dose to 6 mg/kg (MUD group 3)
did not significantly increase the rate of acute and chronic GVHD. In the group receiving 4
mg/kg ATG (MUD group 4) 44% of patients developed severe acute GVHD (grade III-IV)
and extensive chronic GVHD.
After univariate analyses, no impact of other known risk factors (older age, high-risk disease
status, CD3+ and CD34+ cell counts in grafts, positive recipient CMV serostatus, male
recipient with female donor, use of an one HLA antigen mismatched graft) on occurrence of
GVHD was found. Therefore, multivariate analyses were not performed. Furthermore, data
were analysed for centre effect, which could be excluded.
Overall survival and transplant and relapse related mortality (Table 4).
Median follow up was 27 (range:17-46), 28 (range:19-38), 11 (range:11-14) and 16
months (range:16-17) for group 1, 2, 3 and 4, respectively. OS and cumulative incidence of
TRM and RRM at one year post-transplant are depicted in Table 4.
A higher dose of ATG did not result in an increased TRM nor RRM. One has to remind, when
interpreting these data, that patient numbers in group 3 and 4 are very small.
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Table 4 Overall survival and cumulative incidence of transplant and relapse
related mortality at 1 year post-transplant
MUD MUD MUD MUD P
group 1 group 2 group 3 group 4
(n=33) (n=19) (n=13) (n=9)
OS, % (SE) 64 (8) 79 (18) 38 (13) 56 (34) ns
TRM, % (SE) 12 (6) 21 (18) 23 (12) 33 (32) ns
RRM, % (SE) 24 (14) 0 38 (26) 11 (20) ns
OS = overall survival; TRM = transplant related mortality; RRM = relapse related mortality; SE = standard error.
Discussion
In this study, we set out to evaluate the effect of 3 different ATG doses (8 mg/kg, 6 mg/kg
and 4 mg/kg) on graft failure and incidence of acute and chronic GVHD among MUD recipi-
ents of partially TCD grafts. ATG was infused pre-transplant, resulting in in-vivo TCD.
Lowering ATG dose from 8 mg/kg to 6 mg/kg did not influence the occurrence of graft fail-
ure nor the incidence of GVHD. However, when ATG dose was decreased to 4 mg/kg the
incidence of severe acute GVHD grade III-IV and extensive chronic GVHD rose significantly.
Low-dose ATG (4 mg/kg) did not affect the incidence of graft failure, suggesting that ade-
quate host immune suppression was achieved.
The effectiveness of ATG (Thymoglobulin™, Sangstat) as prophylaxis of GVHD in recipients
of MUD grafts has been described by others8-12. In these studies, no in-vitro TCD of grafts
was performed and prophylaxis of GVHD consisted of ATG, cyclosporine A and a short-
course of methotrexate. The incidence of acute (grade III-IV) and chronic GVHD was highly
variable (see Table 5). A dose-response effect was only seen in individual studies, but not
between the varying studies. The results of our study are very favourable compared to those
described in Table 5, as long as 6-8 mg/kg ATG was used. In other studies14-18 ATG was
derived from a different company (Fresenius). ATG-Fresenius is not equipotent to ATG
33
  	 
 
Table 5 Effect of ATG on incidence of acute and chronic GVHD 
ATG dose Acute GVHD, Chronic GVHD
(Thymoglobulin™, Sangstat) grade III-IV
15 mg/kg 11%8 41%8
7%9 0%9
7,5 mg/kg 41%8 55%8
38%9 27%9
4,5 mg/kg 0%10 27%10
3%11* 38%11*
10%12 44%12
no ATG 54%10 57%10
* In this report data are presented from recipients of matched related donor grafts (n=42) and alternative donor grafts
(n=28), subgroup analysis showed no difference; superscript numbers are references.
(Thymoglobulin™, Sangstat) as used in our study. This makes a direct dose-response com-
parison between these and our study impossible.
Recently we reported high-dose ATG (20 mg/kg), used before 1999, to be associated with a
highly increased incidence of fatal infectious complications compared to intermediate-dose
ATG (8 mg/kg) used after 199920,21. Furthermore, total lymphocyte, CD3+ and CD4+ T cell
reconstitution was significantly lower in transplant recipients of unrelated grafts treated
with high-dose ATG (15 mg/kg) compared with intermediate-dose ATG (7,5 mg/kg)9.
Another drawback of ATG treatment is a possible increased relapse incidence8-10, although
this is not supported by data from recent studies of Kroger et al17 and Duggan et al12 in
which ATG was very effective in reducing the incidence of GVHD without affecting the
relapse rate. Duggan et al12 compared incidence of GVHD, relapse, TRM, OS and disease
free survival in recipients of un-manipulated MUD transplants with outcome in recipients of
un-manipulated matched related donor grafts. All patients received GVHD prophylaxis con-
sisting of cyclosporine A and short-course methotrexate, while MUD recipients were also
treated with low-dose (4,5 mg/kg) ATG given pre-transplant over 3 days. Outcome was
highly comparable in both groups. Relapse incidence at 3 years was 45% (SE 7%) in the
MUD group and 42% (SE 7%) in the matched unrelated donor group.
In the current study, the highest dose of ATG (8 mg/kg) did not result in an increased TRM
nor RRM. However, patient numbers in group 3 and 4 are very small, therefore, these data
should be interpreted with caution.
Considering the immunosuppressive and direct toxic effects of high-dose (15-20 mg/kg)
ATG, a dose reduction is mandatory. In the setting of SCT with (partially) TCD grafts from
MUDs, using limited post-transplant immunosuppression with cyclosporine A, we recom-
mend the use of ATG in a total dose of 6-8 mg/kg.
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Abstract
Reactivation of the Epstein-Barr virus (EBV) after allogeneic stem cell transplantation (SCT)
may evoke a protective cellular immune response or may be complicated by the develop-
ment of EBV-lymphoproliferative disease (EBV-LPD). So far, very little is known about the
incidence, recurrence, and sequelae of EBV reactivation following SCT. EBV reactivation was
retrospectively monitored in 85 EBV-seropositive recipients of a T cell depleted (TCD) SCT
and 65 EBV-seropositive recipients of an unmanipulated SCT. Viral reactivation (more than
50 EBV copies (c) /ml) was monitored frequently by quantitative real-time plasma poly-
merase chain reaction (PCR) until day 180 after SCT. Probabilities of developing viral reacti-
vation were high after both unmanipulated and TCD allogeneic SCT (31% ± 6% versus 65%
± 7%, respectively). A high CD34+ cell number of the graft appeared as a novel significant
predictor (p=0.001) for EBV reactivation. Recurrent reactivation was observed more fre-
quently in recipients of a TCD graft, and EBV-LPD occurred only after TCD SCT. High-risk
disease status, TCD, and use of Antithymocyteglobulin (ATG) were predictive for developing
EBV-LPD. Plasma EBV DNA quantitatively predicted EBV-LPD. The positive and negative
predictive values of a viral load of 1000 c/ml were, respectively, 39% and 100% following
TCD. Treatment-related mortality did not differ significantly between TCD and non-TCD
transplants, but the incidence of chronic graft-versus-host disease was significantly less in
TCD patients. It is concluded that EBV reactivation occurs frequently after TCD and unma-
nipulated SCT, especially in recipients of grafts with high CD34+ cell counts. EBV-LPD,
however, occurred only after TCD and EBV viral load quantitatively predicted EBV-LPD in
recipients of a TCD graft.
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Introduction
Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) is a serious complica-
tion of allogeneic stem cell transplantation (SCT) and solid organ transplantation1-3.
Although the incidence of EBV-LPD is generally less than 2% after SCT, it may increase to
20% in patients with established risk factors, such as unrelated donor SCT, the use of T cell
depleted (TCD) grafts, use of Antithymocyteglobulin (ATG) and immuno-suppression for
prevention and treatment of graft-versus-host disease (GVHD)4-8. EBV-LPD is associated
with a poor prognosis despite the use of anti B lymphocyte monoclonal antibody therapy,
donor lymphocyte infusion (DLI) and infusion of EBV-specific cytotoxic T cells (CTL)9-15.
Therefore, early diagnosis and preventive measures such as B cell depletion of the donor
graft, and pre-emptive therapy may be clinically useful4,7,16-24.
We developed a real-time polymerase chain reaction (PCR) assay for the quantitative detec-
tion of EBV-DNA in plasma25. The assay accurately monitors viral load in plasma from
patients with infectious mononucleosis and immunocompromised patients at risk of EBV-
LPD or with established EBV-LPD25,26. In contrast to cytomegalovirus (CMV) antigenemia
after SCT and the risk of developing CMV-disease, little is known about reactivation of EBV
during the first 3 to 6 months after SCT and the predictive value of EBV reactivation for sub-
sequent EBV-LPD. Although several studies have shown an association of viral load and a
diagnosis of EBV-LPD, no study has longitudinally followed a larger cohort of SCT recipients
with multiple risk factors27-43. We set out to monitor EBV reactivation by real-time PCR at
regular time intervals after SCT. Incidences, risk factors and sequelae of EBV reactivation
were compared between patients receiving a TCD SCT and patients transplanted with an
unmanipulated stem cell graft. We show that subclinical EBV reactivation is a very frequent
event after SCT and that quantification of EBV DNA appears useful to identify patients at
risk of progression to overt EBV-LPD.
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Methods
Patients The study population consisted of 152 consecutive patients treated at 4 trans-
plant centres, who received stem cell transplants between March 1996 and June 1999.
Patients underwent allografting at the department of haematology of the university hospi-
tals of Utrecht (TCD SCT) or Rotterdam (TCD SCT), the Netherlands; Essen (non-TCD SCT),
Germany; or Genoa (non-TCD SCT), Italy. Transplant protocols were approved by local
institutional review boards and all patients provided informed consent. Patient characteris-
tics are presented in Table 1. Eighty-five patients received a TCD SCT and 67 patients
received a non-TCD SCT. Median age was 41 years (range, 17-55 years) in the TCD group
and 31 years (range, 17-56 years) in the non-TCD group (p<0.01). Low-risk patients had a
diagnosis of acute lymphoblastic leukaemia (ALL) in first complete remission (CR1), acute
myeloid leukaemia (AML) in CR1, chronic myeloid leukaemia (CML) in first chronic phase
and untreated (very) severe aplastic anaemia (SAA), all other diagnoses were considered
high-risk. The non-TCD group included more patients with CML and fewer patients with
lymphoma, multiple myeloma or high-risk disease (p=0.001). Unrelated donor grafts were
used more frequently in the non-TCD group (p=0.001). The use of ATG added to the condi-
tioning regimen for prevention of rejection was confined to patients transplanted with TCD
grafts from unrelated donors.
Transplantation The conditioning regimen preceding a TCD SCT consisted of
cyclophosphamide (120 mg/kg) and total body irradiation (TBI) (12 Gy in 2 fractions).
Rabbit ATG (Thymoglobulin™, Sangstat, Amstelveen, the Netherlands) was given for pre-
vention of rejection prior to SCT in recipients of a TCD unrelated donor graft. If patients had
previously been treated with locoregional irradiation, the conditioning regimen consisted of
oral busulfan (4 mg/kg on each of 4 successive days) and cyclophosphamide (120 mg/kg).
The conditioning regimen in case of an unmanipulated SCT consisted of cyclophosphamide
(120 mg/kg) and TBI (10 Gy in 4 fractions or 10 Gy in 3 fractions).
Partial T cell depletion was performed using sheep erythrocyte rosetting (n=53) or CD34
selection (CellPro, Wezembeek, Belgium) (n=32). Median T cell numbers differed more
than 2 logs between TCD and unmanipulated grafts (2.0x105/kg versus 510x105/kg), but
numbers of CD34+ cells did not differ significantly between the groups of patients.
Peripheral blood-derived stem cells were used relatively more often than bone marrow-
derived stem cells in patients receiving a TCD graft as compared with patients receiving an
40
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Table 1 Patient characteristics
Characteristics TCD SCT nonTCD SCT P
(n=85) (n=67)
Age, y (range) 41 (17-55) 31 (17-56) <0.01
Diagnosis 
AML CR1 11 3
AML >CR1 8 8
ALL CR1 10 6
ALL >CR1 7 2
MDS 3 1
CML CP1 8 28
CML >CP1 5 16
SAA 5 0
MM 15 1
NHL 10 2
Other 3 0
Risk status: low/high 25/60 37/30 0.001
Donor: MRD/MUD 61/24 30/37 0.001
Graft characteristics
T cells (range; x 105/kg) 2.0 (0.01-9.32) 510 (7.40-2195) <0.001
CD34+ cells (range; x 106/kg) 1.25 (0.06-6.43) 2.2 (0.04-14.10)
Conditioning regimen
Cy/TBI 59 67
Cy/TBI/ATG 23 0
Other 3 0
EBV serostatus
R-/D- 0 2
R+/D+, R+/D-, R-/D+ 85 65
Stem cell source: BM/PB 66/19 63/4 <0.01
Data are no. of patients, unless otherwise indicated; AML CR1 or >CR1 = acute myeloid leukaemia in first or subsequent
complete remission; ALL CR1 or >CR1 = acute lymphoblastic leukaemia in first or subsequent CR; MDS =  myelodysplas-
tic syndrome; CML CP1 or >CP1 = chronic myeloid leukaemia in first or subsequent chronic phase; SAA = severe aplastic
anaemia; MM = multiple myeloma; NHL =  Non-Hodgkin’s lymphoma; MRD = matched related donor; MUD = matched
unrelated donor; Cy =  cyclophosphamide; TBI =  total body irradiation; ATG = Antithymocyteglobulin; R/D = recipi-
ent/donor;  BM = bone marrow; PB = peripheral blood.
unmanipulated graft (p<0.01). Graft-versus-host (GVH) prophylaxis was cyclosporin A
(3 mg/kg) from day -3 until day +100 after TCD SCT, and the combination methotrexate
(15 mg/m2 on day 1; 10 mg/m2 on day 3, 6 and 11) and cyclosporin A was used in recipi-
ents of an unmanipulated SCT.
All patients received ciprofloxacin and fluconazole for prevention of infection during neu-
tropenia, and cotrimoxazole was given after neutrophil recovery until day 180 to 360 after
SCT. Patients transplanted in Utrecht (TCD SCT) and Genoa (non-TCD SCT) received long-
term acyclovir prophylaxis from day 0 until day 360. Blood products were leukocyte
depleted and subsequently irradiated (25 Gy). Patients were hospitalised in reverse isolation
and rooms with high-efficiency particulate-filtered air. All patients received food with a low
microbial count until discharge, and parenteral alimentation was given in case of severe
mucositis.
Real-time Taqman assay Taqman PCR primers were selected from the EBV-DNA
genome encoding for the non-glycosylated membrane protein BNRF1-p143 and generated a
DNA product of 74 base-pairs, as described before25. A known EBV-DNA copy number based
on a reference standard quantified by electron microscopy (ABI Advanced Biotechnologies,
Columbia, MA, USA) was used for standardization. Serial dilutions ranging from 10 to 107
EBV-DNA c/ml were made to characterize linearity, precision, specificity and sensitivity. The
Taqman assay appeared to detect viral DNA in plasma over a linear span between 50 and
107 c/ml with an average coefficient of variation of 1.56% (range, 0.7- 7.0%). Test results
below 50 c/ml were considered negative. No viral DNA was detected in plasma of healthy
EBV-seropositive individuals25. EBV reactivation was defined as a plasma EBV-DNA level
exceeding 50 c/ml. Recurrent reactivation was defined by a positive PCR (more than
50 c/ml) after (at least) two consecutive negative PCR results following a preceding episode
of reactivation. Viral load was monitored in blood samples drawn at 2-week intervals start-
ing at SCT until day 180 after SCT.
EBV-LPD diagnosis A diagnosis of EBV-LPD was preferably based on lymph node his-
tology or cytology and was classified according to the criteria of Knowles et al44.
Immunohistology included antibody staining with CD19-specific (Becton Dickinson, San
José, CA, USA), CD20-specific (DAKO, Glostrup, Denmark) and EBV latent membrane pro-
tein-1-specific (DAKO) monoclonal antibodies. Furthermore, clonality was assessed using
immunohistochemical staining with monoclonal antibodies to kappa and lambda light
chains (DAKO). In situ hybridisation was performed to detect EBV-encoded small RNA mole-
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cules (EBV-EBER) using an EBV-EBER probe (DAKO) and PCR for detection of EBV-DNA
encoding for the BamHI fragment. EBV-LPD staging included physical examination, whole-
body computed tomography scanning (CT) scanning, and flow cytometric detection of mon-
oclonal B lymphocytes in blood, bone marrow and, if indicated, cerebrospinal fluid.
Endpoints and statistical analysis The data were analysed as of January 2000.
Patient characteristics of non-TCD patients and TCD patients were compared using Fisher
exact test or Pearson chi-square test, whichever was appropriate, in case of discrete vari-
ables, or the Wilcoxon rank-sum test in case of continuous variables. End points of the study
included time to EBV reactivation, EBV-LPD, acute GVHD grades II to IV, chronic GVHD and
treatment-related mortality (TRM). Time to first EBV reactivation was determined from the
date of transplantation until day 180 and patients were censored at the date of last serum
sample if this sample had been taken before day 180. Time to EBV-LPD was measured from
SCT until EBV-LPD. Patients who died without EBV-LPD were censored at the date of death.
Patients still alive at the date of analysis were censored at the last follow-up date. Two EBV-
seronegative donor-recipient pairs were excluded from the analysis of EBV reactivation and
EBV-LPD. GVHD was diagnosed and graded according to consensus criteria45. Chronic
GVHD was evaluated among patients who survived at least 100 days after transplantation.
TRM was defined according to standard criteria46. Time to EBV reactivation, EBV-LPD, acute
and chronic GVHD, and TRM were estimated by the Kaplan-Meier method, and Kaplan-
Meier curves were generated to illustrate differences between subgroups of patients47. The
following variables were included in the analysis of prognostic factors: sex, male patient and
female donor, age, risk status, donor (MRD versus MUD), source of stem cells (bone marrow
versus peripheral blood), type of transplant (non-TCD versus TCD without ATG versus TCD
with ATG) and graft characteristics (number of mononuclear cells, number of CD34+ cells,
number of CD3+ cells and granulocyte-macrophage colony forming units infused).
Univariate survival analysis was performed using the log-rank test48. The variables that
appeared significant in the univariate analysis were included in a multivariate Cox regres-
sion49. Moreover, Cox regression was performed using EBV reactivation within day 180 as a
time-dependent covariate to assess whether EBV reactivation predicted EBV-LPD and TRM.
All reported P-values are 2-sided and a significance level of p=0.05 was used.
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Results
EBV-reactivation The probability of developing EBV reactivation was greater after
TCD allogeneic SCT than after non-TCD SCT (Figure 1, Table 2). That difference, however,
could be largely attributed to the use of ATG in conjunction with TCD (Figure 1, Table 3).
Probabilities of viral reactivation were not different between recipients of a non-TCD SCT
and recipients of TCD SCT without concomitant ATG. Median time to first reactivation was
58 days (range, 5-180 days) in the TCD group and 63 days (range, 2-107 days) in the non-
TCD group (not significant). Plasma EBV-DNA levels measured at the peak of the first reacti-
vation did not differ between the groups. Recurrent reactivation was significantly more
frequent after TCD (Table 2): 14 of 85 patients (16%) experienced multiple episodes of EBV
reactivation after TCD SCT, including 8 patients with 2 episodes, 5 patients with 3 episodes,
and 1 patient showing 4 distinct periods of reactivation. This is exemplified for a recipient of
a TCD donor graft who experienced 3 episodes of EBV reactivation without developing EBV-
LPD (Figure 2). In contrast, only 2 of 65 patients (3%) receiving non-TCD grafts had a sec-
ond period of reactivation. ATG appeared not to be associated with recurrent reactivation,
as only 2 out of 14 patients with recurrent reactivation after TCD also received ATG as part
of the conditioning regimen.
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Table 2 EBV reactivation and EBV-LPD
TCD SCT non-TCD SCT
Parameter (n=85) (n=65)
No. of patients with  EBV reactivation (%) 46 (54) 18 (28)
Days post-transplant to first EBV reactivation 58 (5-180) 63 (2-107)
Maximum VL (c/ml) of first reactivation 535 (50-3200000) 808 (55-540000)
No. of patients with recurrent reactivation (%) 14 (16) 2 (3)
No. of patients with EBV-LPD (%) 10 (12) 0
Days post-transplant to EBV-LPD 87 (50-168) 0
Days from first EBV reactivation to EBV-LPD 22 (13-120) 0
EBV-LPD VL (c/ml) 110000 (1800-790000) 
Data  are expressed as median (range), unless otherwise indicated; VL = viral load; other abbreviations: see Table I.
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Figure 1
Upper panel: Incidence of EBV-reactivation after TCD allogeneic SCT with ATG (n=24), TCD SCT
without ATG (n=61), and non-TCD SCT (n=65). Only TCD combined with ATG significantly
increased the risk of EBV reactivation (p<0.001). 
Lower panel: Incidence of EBV reactivation by number of CD34+ cells in the graft. The median
number of CD34+ cells was 1.35 x 106/kg. Patients with grafts containing more than 1.35 x
106/kg  CD34+ cells were at higher risk (p=0.001) of EBV reactivation.
Several risk factors predicted for first reactivation in univariate analysis (Table 3), including
TCD (p=0.02), use of ATG in the conditioning regimen (p<0.001), transplantation of unre-
lated donor graft (p=0.02), and a high CD34+ cell number of the graft (p=0.001)
(Figure 1). Following multivariate analysis, only use of ATG, a high CD34+ cell count
(>1.35x106/kg) and a high-risk disease status remained independently associated with EBV
reactivation (Table 3). Numbers of CD34+ and CD3+ cells were not associated with each
other.
EBV-LPD EBV-LPD was only observed following TCD SCT (Table 2, Figure 3). Five
patients developed EBV-LPD after HLA identical sibling SCT and 5 after unrelated donor
SCT (Table 4). Five of these patients had received ATG before unrelated donor SCT, and 9
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Figure 2
Monitoring of EBV viral load after a matched unrelated SCT. A 16-year-old EBV-seropositive male
with a philadelphia chromosome-positive (Ph+) ALL in first complete remission received a TCD
matched unrelated donor graft from an EBV-seropositive donor. Multiple EBV reactivations were
observed; however, no EBV-LPD ensued. Frequent examination of bone marrow for the presence
of monoclonal B cells and whole-body CT to detect lymphadenopathy were negative at various
time points (*). At day 211, DLI (1.0 x 105 CD3+ T cells/kg) was administered because of molec-
ular relapse of his Ph+ ALL. Currently, the patient is free of disease and well at day 800 after
SCT. CyA indicates cyclosporin A.
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Table 3 Univariate and multivariate Cox regression analysis of risk factors for
Epstein-Barr virus reactivation
Risk factor Univariate Analysis Multivariate analysis
RR 95% CI P RR 95% CI P
TCD, no ATG 1.5 0.8-2.7 0.02 1.5 0.8-2.9 0.3
TCD, ATG 3.5 1.8-6.9 < 0.001 3.4 1.6-7.1 0.001
High-risk status 1.6 1.0-2.8 0.07 1.4 0.8-2.6 0.02
MUD 1.8 1.1-2.9 0.02 0.9 0.3-2.9 0.8
CD34+ cell count* 2.4 1.4-4.1 0.001 2.6 1.5-4.6 0.001
* = >1.35 x 106/kg.
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Figure 3
Incidence of EBV-LPD (n=10) after TCD allogeneic SCT combined with ATG (n=24), TCD SCT
without ATG (n=61), and non-TCD SCT (n=65).
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of them had been treated for high-risk disease. All EBV-LPD donor-recipient pairs were EBV-
seropositive. One donor had negative EBV serology before transplantation. Median time
from first reactivation to EBV-LPD was 22 days (range, 13-120 days) (Table 2). Median EBV-
DNA level at EBV-LPD diagnosis was 110000 c/ml (range 1800-790000). Histological proof
of a diagnosis of EBV-LPD and classification according to the criteria of Knowles et al44 were
obtained in 8 patients. Patient 8 (Table 4), who received an HLA-identical sibling SCT for
multiple myeloma, was diagnosed with EBV-LPD by the presence of monoclonal B cells in
his cerebrospinal fluid and an elevated plasma EBV-DNA level. Patient 9, who received an
unrelated donor SCT because of SAA, was diagnosed with EBV-LPD because of massive lym-
phadenopathy on CT scanning and a highly elevated plasma EBV-DNA level. Six patients
received anti B cell monoclonal antibody therapy (rituximab), 5 patients received DLI, and
immune suppression was discontinued in 8 patients (Table 4). Five patients obtained a com-
plete remission and 5 other patients died of progressive EBV-LPD. Two responding patients
are currently alive with a follow-up of 620 and 351 days. Three responding patients devel-
oped severe GVHD, 2 following DLI, and died due to GVHD-related complications. Use of
ATG, application of TCD, and high-risk status of underlying disease significantly predicted
EBV-LPD in univariate analysis. Multivariate analysis was not performed because the latter 3
variables appeared strongly associated and the small number of events did not allow a reli-
able multivariate analysis.
Several risk factors occurring after SCT were evaluated for a possible association with EBV-
LPD by time-dependent analysis. A lower lymphocyte count at first EBV reactivation
appeared not predictive for developing EBV-LPD. In contrast, EBV load significantly pre-
dicted EBV-LPD in a quantitative manner. A stepwise increase of EBV DNA by 1 log (Table
5) yielded a hazard ratio (HR) of 2.9 (95% confidence interval [CI], 1.7-4.8) for those
patients receiving a TCD graft (p<0.001). Numbers of patients with a TCD SCT with plasma
levels of EBV DNA exceeding a certain threshold value and the corresponding positive and
negative predictive values for EBV-LPD for that subset of patients are shown in Table 5.
Although the positive predictive value was 24% for patients with a copy number of 100 c/ml
or higher, it rose to 100% at the level of 500000 c/ml. However, only one patient with EBV-
LPD reached that high number, and consequently the negative predictive value measured
89%.
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Graft-versus-host disease The actuarial probability of acute GVHD II-IV at day 100
was 57% ± 4% for the whole group and was not significantly different for patients receiving
a TCD graft as compared with patients following unmanipulated SCT. An unrelated donor
graft and a high CD34+ cell count of the graft (independent from the number of CD3+ T
cells in the graft) were the only significant risk factors for developing acute GVHD following
multivariate analysis. EBV reactivation was not associated with acute GVHD. Actuarial prob-
abilities of chronic limited and extensive GVHD at 12 months post SCT were significantly
higher for non-TCD patients (83% ± 5%) than for TCD patients (38% ± 6%) (p<0.001).
Treatment-related mortality The actuarial probability of TRM was 29% ± 4% at 1
year for all patients and did not differ between TCD and unmanipulated SCT. Higher age
and a higher CD34+ cell count (> 1.35 x 106/kg) of the graft predicted higher TRM in mul-
tivariate analysis. Following time-dependent analysis, EBV reactivation (HR: 1.9, 95% CI:
1.0-3.3, p=0.04) and acute GVHD grade I-IV (HR: 1.8, 95% CI: 1.0-3.3, p=0.05) were asso-
ciated with higher TRM. In addition, a higher lymphocyte count (> 0.6 x 109/l) at the time
of first EBV reactivation significantly predicted less TRM (HR 0.3; 95% CI, 0.1-0.8; p=0.02).
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Table 5 Incidence of EBV-LPD by viral load 
No. of No. of Predictive value
EBV viral load patients with patients with
(c/ml) reactivations EBV-LPD Positive (%) Negative (%)
100 41 10 24 100
1000 26 10 39 100
10000 14 7 50 96
100000 7 5 71 94
500000 1 1 100 89
Abbreviations: see Table 1.
Discussion
This study demonstrates that EBV reactivation is a very frequent event after both TCD and
unmanipulated SCT. In particular, recipients of stem cell grafts with high numbers of
CD34+ cell counts appeared to be at risk for EBV reactivation. However, patients receiving a
TCD SCT were at significantly higher risk for recurrent reactivation and only these patients
developed EBV-LPD. The development of impending EBV-LPD in these patients could be pre-
dicted quantitatively by monitoring viral load in plasma at regular intervals during the first 6
months after SCT.
EBV reactivation was observed frequently after TCD SCT and after unmanipulated SCT as
well. The high incidence of first EBV reactivation after TCD SCT could be largely attributed
to the use of ATG and, as a result, TCD per se did not appear to be an independent risk fac-
tor for early EBV reactivation. However, patients receiving a TCD SCT showed more recur-
rence of reactivation and EBV-LPD was observed only after TCD. Because the conditioning
regimen has eradicated autologous EBV-specific immunity after both TCD and unmanipu-
lated SCT, early EBV reactivation may occur after both modes of SCT50,51. However, the sig-
nificantly higher risks for recurrent EBV reactivation and EBV-LPD in TCD SCT as compared
with unmanipulated SCT may be explained by the impaired capacity of patients receiving
TCD grafts to mount an effective immune response to the reactivating virus. The strongly
reduced numbers of EBV-specific memory T cells in TCD as compared with unmanipulated
grafts may play a major role in this respect52,53. Apart from the use of ATG as part of the con-
ditioning regimen, we identified the number of CD34+ cells in the graft as a novel inde-
pendent risk factor for developing EBV reactivation (Table 3, Figure 1), and also for acute
GVHD and TRM. Przepiorka et al54 recently reported that recipients of peripheral blood stem
cell grafts with high CD34+ cell counts were at higher risk for acute GVHD, an effect that
appeared independent of the number of CD3+ T cells54. They suggested that GVHD at high
CD34+ cell doses may be exacerbated by cytokines released by the markedly expanding
myeloid population at the time of engraftment. This explanation is supported by high levels
of pro-inflammatory cytokines in patients with severe GVHD55-57. In the present study, acute
GVHD significantly predicted TRM in a time-dependent analysis. Therefore, the association
of CD34+ cell dose and TRM might be explained by an increased incidence of GVHD. The
association of CD34+ cell dose and EBV reactivation is, however, less likely to be explained
by more GVHD, as EBV reactivation preceded the onset of acute GVHD in a significant num-
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ber of patients. Alternative explanations may include infusion of a higher number of EBV-
infected B cells together with larger stem cell grafts, or stimulation of B-cell proliferation by
cytokines produced by the higher number of rapidly maturing myeloid progenitors. The lat-
ter explanation is supported by a number of preclinical as well as clinical studies showing
that proinflammatory cytokines, such as interleukin-1 (IL-1), tumor necrosis factor α and -β,
and IL-6, may very effectively stimulate the growth of EBV-infected B cells58. In particular,
IL-6 may play an important role as a growth factor, promoting the progression toward overt
EBV-LPD59-62. Apart from monocyte-macrophages and endothelial cells as an established
source of proinflammatory cytokines, the rapid proliferating myeloid population of grafts
containing high CD34+ cell doses may add to cytokine release and thus contribute to viral
reactivation.
A number of studies have demonstrated a correlation between high levels of viral load and a
diagnosis of EBV-LPD after both SCT and solid-organ transplantation26-43. No study, how-
ever, has longitudinally followed SCT recipients with multiple risk factors from day 0 until
day 180 and reported positive and negative predictive values. Lucas et al41 evaluated the
predictive value of a quantitative PCR using DNA extracted from peripheral blood MNCs in a
cohort of 195 patients receiving a solid-organ transplantation41. Although the negative pre-
dictive value appeared very high (100%), the positive predictive value was 38%. Our results
observed in recipients of an SCT are in line with these findings. Considering both TCD and
non-TCD transplants, the negative and positive predictive values of a copy number of 1000
c/ml were, respectively, 100% and 28%. Higher predictive values were obtained when the
analysis was restricted to patients receiving a TCD SCT. The positive predictive value of a
high EBV-DNA level of more than 1000 c/ml and more than 10000 c/ml for patients receiv-
ing a TCD SCT were 39% and 50%, respectively (Table 5).
Although highly significant, these predictive values also indicate that most patients (even
recipients of TCD grafts) were able to mount an effective immune response and clear their
viral reactivation. Monitoring of the reconstitution of HLA-specific T lymphocytes may add
to the predictive value of viral load quantification. For this purpose, rapid assays are now
available, such as the enumeration of EBV-specific T lymphocytes by tetramer binding or the
induction of intracellular interferon-γ in T cells after specific stimulation63. The accurate pre-
diction of impending EBV-LPD in patients at risk is important because pre-emptive therapy
might be more effective than therapy of established EBV-LPD. Despite the application of new
treatment modalities such as DLI and anti B cell immunotherapy, the mortality of patients
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with established EBV-LPD is still high. Ten patients developed EBV-LPD in the present study:
5 died due to progressive EBV-LPD and 3 patients secondary to GVHD following DLI, result-
ing in a 80% (8 of 10) mortality. Pre-emptive infusion of EBV-specific cytotoxic T cells has
been shown to reduce viral load and may prevent the evolution toward EBV-LPD20.
However, the preparation and use of such EBV-specific T cells is expensive and difficult to
implement on a wide scale. B cell depletion of the donor graft has been shown to effectively
reduce the incidence of EBV-LPD7,16. Therefore, anti B cell immunotherapy aimed at in vivo
B cell depletion after SCT in patients at high risk of EBV-LPD might be a promising new
means of pre-emptive therapy. A prospective phase II study with that specific aim is cur-
rently being performed64. Because the depletion of B cells may add to the impaired immune
status of these patients, one may argue to restrict pre-emptive therapy to those patients at
highest risk. A threshold of 1000 c/ml, as observed in our patient population, may thereby
serve as a critical level of viral load to start pre-emptive therapy. Thus, pre-emptive therapy
may be administered selectively to high-risk patients to prevent EBV-LPD and to avoid treat-
ment of patients who have recovered their EBV-specific immunity to protective levels. The
frequent monitoring of EBV load after SCT may therefore be considered for patients with a
high-risk profile for EBV-LPD and may preferably be combined with close monitoring of the
reconstitution of EBV-specific T lymphocytes.
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Abstract
Recipients of allogeneic stem cell transplants often have Epstein-Barr virus (EBV) reactiva-
tions which may progress to EBV-associated lymphoproliferative disorders. It is not known
whether these EBV reactivations are true reactivations of the endogenous EBV strain or re-
infections with an exogenous EBV strain. Fifty-three recipients of matched related or
matched unrelated donor grafts were studied. EBV monitoring was based on a realtime
TaqMan™ EBV DNA PCR assay in plasma. In 17 patients EBV DNA PCR monitoring was per-
formed in peripheral blood mononuclear cells (PBMCs) as well. From all patients and family
donors mouth washes (MWs) were collected pre-transplant. Both pre-transplant EBV DNA
from MWs and post-transplant EBV DNA from plasma or PBMCs was successfully obtained
in 6 patients. A nested PCR targeting the EBV LMP-1 C-terminus gene was used to determine
sequence variations enabling EBV strain typing. In 3 of 6 patients the post-transplant EBV
sequence pattern differed from the pre-transplant pattern, indicating a re-infection post-
transplant with an exogenous strain instead of a reactivation of the original endogenous
EBV strain. In the other 3 patients the endogenous strain was identified. EBV reactivations
frequently result from a re-infection with an exogenous EBV strain instead of a true reactiva-
tion of the endogenous strain.
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Introduction
Recipients of allogeneic stem cell transplants (SCT) often have Epstein-Barr virus (EBV)
reactivations1. Patients with EBV reactivations are at risk for developing EBV-associated lym-
phoproliferative disorders (EBV-LPD)2, especially when other risk factors are present like: 1)
T cell depletion (TCD) of stem cells using monoclonal antibodies (Moabs) directed at T cells
or T and NK cells or using E-rosetting, 2) use of unrelated or ≥ 2 HLA antigen mismatched
related donors, 3) use of Antithymocyteglobulin for prophylaxis or treatment of acute graft-
versus-host disease (aGVHD) and 4) treatment of aGVHD with anti CD3 Moabs1,3.
Currently it is not known whether these EBV reactivations are true reactivations of the
endogenous EBV strain or re-infections with an exogenous EBV strain. EBV strains can be
identified by examining size variation of the EBV nuclear antigen (EBNA) proteins (ebnotyp-
ing) or genes4,5. Ebnotyping requires the production of EBV transformed lymphoblastoid cell
lines (LCLs). This technique is laborious and not all EBV strains are capable of efficient
transformation of B cells4. Others have used DNA restriction fragment length polymorphisms
(RFLP) of EBV DNA6,7 or sequence analysis of the latent membrane protein (LMP)-1 gene8-11
to characterise EBV strains. Here we report results of the LMP-1 sequencing approach for
EBV strain identification in recipients of partially T cell depleted allogeneic SCT, using a
nested PCR and direct sequencing targeting the EBV LMP-1 C-terminus gene to determine
sequence variations.
Materials and Methods
Patients For this study data of 53 consecutively treated patients receiving either stem
cells from matched related donors (MRD, n=26) or from matched unrelated donors (MUD,
n=27) were analysed. EBV monitoring was performed weekly by quantitative EBV DNA
detection in plasma samples until day 180 post-transplant. In 17 patients EBV DNA detec-
tion was performed in PBMCs as well. From all patients and family donors mouth washes
(MWs) were collected pre-transplant to acquire endogenous EBV DNA. In 6 patients pre-
and post-transplant EBV DNA could be obtained and analysed.
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Patients with acute leukaemia in first complete remission, chronic myeloid leukaemia (CML)
in first chronic phase and untreated severe aplastic anaemia (SAA) were considered low-risk
regarding transplant related mortality (TRM) and relapse. All patients with other diseases
were considered high-risk. Transplantations were performed between April 2001 and May
2002 at the Department of Haematology of the University Medical Centre Utrecht. Patients
were treated according to clinical protocols approved by the local investigation review board
after informed consent was obtained.
Transplantation procedures, pre-emptive treatment of CMV reactivations and treatment of
CMV disease were performed as described12.
Conditioning regimen The conditioning regimen consisted of cyclophosphamide (60
mg/kg/day) on each of two successive days, followed by total body irradiation (TBI) (600
cGy/day) on each of 2 successive days, with partial shielding of the lungs (total lung dose
850 cGy). The graft was infused after the second TBI fraction (day 0). Antithymocyte-
globulin (ATG) (Thymoglobulin™, Sangstat, Amstelveen, the Netherlands) was given to
MUD patients before cyclophosphamide was infused, in a dose of 2 mg/kg/day for 4 days.
TCD In vitro TCD of bone marrow (BM) from unrelated donors was performed using the
immunorosette depletion technique as described12. MRD patients received a peripheral
blood stem cell (PBSC) graft. TCD of these G-CSF stimulated PBSC grafts was performed by
positive selection of CD34+ cells (CliniMacs™, Miltenyi Biotec, Bergisch Gladbach,
Germany). After these maximal TCD procedures the residual number of T cells was counted
and nonmanipulated T cells (from a small BM/PBSC fraction that was set apart) were added
to obtain the desired fixed low number of T cells (1-2 x 105 T cells/kg recipient weight).
HLA-matching In MRD recipient/donor pairs HLA-A, B and Cw matching was based on
serological typing and HLA-DRB1 and DQB1 matching on low resolution molecular typing
with sequence specific primers (SSP). In MUD recipient/donor pairs HLA-A, B and DRB1
matching was based on high resolution sequence based typing and HLA-Cw and DQB1
matching on low resolution molecular typing with SSP.
CMV monitoring CMV monitoring was based on a realtime TaqMan™ CMV DNA PCR
assay in EDTA-plasma13 and was performed weekly until day 180 post-transplant in CMV-
seropositive recipient/donor pairs. In patients with active GVHD or with CMV reactivation,
defined as a viral load (VL) > 400 copies (c) /ml, monitoring was performed twice a week.
Pre-emptive antiviral treatment of CMV reactivations was instituted when VL was > 1000
c/ml.
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EBV serostatus Serum samples were tested for IgG antibodies to Epstein-Barr viral
capsid antigen (VCA) by an indirect immunofluorescence assay using slides coated with
EBV-infected P3HR-1 cells. Individuals were considered positive when reactivity against EBV
VCA could be detected at a serum dilution of 1:10 or higher.
EBV monitoring EBV monitoring was based on a realtime TaqMan™ EBV DNA PCR
assay in plasma and was performed weekly until day 180 post-transplant in all patients. In
17 patients EBV DNA PCR monitoring was performed in PBMCs as well. In patients with
active GVHD or with EBV reactivation, defined as a VL > 50 c/ml plasma, monitoring was
performed twice a week. Pre-emptive treatment of EBV reactivations was instituted when
the EBV VL was > 1000 c/ml and consisted of rituximab (Mabthera™, Roche, Basel,
Switzerland), an anti CD20 monoclonal antibody, given as a single infusion (375 mg/m2) as
described1,14. Immunosuppressive medication was decreased or stopped if possible.
Furthermore, valacyclovir, given to all patients prophylactically in a dose of 500 mg twice a
day, was increased to 1 gram 3 times a day.
Mouth washes From all patients and family donors MWs were collected pre-transplant
by gargling the mouth with 15 ml phosphate buffered salt (PBS) during 1 minute. After cen-
trifugation of the MWs for 10 minutes at 900g, the cell pellet (resuspended in 400 µL PBS)
and the supernatant were stored separately at -70° C until use. The cell pellet was used to
detect EBV by realtime Taqman™ EBV DNA PCR assay. When EBV was detected in these
MWs, also post-transplant MWs were collected.
Peripheral blood mononuclear cells In 17 patients EBV DNA PCR monitoring
post-transplant was performed in PBMCs as well. EBV reactivation in PBMCs was defined as
a VL > 50 c/106 cells. PBMCs were isolated from 9 ml of EDTA-anticoagulated peripheral
blood by Ficoll-Paque density centrifugation (Amersham Pharmacia Biotech AB, Uppsala,
Sweden) at 1000g for 10 minutes, without brake. PBMCs were washed twice with PBS and
stored at -70° C.
DNA isolation DNA from plasma was isolated with the MagNA Pure LC™ total nucleic
acid isolation kit - large volume (Roche Diagnostics, Almere, the Netherlands). DNA from
MWs-cell pellets or PBMCs was isolated with the MagNA Pure LC™ DNA isolation kit I by an
automated nucleic acid extractor (MagNA Pure extractor, Roche Diagnostics, Almere, the
Netherlands).
63
 	

Realtime TaqManTM EBV DNA PCR A quantitative realtime EBV DNA PCR assay
was performed as described by Niesters et al15. Test results were quantified by comparison
with a standardised control (EBV B95-8, Advanced Biotechnologies Incorporated, Columbia,
Md.). As an internal control a standardised quantity of phocine herpes virus was added to
each sample. EBV test results < 50 c/ml were considered negative. In order to quantify EBV
DNA in MWs-cell pellets and PBMCs an albumin realtime TaqMan™ PCR was performed in
these samples as well. The primers used for the albumin PCR were 5’-TGA.AAC.ATA.
CGT.TCC.CAA.AGA.GTT.T-3’ (forward primer) and 5’-TCT.CTC.CTT.CTC.AGA.AAG.TGT.
GCA.TA-3’ (reverse primer). A fluorogenic probe (5’-TGC.TGA.AAC.ATT.CAC.CTT.CCA.TGC.
AGA-3’) was synthesised by PE Biosystems (Nieuwerkerk ad IJssel, the Netherlands) with a
FAM reporter molecule attached to the 5’ end and a TAMRA quencher linked at the 3’ end.
VL in PBMCs is depicted as c/106 cells.
EBV strain typing Because EBV DNA encoding the EBV LMP-1 gene is most variable, a
nested PCR targeting the EBV LMP-1 C-terminus gene was used to determine sequence vari-
ations. The PCR was performed using a modified primer scheme according to Knecht et al8.
Sequences of the outer primers 5 and 12 (primer 12 was modified) were: 5’-
CTA.CAA.CAA.AAC.TGG.TGG.ACT-3’, position (168.843-168.823) and 5’-AGA.CAG.TGT.
GGC.TAA.GGG.AGT-3’, position (168.059-168.039), respectively. Sequences of the inner
primers 8’ and 11 were: 5’-TGC.TCT.CAA.AAC.CTA.GGC.GCA-3’, position (168.609-
168.589) and 5’-TGA.TTA.GCT.AAG.GCA.TTC.CCA-3’, position (168.075-168.095), respec-
tively. The nested PCR product of the LMP-1 C-terminus PCR was used for sequencing as
described11. Positions of the nucleotides were compared to the reference strain B95-816.
Statistical analysis Differences between groups were compared using Fisher’s exact
test or Pearson chi-square analyses, whichever was appropriate, in case of discrete variables.
In case of continuous variables a Students t-test or Mann Whitney U test, whichever was
appropriate, was used. Probability of EBV reactivation was calculated by the cumulative inci-
dence procedure, death without EBV reactivation being the competing risk. The following
variables were included in the analysis of prognostic factors: age, risk status (low vs high),
recipient CMV serostatus (negative vs positive), donor type (related vs unrelated), graft
characteristics (CD34+ cell count, T/B cell ratio), CMV reactivation (no vs yes), aGVHD
(No-I vs II-IV). Univariate analyses were performed using the log rank test. Variables which
showed to influence EBV reactivation at a level of p<0.1 were used in a multivariate Cox
regression analysis. P values from regression models were calculated with the Wald test. The
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post-transplant variables ‘CMV reactivation’ and ‘aGVHD’ were as well analysed as time-
dependent covariates. Calculations were performed using SPSS/PC+ 10.0 (SPSS Inc,
Chicago Il, USA).
Results
Patients (Table 1). Fifty-three patients were monitored weekly for EBV reactivation by
quantitative EBV DNA detection in plasma. Twenty-six patients received grafts from MRDs,
27 from MUDs. MRD recipients were significantly older and were more often diagnosed with
aGVHD grade II-IV compared to MUD recipients (44 vs 35 year and 50% vs 22%, respec-
tively). The incidence of CMV reactivations was 4% in the MRD group compared to 22% in
the MUD group, however, this difference was not significant.
EBV reactivations in plasma samples (Table 2). Among MRD recipients 7 (27%)
patients showed an EBV VL > 50 c/ml. All 7 patients were EBV-seropositive and had a
seropositive donor. Two of these 7 had a VL > 1000 c/ml and received anti B cell therapy
with rituximab which resulted in clearance of plasma EBV DNA in one patient. The second
patient suffered from aGVHD grade III and was given rituximab 3 times with intervals of one
week. EBV VL was not responding. She finally died from pulmonary bleeding during severe
aGVHD, without symptoms of EBV-LPD.
Among MUD recipients 16 (59%) patients showed an EBV VL > 50 c/ml. Twelve
patient/donor pairs were EBV-seropositive (R+/D+), 2 patients were seropositive while
their donor serostatus was unknown, one patient was seropositive and had a negative
donor, one patient/donor pair was seronegative (R-/D-). Nine of these 16 had a VL > 1000
c/ml and received anti B cell therapy with rituximab which resulted in clearance of plasma
EBV DNA in 6 patients. One of these 6 patients had lymphadenopathy and an EBV VL 
> 1000 c/ml at the same day. Pathologic and immunohistochemical examination of a lymph
node was consistent with EBV-LPD. The seventh patient most probable was suffering from
EBV-LPD with central nervous system (CNS) involvement. This patient received intensive
immunosuppression because of aGVHD grade III and was treated with rituximab once,
thereafter further treatment was refused and death resulted from rapid neurological deterio-
ration. The two other patients showed increasing VL after treatment with rituximab given
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Table 1 Patient characteristics
MRD MUD P-value
(%) (%)
No. of patients 26 27
Age (range) 44 (21-53) 35 (17-55) 0.002
Diagnosis ns
AML 4 (15) 8 (30)
ALL 4 (15) 6 (22)
CML 3 (12) 6 (22)
SAA 1 (4) 0
Other 14 (54) 7 (26)
Risk status ns
Low 10 (39) 6 (22)
High 16 (61) 21 (78)
EBV serostatus ns
R+/D+ 23 (89) 19 (70)
R+/D? 0 4 (15)
R+/D- 1 (4) 3 (11)
R-/D+ 2 (8) 0
R-/D- 0 1 (4)
CMV serostatus ns
R+/D+ 10 (39) 8 (30)
R+/D- 4 (15) 7 (26)
R-/D+ 1 (4) 4 (15)
R-/D- 11 (42) 8 (30)
aGVHD 0.035
No-I 13 (50) 21 (78)
II-IV 13 (50) 6 (22)
CMV VL>1000 c/ml ns
Yes 1 (4) 6 (22)
No 25 (96) 21 (78)
/ = recipient/donor.
twice. Donor lymphocytes were infused (1 x 105 T cells/kg), resulting in a clearance of
plasma EBV DNA in both patients.
Median time to EBV reactivation and median maximum VL showed a trend to be shorter and
higher, respectively, in MUD compared to MRD recipients (57 vs 109 days and 1788 vs 190
c/ml, respectively, ns). Seven patients had complete responses after rituximab therapy. In 6
patients rituximab was given once, in the seventh patient twice. Median time to clearance of
plasma EBV DNA after rituximab infusion was 10 days (range: 7-34). No recurrent EBV reac-
tivations were diagnosed.
After multivariate analysis of prognostic factors for EBV reactivation (VL > 1000 c/ml) only
CMV reactivation and a lower CD34+ cell count in the graft affected the incidence of EBV
reactivation (p<0.001 and p=0.072, respectively). Multivariate analysis of only pre-trans-
plant factors revealed that ‘donor type’ was the most important factor influencing the inci-
dence of EBV reactivation (p=0.036, Figure 1). Since 6 of 7 CMV reactivations occurred in
MUD recipients (see Table I), it is obvious there is an interaction between ‘CMV reactivation’
and ‘donor type’.
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Table 2 Characteristics of EBV reactivations in plasma samples of MRD and MUD
recipients
MRD MUD P-value
(n=26) (n=27)
No. of patients with EBV VL>50 c/ml (%) 7 (27) 16 (59) 0.018
No. of patients with EBV VL>1000 c/ml (%) 2 (8) 9 (33) 0.021
Median time to EBV reactivation 109 57 ns
(d; range) (24-172) (17-180)
Median maximum viral load 190 1788 ns
(c/ml; range) (135-9958) (85-139.495)
Median time to EBV DNA clearance after 
rituximab in complete responders (d; range) 10 (7-34)
d = days.
EBV reactivations in plasma and PBMC samples (Table 3). In 17 patients
(MRD: n=9; MUD: n=8) EBV monitoring was performed in plasma and PBMCs as well.
Only 4 of 17 (23%) patients showed a reactivation in plasma samples compared to 15 of 17
(88%) in PBMC samples (p<0.001). Median time to EBV reactivation and median maximum
VL showed a trend to be shorter and higher, respectively, in PBMC samples compared to
plasma samples (49 vs 95 days and 5568 vs 2470 c/ml, respectively, ns). None of the
patients with a reactivation in PBMCs only received rituximab and none progressed to EBV-
LPD.
LMP-1 sequences of EBV in mouth washes and plasma or PBMC samples
(Table 4). In six patients pre-transplant EBV DNA from mouth washes and post-transplant
EBV-DNA from plasma or PBMCs were successfully obtained and could be used for sequence
analysis. In two of these, patient 5 and 6, also post-transplant mouth washes were analysed.
Patient 1 and 2 were recipients of related grafts, only from donor 1 an EBV DNA positive
mouth wash was obtained. Patients 3-6 were recipients of unrelated grafts, no donor mouth
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Figure 1
EBV reactivations in recipients of MUD or MRD grafts.
washes were available. In 5 of 6 patients EBV serostatus was positive in both patients and
donors. Patient 5 had a positive EBV serostatus, whereas donor serostatus was unknown.
In all 15 samples tested, a sequence pattern could be determined. Eight of these 15 patterns
were unique. In 3 of 6 patients (patient 2, 3, and 5) the post-transplant EBV sequence pat-
tern differed from the pre-transplant pattern, indicating a re-infection post-transplant with
an exogenous strain rather than a reactivation of the original endogenous EBV strain. In
patient 1 it is not possible to differentiate since pre-transplant, post-transplant and donor
sequence patterns were identical. In patient 4 pre- and post-transplant sequence patterns
were identical too, which indicates that a reactivation of the endogenous EBV strain is likely
in this patient. Post-transplant EBV strains of patient 6 differed by only one nucleotide from
the pre-transplant strain. This might have been the result of a point mutation during viral
replication, making a definite conclusion about reactivation or re-infection impossible
although it is more likely that this patient suffered a reactivation.
Finally, 3 of 53 recipients were EBV-seronegative pre-transplant. In 2 of these patients
(1 MRD recipient with an EBV-seropositive donor; 1 MUD recipient with an EBV-seronega-
tive donor) an EBV primo-infection was documented post-transplant.
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Table 3 Results of double monitoring in plasma and PBMC samples of 17
patients
Plasma PBMC P-value
No. of patients with EBV VL>50 c/ml (%) 4 (23) 15 (88) <0.001
Median time to EBV reactivation 95 49 0.079
(d; range) (47-159) (17-131)
Median maximum viral load 2470 5568 ns
(c/ml; range) (135-12.175) (190-937.500)
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Table 4 LMP-1 sequences of EBV in mouth washes and plasma or  PBMC samples
168357 C G A G A A G G G A A A
168356 A C G G
168355 A T T T T T
168352 G T
168341 T A
168339 G C C C C
168337 A C C
168330 G C
168329 G A
168320 A G G G G G G G G G G
168309 T C
168308 T C C C C C C C C C C C
168295 A T T T T T T T T T T T
168293 G A
168279 C - - A A - - -
168275 A - - C - - -
168269 G - - C C - - -
168267 C A - - - - -
168266 A G G - - G G G - - -
168257 G A - - - - -
168253 T C C C C
168248 A C
168238 G A A A A A
No. of differences 0 10 11 0 5 1
Donor type MRD MRD MUD MUD MUD MUD
SS R/D +/+ +/+ +/+ +/+ +/? +/+
SS= EBV serostatus; R/D= recipient/donor.
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Discussion
Our study shows that EBV reactivations in recipients of partially TCD SCT occur very fre-
quently, especially among recipients of MUD transplants. When EBV DNA was monitored in
PBMCs, significantly more patients showed EBV reactivations compared to plasma samples.
In all patients with a PBMC EBV reactivation only, a spontaneous clearance of EBV DNA was
observed and none progressed to EBV-LPD. Of 11 patients with a plasma EBV reactivation
and a VL > 1000 c/ml, two developed EBV-LPD (18%) despite pre-emptive therapy with
anti CD20 Mabs. In 6 patients, LMP-1 sequences could be determined in pre- and post-trans-
plant samples, enabling EBV strain identification. In 3 of 6 patients the post-transplant EBV
strain differed from the pre-transplant strain, indicating a re-infection with an exogenous
strain.
In patient 1, who received a graft from a matched related donor, the pre-transplant, post-
transplant and donor strains were identical. It is known from other studies6,17 that intrafa-
milial spread does play an important role in EBV transmission. In these two studies, EBV
DNA RFLP and size variation of the EBNA proteins expressed in EBV transformed lym-
phoblastoid cell lines (ebnotyping) were used to distinguish EBV strains. It was found that
different members of the same family could carry the same EBV strain and that a given EBV
strain was observed only within a single family. All unrelated individuals (apart from one
husband and wife) did carry individually distinct viral strains17. In the setting of allogeneic
SCT, in 4 of 6 related patient/donor pairs similar strains were isolated pre-transplant in
patients and donors18. Therefore, our finding of identical recipient and sibling donor strains
is not unusual and does not allow differentiation between reactivation and re-infection.
Identical strains in pre- and post-transplant samples were also found in patient 4, a MUD
recipient. These results also indicate the feasibility of LMP-1 sequence analysis for strain
identification.
The technique we used to characterise EBV strains has also been used by others9-11. In those
studies and the present report the EBV strain found in patient 1 and 4 is relatively common,
making a definite exclusion of a re-infection impossible. All other identified strains showed
unique sequences. The finding that a specific EBV strain was carried by several unrelated
individuals, is different from data published by Gratama et al17 and Katz et al6. These
authors showed that all unrelated individuals carried individually distinct viral strains, when
strain identification was performed by ebnotyping or RFLP.
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The post-transplant EBV strains of patient 6 differed by only one nucleotide from the pre-
transplant strain. This might have been the result of a point mutation acquired during viral
replication, making it more likely that this patient suffered a reactivation instead of a re-
infection.
In combination with previously published data, the present data show that the original EBV
strain could no longer be detected post-transplant in 5 of 9 patients (see Table 5). We con-
clude that in these patients a re-infection with an exogenous strain has occurred. It is well
known that EBV persistence requires the establishment of a latent infection in circulating B
cells. As EBV replicates poorly in B cells in vitro, oropharyngeal epithelial cells have long
been considered to be the site of EBV replication19,20,21. If the oropharyngeal epithelium is a
permanent EBV reservoir, one would expect the pre-transplant EBV strain of the recipient to
persist after SCT. The absence of the pre-transplant EBV strain in 5 of 9 patients, however, is
inconsistent with that assumption. Furthermore, in patients with X-linked agammaglobu-
linemia, who are deficient in mature B cells, no evidence of past or present EBV infection in
mouth washings and peripheral blood samples could be found19,20. However, our findings
can not prove the eradication of endogenous strains, since multiple infections do occur in
immunocompromised patients22-25 and the original endogenous strain might have become
non-dominant.
72
 
Table 5 Results of studies performing EBV strain typing in patient/donor pairs
Study No. of patients Origin of EBV strain post-transplant
Endogenous Exogenous
Gratama4* 2 0 2 (1 donor, 
1 husband)
Gratama18* 1# 1 0
Van Kooij11** 1 1 0
Present study ** 5# 2$ 3
* = EBV strain typing with "Ebnotyping"; ** = EBV strain typing using LMP-1 sequence analysis; # = In both studies more
patient/donor pairs (n=4 in Gratama et al; n=1 in the present study) were analysed. These pairs were related and pre-,
post-transplant and donor strains were identical. Therefore, no differentiation was possible between endogenous reactiva-
tion or exogenous re-infection; $ = Exogenous re-infection is unlikely, however, has not been excluded.
In 20 healthy asymptomatic EBV carriers, EBV strains present in mouth washes and periph-
eral blood were recently found to differ very often26. These authors used a very sensitive
heteroduplex tracking assay. Their findings are not supported by other studies among a total
of 267 healthy individuals23,27. We were able to compare EBV strains from mouth washes
with strains from PBMCs in two patients. In both patients, EBV strains from the two com-
partments were identical. Therefore, current knowledge does not support the hypothesis of
compartmentalisation of EBV infections.
Analysis of two solid organ transplant recipients with EBV-LPD, showed that EBV transmis-
sion from donor cells to host cells is possible. The EBV strain identified was of donor origin,
while in both patients the lymphoma resulted from proliferation of B lymphocytes of recipi-
ent origin7. This finding suggests that, apart from EBV transmission from transplant B cells
to host cells, other routes of transmission (oral or by transfusions) are possible as well,
which is supported by the documented primo-infection of our EBV-seronegative (Recipient-
/Donor-) patient.
In conclusion, EBV reactivation is a very frequent event, especially in recipients of TCD
grafts from matched unrelated donors and it frequently results from a re-infection with an
exogenous EBV strain instead of a true reactivation of the endogenous strain.
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Abstract
In this report the influence of T vs T and B cell depletion of grafts on the incidence of EBV-
associated lymphoproliferative disorders (EBV-LPD) after bone marrow transplantation
(BMT) from matched unrelated donors (MUD) is analysed. From 1982 to 1997 the Soy Bean
Agglutinin/Sheep Red Blood Cell (SBA/SRBC) method, which has a risk of transmitting pri-
ons or viruses, was used for T cell depletion. Because of this risk a new T cell depletion
method was introduced, using CD2 and CD3 monoclonal antibodies (CD2/3 method), which
led to an unexpected increase in EBV-LPDs in MUD recipients. SBA depletion was reintro-
duced and combined with the CD2/3 method (SBA/CD2/3) in this patient population, later
replaced by B cell specific (CD19 and CD22) antibodies (CD3/19/22 method). The number
of T (x105/kg) and B (x105/kg) cells in the graft was 1.5 ± 0.8 and 2 ± 1 (T/B ratio 0.75),
2.2 ± 2.0 and 41 ± 21 (ratio 0.055), 5.0 ± 0.0 and 2 ± 1 (ratio 2.5), 2.5 ± 1.2 and 10 ± 6
(ratio 0.25) using the SBA/SRBC, CD2/3, SBA/CD2/3 and CD3/19/22 techniques, respec-
tively. When B cell depletion was performed 4 out of 31 (13%) MUD recipients developed
an EBV-LPD. Without B cell depletion (CD2/3 method) this occurred in 5 out of 7 patients
(71%) (p<0.05). A T/B cell ratio in the graft of ≥ 0.25 seems sufficient to reduce signifi-
cantly the incidence of EBV-LPD after BMT from MUDs.
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Introduction
After bone marrow transplantation (BMT) from a matched unrelated donor (MUD) trans-
plant related morbidity and mortality are increased compared to BMT from a matched
related donor (MRD). This is largely due to an increased incidence of graft-versus-host dis-
ease (GVHD) and infectious complications1,2. T cell depletion reduces the incidence and
severity of GVHD but has also important side-effects3. Curtis et al4 showed that the risk of
Epstein-Barr-virus-associated lymphoproliferative disorders (EBV-LPDs) was strongly associ-
ated with T cell depletion of donor marrow. Use of Antithymocyteglobulin (ATG) and of
grafts from unrelated or HLA-mismatched related donors were other adverse risk factors for
the development of EBV-LPD. The risk for EBV-LPD varied according to the techniques used
for T cell depletion, being lowest when the Campath-1 method was used which, in contrast
to T cell specific monoclonal antibodies (Moabs), removed both T and B cells4.
In this report the influence of the T vs T and B cell depletion method on the incidence of
EBV-LPD among MUD transplant recipients is described, as was observed at our institute.
From 1982 to 1997 the Soy Bean Agglutinin/Sheep Red Blood Cell (SBA/SRBC) method
was used for T cell depletion. This technique has been well established, but the use of SRBC
has a risk of transmitting prions or viruses. Therefore, a new T cell depletion method was
introduced, the immunorosette (IR) technique, using tetrameric complexes with T cell spe-
cific CD2 and CD3 Moabs instead of sheep red blood cells. Unfortunately, this led to an
unexpected high number of EBV-LPDs in patients receiving transplants from MUDs. Since it
was suspected that this was caused by the relatively high number of B cells in the graft, SBA
depletion -which results in B cell depletion of 1 to 1.5 log- was reintroduced and combined
with CD2/3 depletion from May 1998 (SBA/CD2/3 method). In March 1999 SBA was
replaced by B cell specific (CD19 and CD22) antibodies (CD3/19/22 method).
Methods
Patients From November 1985 to April 2000 a total of 313 patients received allogeneic
BMT, 49 from a MUD and 264 from a Matched Related Donor (MRD). Eleven MUD and 63
MRD transplant recipients died within 6 months after BMT from relapse or transplant
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related toxicity, apart from EBV-LPD and were therefore not evaluable for this study. The
interval of 6 months was chosen because most EBV-LPDs develop during the first 6 months
post-transplant4. The distribution of patients according to T cell depletion used is shown in
Table 1. Characteristics of recipients of MUD transplants are described in Table 2. All
patients were treated with clinical protocols approved by the local investigation review
board and gave informed consent.
Transplantation procedure Conditioning regimens consisted of cyclophosphamide
(60 mg/kg/day) on each of two successive days, followed by total body irradiation (600
cGray/day) on each 2 successive days. The graft was infused after the second TBI fraction
(day 0). ATG (Thymoglobulin™, Sangstat, Amstelveen, the Netherlands) was given to MUD
patients before cyclophosphamide was started, at a total dose of 20 mg/kg intravenously. It
was lowered to a total dose of 8 mg/kg since April 1999. All patients received cyclosporin
from day -2 in a dose of 3 mg/kg/day by continuous infusion for 4 weeks, thereafter it was
given orally for 4-6 weeks in a dose that gave comparable through levels, followed by taper-
ing. Cyclosporin was discontinued within 3 months after transplantation if no active GVHD
was observed. Infection prevention for all patients consisted of ciprofloxacin, fluconazole
and amphotericin B given orally until granulocyte counts exceeded 500 cells/mm3.
Cephalothin was given intravenously for 10 days from day +3. Furthermore co-trimoxazole
and valacyclovir were given orally from day +1 until 12 months post-BMT. GVHD was diag-
nosed according to the Seattle criteria5. Acute GVHD grade I was treated with topical corti-
costeroids; grade II or higher was treated with systemic corticosteroids as described6.
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Table 1 Number of BMTs according to depletion technique
Depletion MUD NE MRD NE
technique patients patients
SBA/SRBC 19 5 202 54
CD2/3 11 4 62 9
SBA/CD2/3 6 0
CD3/19/22 13 2
SBA/SRBC = soy bean agglutinin/sheep red blood cell; SBA/CD2/3 = SBA agglutination followed by depletion with anti
CD2 and CD3 Moabs; CD2/3 = depletion with anti CD2 and CD3 Moabs; CD3/19/22 = depletion with anti CD3, CD19 and
CD22 Moabs; NE = not evaluable because of early death.
Extensive chronic GVHD was treated with systemic corticosteroids, sometimes combined
with cyclosporin. During the first 4 months post-transplant, CMV-seropositive patients who
demonstrated reactivation of CMV infection or those who were treated with high-dose corti-
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Table 2 Characteristics of recipients of MUD transplants
SBA/SRBC CD2/3 SBA/CD2/3 CD3/19/22
No. of patients 14 7 6 11
Age, year (range) 29 (17-47) 28 (18-37) 31 (22-47) 32 (18-48)
Diagnosis
ALL 5 1 1 2
AML 0 3 0 4
CML 6 1 2 4
MDS 1 0 1 1
SAA 2 2 2 0
Sex
F/F 3 0 0 3
M/M 5 3 3 4
M/F 5 1 2 3
F/M 1 3 1 1
CMV serostatus R/D
-/- 2 2 3 3
+/+ 1 2 1 2
-/+ 5 1 1 4
+/- 6 2 1 2
GVHD
Acute
I/II 10 4 2 5
III/IV 1 1 0 2
None 3 2 4 4
Chronic 
L 3 1 0 0
E 6 0 1 0
NE 0 3 0 1
None 5 3 5 10
R/D = recipient/donor; NE = not evaluable; L = limited;  E = extensive.
costeroids received pre-emptive or prophylactic therapy, respectively, with ganciclovir in a
dose of 2.5 mg/kg intravenously twice a day for 14 days7.
HLA-matching In all MRD patient/donor pairs, class I antigens (A, B and Cw) were
analysed by serological typing, in case of doubt low resolution molecular typing was per-
formed. Class II antigens (DRB1, DRB3, DRB4, DRB5 and DQB1) were analysed by serologi-
cal typing until 1993 and since 1993 by low resolution molecular typing with sequence
specific primers. In MUD patient/donor pairs HLA analysis was performed as in MRD recipi-
ents until 1993, thereafter class I antigens (A, B) were analysed by serological typing, in
case of doubt low resolution molecular typing was performed. Class I Cw and class II anti-
gens (DRB1, DRB3, DRB4, DRB5 and DQB1) were analysed by low resolution molecular typ-
ing with sequence specific primers and DRB1, B3, B4 and B5 antigens were as well defined
by high resolution typing since January 1999.
T and B cell depletion SBA/SRBC T cell depletion was performed as described8. The
immunorosette depletion technique (CD2/3) was performed as described by Slaper-
Cortenbach et al9. In short, tetrameric complexes (CLB, Amsterdam, the Netherlands) were
formed by addition of cross-linking RaMIgG1 Moabs to a mixture of murine IgG1 Moabs,
one directed against glycophorin A in the membrane of human erythrocytes and another
against T cell specific antigens (CD2 or CD3). These complexes were then bound to donor
erythrocytes (in case of a MUD transplant obtained from a healthy O-rhesus negative donor
from the blood bank) and the coated erythrocytes were washed. After addition of the coated
erythrocytes to the bone marrow buffycoat cells, prepared using the COBE 2991,
immunorosettes formed. These immunorosettes were removed using Ficoll density separa-
tion (d=1.077 g/cm3). In the SBA/CD2/3 method Ficoll density separation was used to pre-
pare mononuclear cells, subsequently SBA was used with the CD2 and CD3 tetrameric
complexes instead of SRBC. The CD3/19/22 method used tetrameric complexes with CD3,
CD19 and CD22 Moabs for depletion of T and B cells. All monoclonal antibodies were tested
for viral and bacterial contamination and, therefore, biosafe. In all T/B cell depletion proce-
dures the residual number of T cells was counted and nonmanipulated T cells (from a small
BM fraction that was set apart before the stem cell manipulation started) were added to
obtain a low fixed number of T cells6. This fixed number of T cells in the graft differed per
depletion technique (SBA/SRBC: 1 x 105 T cells/kg; CD2/3: 1 x 105 T cells/kg; SBA/CD2/3:
5 x 105 T cells/kg; CD3/19/22: 2 x 105 T cells/kg). In some grafts the residual number of T
cells after depletion was above the fixed number, no T cell add-back was performed in these
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grafts. T/B cell depletion was evaluated by Facs analysis (FACScan, Becton Dickinson
Immunocytometry Systems (BDIS), San Jose, CA) on unmanipulated bone marrow and
depleted marrow using monoclonal antibodies (CD2-FITC, CD3-PE, CD19-PE, CD20-FITC,
CD45-PERCP (Becton Dickinson)).
EBV-LPD EBV-LPD was diagnosed by standard histological criteria10. CD20 antibodies
were used to assess the B cell origin of the LPD. The presence of EBV infection was deter-
mined immunohistochemically by detection of EBNA-2 and LMP-1 proteins and with in-situ
hybridisation to detect EBV-encoded RNA (EBER).
Statistics Data are expressed as mean ± SD. Mean differences between groups were
assessed by the Mann Whitney U test or Chi square analysis. Calculations were performed
using SPSS/PC+ 8.0 (SPSS Inc, Chicago Il, USA).
Results
Incidence of EBV-LPD The incidence of EBV-LPD is summarized in Table 3. When B
cell depletion was performed (SBA/SRBC, SBA/CD2/3, CD3/19/22) 4 out of 31 patients
(13%) receiving BMT from a MUD developed an EBV-LPD, being the cause of death in 3
patients. Without B cell depletion (CD2/3) 5 out of 7 patients (71%) receiving BMT from a
MUD developed an EBV-LPD and two died of this disease. This resulted in a significant dif-
ference (p<0.05) between B cell depleting techniques and a non-B cell depleting technique
concerning the incidence of EBV-LPDs. In contrast to MUD recipients, among patients receiv-
ing BMT from an HLA-identical sibling donor the incidence of EBV-LPD was similar when a
T and B cell depletion method was used (SBA/SRBC) compared to a T without B cell deple-
tion method (CD2/3). The incidence was 5 and 4%, respectively.
T and B cell numbers in the graft T and B cell counts in the MUD grafts ‘according
to depletion technique’ are shown in Table 4. The SBA/CD2/3 group received significantly
more T cells (p<0.05), compared to all other groups. This was not due to depletion failure
as can be seen from the log depletion reached. In fact, the SBA/CD2/3 was the most effi-
cient T cell depletion method. As has been described earlier, after T cell depletion the resid-
ual number of T cells was counted and nonmanipulated T cells were added to obtain a low
fixed number of T cells (1-5 x 105 T cells/kg recipient weight). In the SBA/CD2/3 group this
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number was set at 5 x 105/kg. In the SBA/SRBC depleted grafts, B cell numbers were not
measured. We can assume, however, that the SBA/SRBC method should yield a B cell deple-
tion comparable to the SBA/CD2/3 method (confirmed by experiments in the laboratory). B
cell numbers were not measured in CD2/3 depleted grafts of unrelated donors as well.
When the incidence of EBV-LPD increased dramatically in MUD recipients and it was sus-
pected to be due to the relatively high number of B cells in the graft, SBA agglutination was
performed prior to CD2/3 depletion. Since then B cells were measured in all grafts (CD2/3
depleted grafts from MRDs, SBA/CD2/3 and CD3/19/22 depleted grafts from MUDs). The
CD2/3 group (data derived from MRD transplants) received significantly more B cells com-
pared to all other groups: 41 ± 21 x 105/kg vs 2 ± 1 (SBA/CD2/3) and 10 ± 6
(CD3/19/22); p<0.001. The T/B cell ratio in the graft according to depletion method was
0.75 for the SBA/SRBC group (ratio was calculated using the B cell count from the
SBA/CD2/3 method), 0.055 for the CD2/3 method, 2.5 for the SBA/CD2/3 group and 0.25
for the CD3/19/22 technique. It should be noted that in this last group ATG dose was
reduced. Therefore in vivo T cell depletion due to ATG in this group is expected to be less
than in the other three groups11.
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Table 3 EBV-LPD according to depletion technique
Depletion MUD EBV-LPD DOD MRD patients EBV-LPD DOD
technique patients (%) (%)
SBA/SRBC 14 3 (21) 2 148 7 (5) 5
CD2/3 7 5 (71) 2 53 2 (4) 0
SBA/CD2/3 6 0 (  0) 0
CD3/19/22 11 1 (  9) 1
EBV-LPD = EBV-associated lymphoproliferative disease; DOD = died of EBV-LPD.
Discussion
The most important observation of this report is the significantly increased incidence of EBV-
LPD in patients receiving BMT from an unrelated donor which was T but not B cell depleted
with an immunorosette technique, using CD2 and CD3 Moabs. Among MRD patients the
incidence of EBV-LPD was not influenced by B cell depletion. The SBA/SRBC depletion
method was abandoned in 1997 because the use of SRBC has a risk of transmitting prions or
viruses. The Moabs used in the immunorosette technique were biosafe (screened for viral
and bacterial contamination). The CD2/3 depletion method had proven to result in a similar
T cell depletion (Table 4). Engraftment and haematopoietic recovery were comparable for
the two techniques (data not shown). Until 1998 there were no reports showing the impor-
tance of B cell depletion for prevention of EBV-LPD. Resting memory B cells are thought to
be the natural reservoir of EBV within the body12. The B cell load of patient origin has been
largely destroyed due to the pre-transplant myeloablative conditioning regimen. Gratama et
al13,14 showed that also latently EBV-infected host cells can be eliminated after BMT.
Therefore, theoretically, B cell depletion of the graft along with T cell depletion might
improve immunological control of EBV infection post-transplant. Indeed, Cavazzana et al15
showed that none of 19 patients receiving transplants from a partially matched related
donor (PMRD) developed EBV-LPD when ex vivo T and B cell depletion was performed,
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Table 4 Depletion of T and B cells from marrow grafts of matched unrelated
donors
Technique T cell count Log B cell count Log ATG Ratio
in graft depletion in graft depletion dose T/B
(x105/kg) T cells (x105/kg) B cells
SBA/SRBCa 1.5 ± 0.8 2.3 ± 0.6 nd HD 0.75
CD2/3b 2.2 ± 2.0 2.3 ± 0.4 41 ± 21 0.2 ± 0.1 HD 0.055
SBA/CD2/3 5.0 ± 0.0 3.2 ± 0.5 2 ± 1 2.0 ± 0.2 HD 2.5
CD3/19/22 2.5 ± 1.2 3.0 ± 0.7 10 ± 6 1.1 ± 0.2 LD 0.25
a = to calculate the T/B cell ratio, B cell count from the SBA/CD2/3 group was taken; b = B cell count was measured in a
group of 24 patients receiving a transplant from a MRD; HD = high dose (20 mg/kg); LD = low dose (8 mg/kg).
whereas 7 out of 19 historical controls developed EBV-LPD when only T cell depletion was
performed. Two other studies showed that B cell depletion might be of benefit for decreas-
ing the incidence of EBV-LPD16,17. Our report emphasizes the importance of B cell depletion,
in patients receiving T cell depleted grafts from matched unrelated donors. In MRD recipi-
ents T cell depletion without B cell depletion did not result in an increased incidence of EBV-
LPD. Therefore, next to ex vivo T cell depletion, there have to be other factors which impair
immune surveillance of the Epstein-Barr virus in MUD recipients. Recently it was shown that
TCD together with the use of ATG were important factors influencing EBV reactivation post-
transplant18. All our MUD patients received ATG, giving in vivo T cell depletion as well11. In
MUD recipients the ratio of T and B cells in the graft seems to be very important for surveil-
lance of EBV. When high dose ATG was used pre-transplant, a T/B cell ratio of 2.5 was suffi-
cient to prevent EBV-LPD in 6 patients (SBA/CD2/3 group). When low dose ATG was used,
a ratio of 0.25 did not prevent EBV-LPD totally: 1 out of 11 patients developed EBV-LPD
(CD3/19/22 group). The actual T/B cell ratio in vivo might have been higher in this group
due to a less severe in vivo T cell depletion. The optimal T/B cell ratio is not known at the
moment and will be dependent on several factors such as use and dosage of ATG. The num-
ber of patients in our study is limited, so further studies are necessary to establish the degree
of B cell depletion needed for efficient prevention of EBV-LPD in patients receiving T cell
depleted grafts from donors other than HLA-matched siblings. In the study of Cavazzana et
al15 B and T cell counts in the grafts were 5 ± 8.5 x 105/kg and 1.5 ± 1.7 x 105/kg, respec-
tively. This gave a ratio of 0.3 and no EBV-LPD was observed post-transplant. These and our
data suggest that a ratio ≥ 0.25 can markedly reduce EBV-LPD in such patients.
In conclusion, our data show that the incidence of EBV-associated lymphoproliferative disor-
ders in recipients of allogeneic bone marrow transplants from matched unrelated donors is
increased when T cell depletion of the graft is performed, without B cell depletion. We
replaced the SBA/SRBC technique for a new technique, based on the use of Moabs instead
of SRBC. This resulted in a disproportional higher number of residual B cells in the graft
and, consequently, in a dramatic increase in EBV-LPD in recipients of T cell depleted stem
cell transplant from matched unrelated donors.
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Abstract
Reactivations of the Epstein-Barr virus (EBV), which may progress to EBV-associated lym-
phoproliferative disorders (EBV-LPD), are a major threat in recipients of allogeneic bone
marrow and solid organs. An overview is given of the monitoring and pre-emptive treatment
of EBV reactivations and the incidence, prevention and therapy of EBV-LPD.
Several risk factors for the development of EBV-LPD after solid organ transplantation (SOT)
and bone marrow transplantation (BMT), respectively, have been identified: 1) primary EBV
infection in EBV-seronegative patients, 2) type of transplanted allograft, 3) cytomegalovirus
(CMV) serostatus mismatch (R-/D+), 4) CMV disease 5) use of T cell antibodies in SOT
recipients and 1) T cell depletion (TCD) of grafts, 2) use of unrelated or ≥ 2 HLA antigen
mismatched related donors, 3) use of Antithymocyteglobulin or 4) anti CD3 monoclonal
antibodies (Moabs) in BMT recipients. In high-risk BMT recipients, monitoring of EBV viral
load (VL) in preferably cell free plasma should be performed once a week until 6 months
post-transplant. No strict guidelines for frequency and duration of monitoring in SOT recipi-
ents can be given, largely due to the variable time period in which post-transplant EBV-LPDs
can occur in this patient group. However, in high-risk SOT recipients monitoring may be
performed fortnightly or at every outpatient visit until 1 year post-transplant. When EBV
reactivation is diagnosed, pre-emptive therapy with anti B cell Moabs is advised in BMT as
well as SOT recipients. In BMT recipients receiving T cell depleted grafts from unrelated
donors, additional B cell depletion can reduce the incidence of EBV-LPD dramatically.
Treatment of EBV-LPD should start with withdrawal of or decreasing immunosuppression
together with anti B cell Moabs. Donor lymphocyte infusion should be reserved for BMT
recipients not responding to anti B cell therapy or with central nervous system (CNS) locali-
sation. SOT recipients with CNS localisation might receive additional radiotherapy and/or
chemotherapy as well. The efficacy of antiviral therapy in preventing or treating EBV-LPD, if
there is any, is very low. Chemotherapy or IFN might be given to SOT recipients when other
treatment options have failed or are not available. Localised disease in this patient group
can be cured with surgery or radiotherapy. When available, EBV-specific cytotoxic T lympho-
cytes (EBVs-CTLs) from HLA-identical donors or autologous EBVs-CTLs can be used as (pre-
emptive) treatment of EBV-LPD in BMT or SOT recipients, respectively. Further studies will
be necessary to evaluate the safety and effectiveness of EBVs-CTLs obtained from (partially)
HLA-matched related and unrelated blood donors in both BMT and SOT recipients, which
will make this approach more accessible.
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Introduction
The link between severe immunosuppression of transplant recipients and increased inci-
dence of lymphoma has long been apparent and the association with EBV is widely recog-
nized1. EBV is the prototype of the gamma subfamily of potentially oncogenic herpes
viruses. Taxonomists have renamed EBV as human herpes virus 4 (HHV4). Two EBV types
(type 1 and 2) circulate in most populations, of which type 1 is far more common in most
populations2. There are various isolates of type 1 and 2 EBV. Persistent infection with more
than one EBV isolate is not unusual, particularly for immunocompromised patients3. In
vitro, efficient EBV infection of cells is restricted to mature human B lymphocytes. This
results in a latent infection in 10% of cells which subsequently proliferate as immortalised
lymphoblastoid cell lines (LCLs). Latently infected B-cells can be induced to become permis-
sive for lytic viral replication, while in some viral replication occurs spontaneously2. The
presence of latent virus in an infected cell can be readily detected using antibodies to any of
the eight different virus proteins that are characteristically expressed in LCLs. These viral
proteins include 6 nuclear proteins (EBNA’s) and two integral membrane proteins (LMPs).
In LCLs also two small nonpolyadenylated RNA’s (EBERs) and highly spliced BAMH1 A
rightward frame (BARF) transcripts are expressed. This type of latency is termed latency
III2,4. EBV lymphoproliferative lesions are considered to result from proliferating latently
infected B cells, expressing latency type III genes, in the absence of EBV-specific cytotoxic
CD8+ T cell surveillance4,5. However, also more restricted patterns of EBV latency are
observed in EBV lymphoproliferative disorders (EBV-LPD) and cases with latency type I
(only expressing EBNA1, BARF transcripts and EBERs) have been described6. In addition to
the expression of latent EBV genes, viral gene products associated with replicative or lytic
infection have been detected in LPDs4,6,7. At the moment it is unclear whether EBV replica-
tion or lytic infection is of significance in the pathogenesis of EBV-LPD. However, the detec-
tion of cell free EBV-DNA and the high sensitivity and specificity of this test in diagnosing
EBV-LPD suggests that lytic EBV infection might be more than a bystander in EBV-LPD.
An excellent review of the 4 different histo-pathological classifications of post-transplant
LPDs is published by Nalesnik1. Most LPDs are of B cell origin, although T cell LPDs some-
times (12%) occur in recipients of solid organ transplants (SOT)8. Van Gorp et al9 report on
3 SOT patients with EBV negative T cell LPDs. A literature search performed by these
authors resulted in 22 transplant (SOT: n=19) recipients diagnosed with T cell LPD. A sum-
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mary of these patients was given and in only 5 of them an association with EBV was estab-
lished. Most of these T cell LPDs were occurring late (>1 year post-transplant, while prog-
nosis was variable. LeBlond et al8 diagnosed 34 cases with LPD after SOT. Four of 34 LPDs
were of T cell origin and three of these four were EBV negative. The other 30 cases were of
B cell origin and 8 of them were EBV negative. EBV negative LPDs more often occurred late
after transplantation (> 2 years), while survival time after diagnosing LPD was significantly
shorter compared to patients with EBV-associated LPDs. All EBV negative B cell LPDs were
monomorphic, meeting the criteria of diffuse large B cell lymphoma according to the
Revised European-American Lymphoma classification. The findings of LeBlond et al8 were
largely supported by other reports10,11. No data are available for T cell LPDs or EBV negative
LPDs after bone marrow transplantation (BMT).
Some studies were undertaken to analyse whether EBV-LPD is derived from donor or host
lymphoid tissue. In both BMT12-14 and SOT15-17 recipients post-transplant lymphomas of
recipient origin as well as donor origin were found. The origin of the EBV strain infecting
these lymphoma (B) cells is unknown. Gratama et al18 showed that conditioning regimen
pre-BMT and/or graft-versus-host disease (GVHD) was able to eliminate the EBV strain of
the host. In this study, one patient became infected with a strain indistinguishable from the
virus isolated from her husband and another with the donor strain. In 2 EBV-seronegative
and 2 EBV-seropositive SOT recipients with EBV-LPD, donor strains and non-donor strains,
respectively, were identified19. At this moment it is unknown how often EBV strains of donor
origin cause re-infection in BMT recipients or primo-infections in seronegative SOT recipi-
ents. Oral transmission or transmission through transfusion of blood products might be
other possibilities, although after BMT irradiated blood products are used which may pre-
vent transfusion related transmission.
Incidence of EBV-LPD
EBV reactivations or EBV primo-infections in severely immunocompromised patients may
result in the development of EBV-LPD, which is associated with a mortality of 80%20-22.The
reported incidence of EBV-LPD varies, but is generally higher in recipients of solid organ
transplants (2-8%;20,23-27) compared to BMT recipients. In SOT recipients EBV-LPDs usually
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develop during the first year post-transplant, however, they continue to occur there-
after1,20,27-30. Primary EBV infection in EBV-seronegative SOT recipients, the type of trans-
planted allograft, cytomegalovirus (CMV) serostatus mismatch (R-/D+), CMV disease and
the type (T cell antibodies) and intensity of immunosuppression are important risk factors
for the development of EBV-LPD in SOT recipients29,31-33. Buda et al34 showed that in heart
transplant recipients hepatitis C virus infection probably is a risk factor as well. Primary EBV
infection and EBV-LPD is of greater concern in paediatric SOT recipients: in children with
small-intestine transplants the incidence of EBV-LPD was 32%35. After BMT the overall
cumulative incidence is 1% in 10 year, with most EBV-LPDs occurring within the first 6
months post-transplant37. Four major risk factors for early EBV-LPD (< 1 yr) after BMT have
been identified36: 1) T cell depletion (TCD) using monoclonal antibodies (Moabs) directed
at T cells or T and NK cells or TCD using E-rosetting, 2) use of unrelated or ≥ 2 HLA antigen
mismatched related donors, 3) use of Antithymocyteglobulin (ATG) for prophylaxis or treat-
ment of acute GVHD and 4) treatment of acute GVHD with anti CD3 Moabs. In patients with
3 or more risk factors the incidence of EBV-LPD was 22%. Other studies reported EBV-LPD
incidences in recipients of matched unrelated donor (MUD) grafts from 4.3-24%12,37,38, in
recipients of matched related donor (MRD) grafts from 0-0.7%12,13,37,38 and in recipients of
unrelated umbilical cord transplants of 2%39.
Monitoring of EBV reactivations
Since 1994 many studies have been performed to analyse the value of EBV-DNA detection in
diagnosing EBV-LPD or other EBV-associated diseases. EBV-DNA detection by polymerase
chain reaction (PCR) techniques can be performed in peripheral blood mononuclear cells
(PBMC), whole blood or cell free plasma. Results of studies performed among SOT and BMT
recipients are summarized in Table 1 and 2. In 5 of 13 studies measuring viral load (VL) in
PBMC the sensitivity for diagnosing EBV-LPD was less than 100%28,40-51. VL detection in cell
free plasma seems to be more accurate: in 5 of 6 studies 100% sensitivity was
obtained22,30,48,52-54. Limaye et al53 report the only patient with a negative PCR result in cell
free plasma, while EVB-LPD was diagnosed. However, the only manifestation of EBV-LPD in
this patient was a skin nodule. Specificity varied from 73-100% and was generally higher
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when VL detection was performed in cell free plasma. Wagner et al48 performed realtime
quantitative EBV-DNA detection in PBMC as well as cell free plasma in recipients of renal
transplants and healthy volunteers. Sensitivity of both methods was 100%, while specificity
of EBV-DNA detection in PBMC was 89% and in cell free plasma 100%. When remission of
EBV-LPD was accomplished, EBV DNA was more effectively cleared in plasma compared to
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Table 1 EBV DNA detection by PCR  in PBMC: sensitivity and specificity for
diagnosing EBV-LPD
Study Method Target gene Tx Sensitivity Specificity Viral Load
cut-off 
Riddler28 Semiquant. EBNA1 SOT 88% 100% 20.000
(c/105 PBMC)
Rooney40 Semiquant. BAMH1H BMT 80% 100% 20.000
(c/µg dna)
George*41 Semiquant. BMLF1 BMT 100% 95% 2.000
(c/µg dna)
Lucas*42,43 Semiquant. BAMH1H BMT 71% 94% 40.000
(c/µg dna) SOT 100% 97% 40.000
Kimura44 Realtime BALF5 LTx 100% 100% 320
(c/µg dna)
Baldanti45 Semiquant. EBNA1 SOT 73% 94% 1.000
(c/0.5µg dna)
Stevens46 Quantitative EBNA1 LuTx 100% 75% 2.000
(c/ml blood)
Hoshino*47 Realtime BALF5 BMT 100% 73% 320
(c/µg dna)
Wagner48 Realtime BAMH1K RTx 100% 89% 5.000
(c/µg dna) BAMH1W
Wagner*49 Realtime EBER1 SOT 100% 77% 4000
(c/µg dna) BMT 100% 89% 4000
Gartner50 Quantitative nd BMT 87% 91% 100.000
(c/µg dna)
Sirvent*51 Semiquant. BAMH1C BMT 100% 81% 300
(c/µg dna)
PBMC = peripheral blood mononuclear cells; BMT = bone marrow transplantation; SOT = solid organ transplantation;
LTx = liver transplantation; LuTx = lung transplantation; RTx = renal transplantation, nd = not described; * = prospec-
tive study.
PBMC, which might suggest that cell free EBV DNA better reflects response to therapy.
Contradictory, Stevens et al46 were not able to detect EBV-DNA in serum of recipients of
lung transplants with EBV-LPD, while 68% of all samples of these 6 patients tested positive
in the PBMC fraction. However, since this is very different from all other reports, these
results might be doubted. It has to be stressed that studies summarized in Table 1 and 2 are
hard to compare since different viral load detection techniques were used. Furthermore,
most were retrospectively performed in selected patients with and without EBV-LPD, while
some were prospectively undertaken. Despite this drawback, in the majority of cases, EBV
viral load was increased in patients with EBV-LPD. Overall, according to sensitivity and
specificity, cell free EBV-DNA detection seems the most accurate technique to predict the
presence or development of EBV-LPD. An increase in EBV VL often preceded the develop-
ment of EBV-LPD in BMT recipients by several weeks40,42,51,52. In SOT recipients the time
period for EBV-DNA detection prior to the development of EBV-LPD was more variable and
ranged from 0 to >10 months28,46.
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Table 2 EBV DNA detection by PCR  in plasma: sensitivity and specificity for
diagnosing EBV-LPD
Study Method Target gene Tx Sensitivity Specificity Viral Load
cut-off 
Fontan30 Qualitative BAMH1W BMT 100% 100% Qualitative
RTx 100% 100%
LTx 100% 100%
Beck52 Qualitative EBNA1 BMT 100% 85% Qualitative
Limaye53 Qualitative EBER1 SOT 83% 100% Qualitative
Esser22 Realtime BNRF1/ BMT 100% 89% 1.000
(c/ml) p143
Wagner48 Realtime BAMH1K RTx 100% 100% 1.000
(c/0.1 ml) BAMH1W
Ohga54 Realtime nd BMT 100% 100% 40.000
(c/ml)
BMT = bone marrow transplantation; SOT = solid organ transplantation; LTx = liver transplantation; RTx = renal trans-
plantation; nd = not described.
Van Esser et al55 monitored plasma VL in 14 BMT recipients with EBV-LPD. In patients with
response to treatment the VL decreased at least 50% within 72 hours after treatment was
started. Patients with progressive disease showed an increase in viral load. VL measure-
ments might therefore also be used to monitor response to therapy.
EBV-DNA detection by PCR techniques has also proven to be useful in some other EBV
related diseases such as infectious mononucleosis30,44,48,56-58, chronic active EBV disorder
(CAEBV)44,59, nasopharyngeal carcinoma60-62 and HIV-associated central nervous system
lymphomas63-65.
Pre-emptive therapy of EBV reactivations
Van Esser et al66 performed a prospective study in recipients of T cell depleted (TCD) BMT.
EBV-DNA in cell free plasma was monitored weekly in 49 patients. Pre-emptive therapy,
consisting of a single infusion of rituximab (anti CD20 monoclonal antibody) was given to
patients with a VL ≥ 1000 c/ml. Seventeen patients showed EBV reactivation of which 15
received pre-emptive therapy. Only one progressed to EBV-LPD, responding completely after
two infusions of rituximab and donor lymphocyte infusion (DLI). In two patients EBV-LPD
and EBV VL ≥ 1000 c/ml was diagnosed at the same day. These patients achieved complete
remission (CR) after 2 rituximab infusions. In a historical control group of 85 recipients of
TCD-BMT 26 patients showed EBV reactivations, of which 10 developed EBV-LPD (38%). In
the prospective study 3 of 17 patients with VL ≥ 1000 c/ml developed EBV-LPD (18%).
Mortality in the historical group was 80% compared to 0% in the prospective study. This
study highlights the importance of monitoring high-risk patients and the effectiveness of
pre-emptive therapy with anti CD20 therapy. Currently no other study has been published
that prospectively analyses the value of pre-emptive therapy to prevent EBV-LPD, apart from
two small studies where 3 and 5 patients were treated pre-emptively with rituximab and
EBV-specific cytotoxic T cells (EBVs-CTL), respectively, for rising EBV VL. One of 5 and none
of 3 patients progressed to EBV-LPD67-68.
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Prevention and treatment of EBV-LPD
Engineering of marrow grafts Development of EBV-LPD is strongly associated with
T cell depletion of donor marrow. The risk for EBV-LPD varied according to the techniques
used for T cell depletion, being lowest (<2%) when the Campath-1 or counterflow elutria-
tion methods were used which, in contrast to T cell specific Moabs, removed both T and B
cells36,69-70. Cavazzana et al71 observed that none of 19 patients receiving transplants from a
partially matched related donor (PMRD) developed EBV-LPD when ex vivo T and B cell
depletion was performed, whereas 7 out of 19 historical controls developed EBV-LPD when
only T cell depletion was performed. One other study showed that B cell depletion might be
of benefit for decreasing the incidence of EBV-LPD72. When in our institute grafts from
MUDs were depleted both from T and B cells, 4 out of 31 patients (13%) developed EBV-
LPD. Without B cell depletion this occurred in 5 out of 7 patients (71%)73. In summary, B
cell depletion of grafts is efficacious in preventing EBV-LPD in recipients of T cell depleted
grafts from MUDs. The degree of B cell depletion needed is still uncertain but is clearly
closely related to the degree of TCD73. A mechanism explaining the importance of B cell
depletion might be a reduction of the EBV viral load transmitted by the marrow graft. This is
probably more important than a reduction of the amount of B cells itself, since EBV-LPDs
not always consist of donor lymphoid tissue (see introduction).
Antiviral therapy Most studies using antiviral drugs have been performed with acy-
clovir and ganciclovir, which are both nucleoside analogues. The nucleosides first have to be
converted to monophosphate by a viral enzyme (which is thymidine kinase (TK) in case of
EBV). Second and third phosphorylations are performed by cellular kinases. Acyclovir or
ganciclovir triphosphate is then preferentially incorporated in DNA by viral DNA polymerase
and acts as an obligate chain terminator74. The effectiveness of newer agents like cidofovir
and foscarnet for prevention or treatment of EBV-LPD has not been studied. Cidofovir is a
nucleotide analogue of deoxycytidine monophosphate, while foscarnet is a pyrophosphate
analogue forming a complex with the pyrophosphate binding site of viral DNA polymerase.
Similar to acyclovir and ganciclovir, both drugs are dependent on viral DNA polymerase
expression to be functional. Thymidine kinase and viral DNA polymerase are enzymes
expressed only during lytic infection, while EBV-LPD is considered to result from latently
infected proliferating B cells. Therefore, theoretically, no effect of these drugs can be
expected with respect to prevention and treatment of EBV-LPD. However, as is described in
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the introduction, some results suggest lytic infection might have a role in the pathogenesis
of EBV-LPD4,6,7.
Prevention Several studies have shown that treatment with acyclovir results in transient
inhibition of EBV shedding in the oropharynx in patients with acute IM and also in long
term carriers. However, the frequency of circulating EBV infected B cells remained com-
pletely unchanged75-78. EBV is also able to transform human lymphocytes despite the pres-
ence of 500 µM acyclovir79, while a 2 week exposure of B lymphoblastoid cell lines to
100 µM acyclovir did not prevent release of infectious EBV virus after irradiation to 75
Gray80. Many non-randomised studies have been published describing a decrease in inci-
dence of EBV-LPD among SOT and BMT recipients treated prophylactically with acyclovir or
ganciclovir, however, an equal amount of studies observed no effect at all of antiviral pro-
phylaxis81. In paediatric liver transplant recipients82 prophylaxis with a short course (2
weeks) ganciclovir (intravenously) followed by long-term oral high-dose acyclovir resulted
in EBV disease in 33% of the recipients compared to 21% in recipients receiving the short
course ganciclovir alone. In other randomised trials among SOT recipients using acyclovir or
ganciclovir prophylaxis, just a trend towards a lower incidence of EBV-LPD was seen81. Mc
Diarmid et al83 treated high-risk (EBV serostatus recipient/donor:-/+) paediatric liver trans-
plant recipients prophylactically with intravenously administered ganciclovir for at least a
100 days. In low-risk patients ganciclovir was replaced by oral acyclovir at discharge.
Semiquantitative EBV-DNA monitoring was performed and immunosuppression was
decreased when VL increased. The overall incidence of EBV-LPD decreased from 10% (his-
torical) to 5%. This study however, does not yield any evidence for effectiveness of ganci-
clovir. The decreased incidence of EBV-LPD might very well be attributed to the EBV-DNA
based reduction of immunosuppressive therapy.
Therapy According to Cohen84 acyclovir therapy generally has not been effective for SOT
and BMT patients with EBV-LPD. The reduction in immunosuppression that often accompa-
nied acyclovir therapy made it difficult to assess the real effectiveness of acyclovir.
Nevertheless, since toxicity of acyclovir therapy is low, treatment with acyclovir is often
instituted when EBV-LPD has been diagnosed. Two case reports describe the achievement of
CR of EBV disease after treatment with ganciclovir or foscarnet85,86. Little information is
available on the effectiveness of newer antiviral agents regarding prevention or treatment of
EBV-LPD.
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Withdrawal of immunosuppressive therapy Withdrawal of or decreasing
immunosuppressive therapy has proven to be effective in solid organ transplant recipients
and is often undertaken as initial strategy87. However, this is associated with a risk of graft
rejection which can be supported better in renal transplant recipients compared to other
SOT recipients. BMT recipients have a far more pronounced immune suppression, which
makes withdrawal of immunosuppressive therapy alone usually not sufficient for treating
EBV-LPD88.
Surgery/Radiotherapy Surgical removal or radiotherapy has been effective in
patients with localised disease. Survival in SOT recipients with localised EBV-LPD treated
with surgical resection alone was 74% compared with 31% in all transplant recipients with
EBV-LPD84.
Chemotherapy Chemotherapy (CT) is generally considered to be a treatment option
when other therapies have failed5,84, although several case reports/small studies are avail-
able demonstrating the effectiveness of chemotherapy89-93. Cohen84 did not detect any sur-
vival advantage for patients treated with chemotherapy. Results of other larger studies are
summarized in Table 3. The only study in which treatment with chemotherapy resulted in a
favourable outcome is the one by Fohrer et al95. Twenty-seven recipients of SOT with EBV-
LPD were treated with chemotherapy consisting of adriamycin, cyclophosfamide, vincristine,
bleomycin and steroids. Granulocyte-colony stimulating factor was given and a total of 6
cycles were scheduled every 2-3 weeks. In 19 patients a CR was observed (70%) of which 7
showed an early relapse (within a median time of 3 months). Actuarial survival at 3, 5 and
10 years was 72%, 66% and 49%, respectively. LeBlond et al97 and Dotti et al96 found, after
univariate analysis, that treatment of EBV-LPD with CT was an adverse risk factor for overall
survival in SOT recipients.
Interferon alpha/anti-interleukine 6 Several case reports are published showing
the effectiveness of Interferon-alpha (IFN) in the treatment of patients with EBV-LPD after
SOT and BMT (summarized in ref.98). In total 14 SOT recipients and 4 BMT recipients with
EBV-LPD received IFN, of which 12 obtained CR. Davis et al99 showed that 8 of 14 recipients
of SOT with EBV-LPD obtained CR after treatment with IFN. Patients were treated daily
(3x106 U/m2) for at least 3 weeks and treatment was continued for 6-9 months in respon-
ders. Gross et al21 describe 26 BMT recipients with EBV-LPD. Thirteen patients received
therapy for EBV-LPD of whom only 2 patients responded. Both these patients were treated
with IFN. It should be noted that all patients described in the varying studies received addi-
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tional therapies. Therefore, it remains unclear whether IFN might be an effective treatment
approach for EBV-LPD.
Results of anti-cytokine (anti-interleukine 6) therapy in 12 SOT recipients were promising
showing CR in 5 of 12 patients with EBV-LPD, PR in 3 of 12 and stable disease in one. Data
were preliminary and larger studies have to be performed to confirm these results100.
T cell immunotherapy T cell immunotherapy is able to control EBV-LPD in recipients
of BMT101. O’Reilly reports data on 18 patients with EBV-LPD who were treated with non-
specific donor T lymphocyte infusions (DLI). In 16 of 18 patients eradication of EBV-LPD
was accomplished. Ten of 18 patients survived in sustained CR, while 3 died from GVHD
and 1 from progressive EBV-LPD. This response rate is rather favourable to data from Lucas
et al42, who observed complete response in 4 of 13 patients while a similar proportion expe-
rienced GVHD and only 2 of 13 patients survived. A major side-effect of DLI is GVHD.
Therefore, Bordignon and Bonini et al102,103 treated 8 patients with relapse or EBV-LPD with
donor T lymphocytes, which were transduced with the herpes simplex virus thymidine
kinase (HSV-tk) suicide gene. Three patients developed GVHD that was successfully treated
with ganciclovir (CR in two, partial remission in one). This approach, however, is still exper-
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Table 3 Results of Chemotherapy
Study Tx CT No. of patients CR OS
total/treated 
with CT
Swinnen24 HTx ProMACE- 19/6 early* none 44% (2yr)
CytaBOM 19/8 late** 75%
Gonzalez94 SOT nd 34/20 42% 33% (2yr)
Fohrer95 SOT ACVBP 27/27 70% 72% (3yr)
66% (5yr)
49% (10yr)
Dotti96 SOT P-VABEC 32/19 26% 6 months 
(median)
SOT = solid organ transplantation; HTx = heart transplantation; nd = not described; CT = chemotherapy; RT = radio-
therapy;  PTLD = post-transplant lymphoproliferative disorder; *early = EBV-LPD < 6 months; **late = EBV-LPD > 6
months; CR = complete remission; OS = overall survival; ACVBP = adriamycin, cyclophosphamide, vincristine, bleomycin,
steroids; P-VABEC = steroids, vincristine, adriamycin, bleomycin, etoposide, cyclophosphamide.
imental. A strategy to limit the risk of GVHD is the administration of EBV-specific cytotoxic T
lymphocytes (EBVs-CTL). Rooney et al104 treated 10 BMT recipients of MUD/PMRD grafts
with EBVs-CTLs of whom 3 had evidence of uncontrolled EBV reactivation. In all VL fell to
normal and symptoms disappeared. In a subsequent study105 39 BMT recipients of
MUD/PMRD grafts received prophylactic EBVs-CTLs. None developed EBV-LPD in contrast
to 7 of 61 controls not receiving prophylactic therapy. Acute GVHD did not develop in any
patient receiving EBVs-CTLs. Gustafsson et al67 describe 9 BMT recipients of whom 5
showed a rapidly rising EBV VL. These patients were pre-emptively treated with EBVs-CTLs,
only one progressed to fatal EBV-LPD. This patient received CTLs lacking an EBV-specific
component. Altogether, the use of donor derived (HLA-matched) EBV-specific CTLs seems to
be very effective, however, is limited by the long time periods required for the generation of
these cells. Furthermore, generating these CTLs for every transplant recipient prior to the
development of EBV-LPD is very expensive. Therefore, this technique will not be available in
every transplantation centre. Another drawback is highlighted by a report of Gottschalk et
al106, in which an EBV deletion mutant was associated with fatal lymphoproliferative disease
unresponsive to therapy with EBVs-CTLs.
Donor derived CTLs are generally not used for prevention or treatment of EBV-LPD in SOT
recipients, since the donor mostly is not available and donor and recipient generally are not
HLA-matched107. However, two case reports have been published in which SOT recipients
with EBV-LPD were treated successfully with DLI from an HLA-identical sibling donor108 and
with EBVs-CTLs from a partially HLA-matched unrelated blood donor109. Several studies
described the development and effectiveness of autologous EBVs-CTLs110-114. As is the case
in BMT, autologous EBVs-CTLs have to be prepared for all SOT recipients prior to the devel-
opment of EBV-LPD, which (again) is time-consuming and expensive. Therefore, the use of
EBVs-CTLs from partially HLA-matched unrelated blood donors, does create new possibili-
ties109.
Anti B cell therapy Several case reports have been published demonstrating the effec-
tiveness of anti B cell therapy for treatment of EBV-LPD in BMT and SOT recipients49,115-120.
Fischer et al121 and Benkerrou et al122 (see Table 4) treated 58 SOT and BMT recipients with
EBV-LPD with anti CD21 plus CD24 antibodies. CR was seen in 61%, while 5 year overall
survival (OS) was 46% compared to 29% in historical controls. However, in recipients of
BMT, 5 year OS was only 35%. Milpied et al123 treated 32 SOT and BMT recipients with
EBV-LPD with rituximab. After a median follow up of only 8 months, one year OS was 73%.
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Response (CR and PR) was 65% for SOT recipients and 83% for BMT recipients. Rituximab
was also given to twelve paediatric BMT recipients124 and to 7 adult SOT recipients125 with
EBV-LPD showing CR rates of 66% and 71%, respectively. Thus, anti B cell therapy seems to
be very promising, especially when it is started pre-emptively in high-risk patients with
increasing EBV VL66. It should be noted that EBV-LPD in the central nervous system (CNS)
generally does not respond to anti B cell Moabs because of lack of penetration in the CNS123.
Recently, one patient with EBV-LPD and CNS localisation was treated with rituximab and
cidofovir, which resulted in a CR. Plasma and liquor EBV VL became negative during treat-
ment126.
Future perspective
Marshall et al127 used HLA class I tetramers complexed with multiple latent and lytic EBV
peptides to characterise the dynamics of EBVs T cells in BMT recipients. In recipients of
unmanipulated allogeneic BMT from related donors it was demonstrated that expansion of
EBVs T cell populations occurred even in the presence of immunosuppressive therapy. The
amount of EBVs T cells correlated with EBV VL in PBMC. In contrast, after in vivo TCD or
unrelated cord blood transplantation EBVs T cells were undetectable, even in the presence
of EBV viremia. Curtis et al37 already showed that TCD and the use of unrelated donor grafts
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 
Table 4 Results of anti B cell therapy
Study Tx No. of Moab CR OS
patients
Benkerrou122 SOT/BMT 58 anti CD21 and 24 61% 46% (5yr)
Milpied123 SOT/BMT 32 anti CD20 63% 73% (1yr)
Faye124 BMT 12 anti CD20 66% nd
Kentos125 SOT 7 anti CD20 71% nd
SOT = solid organ transplantation; BMT = bone marrow transplantation; Moab = monoclonal antibody; CR = complete
remission; OS = overall survival; nd = not described.
were risk factors for EBV-LPD. Nevertheless, the use of these tetramers might enable us to
detect transplant recipients without circulating EBVs T cells. These patients have a high risk
of developing EBV-LPD and should be monitored intensively to institute pre-emptive therapy
(anti CD20 Moabs, EBVs-CTLs) when EBV VL is rising.
Conclusion
In high-risk BMT recipients monitoring of EBV VL in preferably cell free plasma should be
performed once a week until 6 months post-transplant. No strict guidelines for frequency
and duration of monitoring in SOT recipients can be given, largely due to the variable time
period in which post-transplant EBV-LPDs can occur in this patient group. However, in high-
risk SOT recipients monitoring may be performed fortnightly or at every outpatient visit
until 1 year post-transplant. When EBV reactivation is diagnosed, pre-emptive therapy with
anti B cell Moabs is advised in BMT and SOT recipients. In BMT recipients receiving T cell
depleted grafts from unrelated donors, additional B cell depletion can reduce the incidence
of EBV-LPD dramatically. Treatment of EBV-LPD should start with withdrawal of or decreas-
ing immunosuppression together with anti B cell Moabs. Donor lymphocyte infusion should
be reserved for BMT recipients not responding to anti B cell therapy or with central nervous
system (CNS) localisation. SOT recipients with CNS localisation might receive additional
radiotherapy and/or chemotherapy as well. The efficacy of antiviral therapy in preventing or
treating EBV-LPD, if there is any, is very low. Chemotherapy or IFN might be given to SOT
recipients when other treatment options have failed or are not available. Localised disease in
this patient group can be cured with surgery or radiotherapy. When available, EBV specific
cytotoxic T lymphocytes (EBVs-CTLs) from HLA-identical donors or autologous EBVs-CTLs
can be used as (pre-emptive) treatment of EBV-LPD in BMT or SOT recipients, respectively.
Further studies will be necessary to evaluate the safety and effectiveness of EBVs-CTLs
obtained from (partially) HLA-matched related and unrelated blood donors in both BMT
and SOT recipients, which will make this approach more accessible.
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Abstract
Whether cytomegalovirus (CMV)-seropositivity still remains a serious adverse risk factor for
overall survival (OS) and transplant-related mortality (TRM) in allogeneic bone marrow
transplantation (BMT) is under debate. We therefore analysed the effect of CMV serostatus
on OS and TRM in 253 consecutively treated patients receiving partial T cell depleted (TCD)
bone marrow from either matched related donors (MRD, n=205) or matched unrelated
donors (MUD, n=48). All patients were given leukocyte-depleted blood products. CMV
monitoring was performed using the pp65 antigenemia assay. Pre-emptive therapy consisted
of short-course (2 weeks) low-dose (2.5 mg/kg intravenously b.i.d.) ganciclovir treatment as
soon as a positive antigenemia assay was obtained (≥ 1 positive staining granulo-
cyte/150.000 cells). Ganciclovir prophylaxis, identical to pre-emptive therapy, was given to
CMV-seropositive patients with acute graft-versus-host disease (aGVHD) grade II-IV who
were treated with high-dose corticosteroids. After multivariate analyses, inferior OS and
increased TRM were predicted by extensive chronic (c) GVHD (p<0.001) in MRD recipients.
Furthermore, high-risk disease status and older age adversely influenced OS (p=0.001) and
TRM (p=0.002), respectively, while older age resulted in a trend towards a decreased OS
(p=0.066). After multivariate analyses in MUD recipients OS and TRM were strongly influ-
enced by patient (but not donor) CMV-seropositivity (p=0.013 and 0.007, respectively),
while aGVHD also predicted for increased TRM (p=0.024). These data show that CMV-
seropositivity is not an adverse risk factor for OS and TRM in MRD recipients of partial TCD-
BMT. However, in MUD recipients, patient CMV-seropositivity has a high impact on OS and
TRM.
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Introduction
Cytomegalovirus (CMV) infections in recipients of allogeneic bone marrow transplants
(BMTs) historically have been an important cause of morbidity and mortality, primarily due
to CMV pneumonia. It did occur mainly in CMV-seropositive recipients by CMV reactivation,
but also in CMV-seronegative recipients who acquired primary CMV infection by transfusion
of unfiltered blood components or unmanipulated bone marrow from CMV-seropositive
donors1. In CMV-seronegative recipients of unmanipulated grafts from CMV-seronegative
donors or T cell depleted (TCD) grafts from CMV-seropositive donors, primary CMV infec-
tion could be prevented by a transfusion policy making use of either CMV-seronegative
donors or leukocyte-depleted blood products2-5. A major step in preventing the occurrence of
CMV pneumonia in CMV-seropositive patients was accomplished by prophylactic long-term
(3-4 months) therapy with antiviral drugs like ganciclovir6-9. However, in these trials overall
mortality was hardly improved because of side effects of long-term ganciclovir prophylaxis
such as neutropenia, resulting in bacterial and fungal infections, and more late-onset CMV
disease7-9. We previously showed that short-course (2 weeks) low-dose (2.5 mg/kg intra-
venously b.i.d.) ganciclovir therapy initiated either prophylactically, when high-dose corti-
costeroids were given for acute graft-versus-host disease (aGVHD), or pre-emptively, when
CMV-antigenemia was detected, almost completely prevented the occurrence of CMV pneu-
monia in CMV-seropositive recipients of partial TCD transplants from matched related
donors10. Furthermore, short-course ganciclovir did not lead to granulocytopenia or late-
onset CMV disease. Whether CMV-seropositivity still remains an important risk factor in
allogeneic BMT, preventing CMV-disease as described above, is under debate. We therefore
analysed the effect of CMV-serostatus on transplant related mortality (TRM) and overall sur-
vival (OS) in 253 recipients of partial TCD BMTs of HLA-identical sibling donors or matched
unrelated donors.
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Methods
Patients For this study data of 253 consecutively treated patients receiving either bone
marrow from matched related donors (MRD) (n=205) or from matched unrelated donors
(MUD) (n=48) were analysed. Patients with acute leukaemia’s in first complete remissions
(CR), chronic myeloid leukaemia (CML) in first chronic phase (CP) and untreated severe
aplastic anaemia (SAA) were considered low-risk. All patients with other diseases were con-
sidered high-risk. TRM was defined as any mortality after transplantation, except relapse.
Transplantations were performed between July 1990 and May 2000 at the Department of
Haematology of the University Medical Centre Utrecht. Patients were treated according to
clinical protocols approved by the local investigation review board after informed consent
was obtained.
Transplantation procedure Conditioning regimens consisted of cyclophosphamide
(60 mg/kg/day) on each of two successive days, followed by total body irradiation (TBI)
(600 cGy/day) on each of 2 successive days, with partial shielding of the lungs (total lung
dose 850 cGy). The graft was infused after the second TBI fraction (day 0).
Antithymocyteglobulin (ATG) (Thymoglobulin™, Sangstat, Amstelveen, the Netherlands)
was given to MUD patients before cyclophosphamide was infused, in a dose of 4 mg/kg/day
intravenously for 5 days. Due to a change in national treatment protocols, ATG dose was
lowered to 2 mg/kg/day for 4 days from April 1999. All patients received cyclosporin from
day -2 in a dose of 3 mg/kg/day by continuous infusion for 3-4 weeks, thereafter it was
given orally for 4-6 weeks in a dose that gave comparable through levels, followed by taper-
ing. Cyclosporin was discontinued within 3 months after transplantation, when no active
GVHD was present. Infection prevention for all patients consisted of ciprofloxacin, flucona-
zole and amphotericin B given orally until granulocyte counts exceeded 500 cells/µl.
Cephalothin was given intravenously for 10 days from day +3. Furthermore co-trimoxazole
and valacyclovir were given orally from day +1 until 12 months post-BMT or longer in case
of active GVHD, in a dose of 480 mg b.i.d. and 500 mg b.i.d., respectively. GVHD was classi-
fied according to the Seattle criteria11. Acute GVHD grade I was treated with topical corti-
costeroids; grade II or higher was treated with high-dose systemic corticosteroids as
described12. Limited chronic GVHD was not treated and extensive chronic GVHD was treated
with systemic corticosteroids, sometimes combined with cyclosporin12.
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CMV monitoring During the first 4 months post-transplant, all CMV-seropositive
patient/donor combinations (R+/D+, R+/D-, R-/D+) were monitored for CMV antigene-
mia. When patient serostatus was positive (R+/D+, R+/D-) the pp65 assay was performed
thrice a week until day 60 after BMT, thereafter twice a week until day 120. In patients with
active GVHD monitoring was continued. When patient serostatus was negative (R-/D+)
antigenemia was tested twice a week until discharge, thereafter once a week until 5 consec-
utive negative tests. Seronegative patient/donor combinations were not monitored. In this
patient group, CMV-seronegativity was readdressed 3 months after BMT.
CMV pp65 assay This assay was performed as described13-14. CMV reactivation was
defined as CMV pp65 antigenemia of ≥ 1 positive staining granulocyte/150.000 cells.
CMV disease Patients with symptoms of pneumonia, gastritis or enteritis underwent
bronchoscopy, gastroscopy or sigmoidoscopy, respectively. CMV pneumonia/gastritis/enteri-
tis was defined histologically by typical cytopathic effects and immunohistochemically by
immunofluorescence with use of monoclonal antibodies to immediate early CMV antigens in
biopsy specimens. When cultures of BAL fluid, saliva, urine and buffy coat were performed
in case of infectious complications, these included always CMV cultures, irrespective of CMV
serostatus.
Ganciclovir therapy CMV-seropositive patients who demonstrated CMV reactivation
or who were treated with high-dose corticosteroids for aGVHD grade II-IV received pre-emp-
tive or prophylactic therapy, respectively, with ganciclovir in a dose of 2.5 mg/kg intra-
venously twice a day for 14 days10. When patients were symptomatic (unexplained fever or
symptoms compatible with CMV disease), CMV antigenemia was rising or remained positive
after 14 days of treatment, ganciclovir dose was doubled or foscarnet treatment was started
instead of ganciclovir in a dose of 60 mg/kg twice a day for 14 days. When serum creatinine
increased above 200 µmol/l, ganciclovir dose was reduced. When granulocyte count
decreased below 500/µl ganciclovir was replaced by foscarnet. CMV disease was treated
with ganciclovir 5 mg/kg twice a day for at least 14 days and continued until symptoms
resolved and/or antigenemia became negative, whichever was latest. In case of disease pro-
gression or rising antigenemia foscarnet treatment was started instead of ganciclovir in a
dose of 60 mg/kg twice a day. Furthermore, treatment with CMV specific immunoglobulins
was added to antiviral therapy in patients with CMV pneumonia.
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HLA-matching In all MRD patient-donor pairs, class I antigens (A, B and Cw) were
analysed by serological typing, in case of doubt low resolution molecular typing was per-
formed. Class II antigens (DRB1, DRB3, DRB4, DRB5 and DQB1) were analysed by serologi-
cal typing until 1993 and since 1993 by low resolution molecular typing with sequence
specific primers. In MUD patient-donor pairs HLA analysis was performed as in MRD recipi-
ents until 1993, thereafter class I antigens (A, B) were analysed by serological typing, in
case of doubt low resolution molecular typing was performed. Class I Cw and class II anti-
gens (DRB1, DRB3, DRB4, DRB5 and DQB1) were analysed by low resolution molecular typ-
ing with sequence specific primers. DRB1, B3, B4 and B5 antigens were as well defined by
high resolution typing since January 1999.
BMT In vitro partial TCD of the marrow was performed using the Soy Bean
Agglutinin/Sheep Red Blood Cell (SBA/SRBC) technique until 199715. Thereafter, the
immunorosette (IR) depletion technique was used16. After this maximal T cell depletion pro-
cedure the residual number of T cells was counted and nonmanipulated T cells (from a
small BM fraction that was set apart) were added to obtain the desired fixed low number of
T cells (1-5 x 105 T cells/kg recipient weight)12. Since May 1998 B cell depletion, for preven-
tion of Epstein-Barr virus-associated lymphoma, was added to grafts from MUDs17.
Statistical analysis OS was estimated by the Kaplan-Meier method. Probabilities of
TRM and aGVHD were calculated by the cumulative incidence procedure. For TRM, death
without TRM was the competing risk; for aGVHD death without aGVHD was the competing
risk. Univariate analyses were performed using the log rank test. Variables which showed to
influence OS/TRM at a level of p<0.1 were used in a multivariate Cox regression analysis. P
values from regression models were calculated with the Wald test. The post-transplant vari-
ables ‘CMV reactivation’, ‘aGVHD’ and ‘cGVHD’ were as well analysed as time-dependent
covariates. Calculations were performed using SPSS/PC+ 10.0 (SPSS Inc, Chicago Il, USA).
Results
Patient characteristics Characteristics of MRD and MUD recipients are described in
Table 1. MRD recipients were significantly older compared to MUD recipients (40 vs 31 yr,
respectively, p<0.001). In contrast to the MUD group, 35% of MRD recipients were multiple
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myeloma or lymphoma patients. Most patients received bone marrow transplants, some
MRD patients received peripheral blood stem cell transplants (PBSCT) (MRD: 89% BMT vs
11% PBSCT; MUD: 100% BMT). Only 40% of recipients of matched related donor grafts and
38% of recipients of matched unrelated donor grafts were considered low-risk. Acute GVHD
developed in 83% and 70% of MRD and MUD recipients, respectively (p=0.086), and grade
II-IV in 50% and 38%, respectively. Chronic GVHD occurred in 56% of evaluable MRD recip-
ients and in 36% of evaluable MUD recipients (p=0.032). The disease was extensive in 27%
and 24% of MRD and MUD recipients, respectively. CMV reactivation was observed in 13%
of all MRD patients (26% of the CMV-seropositive recipients) and in 25% of all MUD recipi-
ents (50% of the CMV-seropositive recipients) (p=0.054). No primary infections were seen
in the group with CMV-seronegative patients with seropositive or seronegative donors. Six
patients developed CMV disease: pneumonia (n=4), gastritis (n=1) and encephalitis (n=1).
All were CMV-seropositive. The disease developed despite pre-emptive treatment with gan-
ciclovir in 3 patients. In the other 3 patients pre-emptive therapy was omitted because of
protocol violation (MRD: n=2, MUD: n=1). Four of the 6 patients died from CMV pneumo-
nia, including the 3 not receiving pre-emptive therapy. Two, while successfully treated for
CMV disease, died from other causes: varicella-zoster pneumonia -one year after CMV dis-
ease- and aspergillus pneumonia -3 months after CMV disease-. Primary graft failure was
observed in two patients (1 MRD, 1 MUD), as was secondary graft failure.
In Table 2 causes of mortality are described. “Other causes” of TRM consist of: acute respira-
tory distress syndrome (ARDS), acute liver failure, pancreatitis with multi-organ failure,
cerebral bleeding or infarction, cardiac toxicity, thrombotic or idiopathic thrombocytopenic
purpura (ITP or TTP) with bleeding and suicide. Mortality from infections was significantly
higher in CMV-seropositive MUD recipients compared to seronegative recipients (38% vs
8%, p=0.016).
Analyses in MRD recipients
Overall survival Median and mean follow up was 20 and 34 (range 1-118) months,
respectively. Median survival was 43 months (CI 95%: 14-72 months). Five year overall sur-
vival was 47% (CI 95%: 39-55%). From Table 3 and 4 it appears that after univariate and
multivariate analyses, high-risk disease status (p<0.001 and 0.001, respectively) and exten-
sive cGVHD (p<0.001) were adverse risk factors for overall survival. After univariate analy-
sis older age significantly affected OS (p=0.003), however, after multivariate analysis a
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Table 1 Patient characteristics
MRD patients MUD patients P
(n=205) (n=48)
Age, mean years (range) 40 (16-58) 31 (17-48) <0.001
Diagnosis
AML cr1 35 (17) 2 (4)
AML>cr1 7 (3) 6 (13)
ALL cr1 17 (8) 1 (2)
ALL>cr1 4 (2) 6 (13)
CML cp1 32 (16) 8 (17)
CML>cp1 7 (3) 8 (17)
SAA 4 (2) 8 (17)
NHL 27 (13) 0
MDS 10 (5) 4 (8)
MM 46 (22) 0
Other 16 (8) 5 (10)
CMV serostatus R/D
+/+ 66 (32) 10 (21) ns
+/- 35 (17) 14 (29)
-/+ 30 (15) 11 (23)
-/- 74 (36) 13 (27)
Source
BM 183 (89) 48 (100)
PB 22   (11)
Risk status
Low 82 (40) 18 (38) ns
High 123 (60) 30 (62)
aGVHD
I 67 (33) 15 (32) 0.086
II-IV 103 (50) 18 (38)
III-IV 8 (4) 7 (15)
No 35 (17) 14 (30)
cGVHD
Lim 50 (29) 4 (12) 0.032
Ext 47 (27) 8 (24)
No 78 (45) 22 (65)
CMV reactivation
Yes 26 (13) 12 (25) 0.054
No 179 (87) 36 (75)
CMV disease
Yes 3 (1.5) 3 (6)
No 202 (98.5) 45 (94)
Data are no. (%) of patients, unless otherwise indicated; AML = acute myeloid leukemia; ALL = acute lymphoid leukemia;
CML = chronic myeloid leukemia; SAA = severe aplastic anaemia; NHL = non-hodgkin lymphoma; MDS = myelodysplas-
tic syndrome; MM = multiple myeloma; R/D =recipient/donor; BM = bone marrow; PB = peripheral blood; aGVHD  =
acute graft-versus-host disease; cGVHD = chronic graft-versus-host disease; Lim = limited; Ext = extensive.
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Table 2 Causes of Mortality
CMV serostatus Recipient/Donor
+/+ +/- -/+ -/-
MRD MUD MRD MUD MRD MUD MRD MUD
No. of patients 35 9 23 11 16 6 31 5
Relapse 12 2 10 2 9 4 12 3 
TRM 23 7 13 9 7 2 19 2 
CMV disease 1 1 1 1 0 0 0 0
EBV-LPD 0 2 2 1 2 2 3 0
Infections (other) 10 1 3 3 3 0 6 0
GVHD 4 1 1 2 0 0 2 1 
IP/toxicity 1 0 4 0 1 0 4 1 
VOD 3 0 0 0 1 0 0 0
Other 4 2 2 2 0 0 4 0
EBV-LPD = Epstein-Barr virus associated lymphoproliferative disease; IP = interstitial pneumonia; VOD = veno-occlusive
disease.
Table 3 Univariate analyses of OS and TRM in MRD recipients
OS in MRD TRM in MRD
P P 
Recipient CMV serostatus (pos vs neg) ns ns
Donor CMV serostatus (pos vs neg) ns ns
Age (continuous) 0.003 0.002
Risk status (high vs low) < 0.001 0.040
R/D sexe (male/female vs other) ns 0.057
Source (pb vs bm) ns 0.028
T cell (graft) (continuous) ns ns
aGVHD (II-IV vs other) ns ns
cGVHD (extensive vs other) < 0.001 < 0.001
CMV reactivation (yes vs no) ns 0.020
Abbreviations: see Table 1.
trend towards decreased survival was observed (p=0.066). The effect of CMV serostatus
was analysed in two ways. First, the 4 groups with all possible patient/donor CMV serosta-
tus combinations were analysed separately (patient/donor: R+/D+, R+/D-, R-/D+, R-/D-).
In a second analysis, the group with CMV-seropositive patients (irrespective of donor serol-
ogy) was compared to the group with CMV-seronegative patients. After both analyses no sig-
nificant differences were observed. Adjusted probability of OS according to recipient CMV
serostatus is displayed in Figure 1.
Furthermore, donor CMV serostatus did not affect outcome. In contrast to the MUD group,
35% of MRD recipients were multiple myeloma or lymphoma patients. Analyses without
these patients gave fully comparable results.
Transplant related mortality TRM at one year was 23% (CI 95%: 17-29%). From
Table 3 it appears that TRM was determined by extensive cGVHD (p<0.001), older age
(p=0.002), CMV reactivation (p=0.020), source (PB) (p=0.028), high-risk disease status
(p=0.040) and recipient/donor sexe (Rm/Df) (p=0.057) after univariate analyses. After
multivariate analysis (Table 4) only extensive cGVHD (p<0.001) and age (p=0.002) pre-
dicted increased TRM. Adjusted probability of TRM according to recipient CMV serostatus is
displayed in Figure 1.
Analyses in MUD recipients
Overall survival Median and mean follow up was 8 and 20 (range 1-102) months,
respectively. Median survival was 7 months (CI 95%: 4-10 months). Five year overall sur-
vival in MUD recipients was 30% (CI 95%: 14-46%). Overall survival in MUD recipients was
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Table 4 Multivariate analyses of OS and TRM in MRD recipients
Overall Survival Transplant Related 
Mortality
RR 95% CI P value RR 95% CI P value
cGVHD (ext. vs other) 2.70 1.68-4.36 < 0.001 3.71 2.01-6.86 < 0.001
Risk status (high vs low) 2.12 1.36-3.28 0.001 ns
Age (continuous) 1.02 1.00-1.04 0.066 1.04 1.02-1.07 0.002
Abbreviations: see Table 1.
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Figure 1
Adjusted probability of overall survival and transplant related mortality in MRD recipients accord-
strongly determined by CMV serostatus (p=0.007) after univariate analyses; age was a less
important factor (p=0.051) (Table 5). Again the effect of CMV serostatus was analysed in
two ways. First, the 4 groups with all possible patient/donor CMV serostatus combinations
were analysed separately (patient/donor: R+/D+, R+/D-, R-/D+, R-/D-). Overall, the
groups differed significantly (p=0.027), which could be ascribed to differences between
group 1 (R+/D+) and 4 (R-/D-) (p=0.012), group 1 (R+/D+) and 3 (R-/D+) (p=0.062)
and group 2 (R+/D-) and 4 (R-/D-) (p=0.068). In a second analysis, the group with CMV-
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Table 5 Univariate analyses of OS and TRM in MUD recipients
OS in MRD TRM in MRD
P P 
Recipient CMV serostatus (pos vs neg) 0.007 < 0.001
Donor CMV serostatus (pos vs neg) ns ns
Age (continuous) 0.051 ns
Risk status (high vs low) ns ns
p/d sexe (m/f vs other) ns ns
T cell (graft) (continuous) ns ns
aGVHD (II-IV vs other) ns 0.002
cGVHD (extensive vs other) ns ns
CMV reactivation (yes vs no) ns 0.066
Abbreviations: see Table 1.
Table 6 Multivariate analyses of OS and TRM in MUD recipients
Overall Survival Transplant Related 
Mortality
RR 95% CI P value RR 95% CI P value
Recipient CMV serostatus 2.77 1.22-5.40 0.013 4.60 1.51-14.00 0.007
(pos vs neg)
aGVHD (II-IV vs other) ns 2.94 1.15-7.51 0.024
Abbreviations: see Table 1.
seropositive patients (irrespective of donor serology) was compared to the group with CMV-
seronegative patients, which revealed a highly significant difference (p=0.007). After multi-
variate analysis (Table 6 and Figure 2) only a positive recipient CMV serostatus influenced
OS (p=0.013), with no effect of donor serostatus.
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Figure 2
Adjusted probability of overall survival and transplant related mortality in MUD recipients accord-
ing to recipient CMV serostatus.
Transplant related mortality After univariate analysis recipient CMV-seropositivity
(p<0.001) and aGVHD (p=0.002) showed a strong adverse effect on TRM (Table 5), which
was also observed after multivariate analysis (recipient CMV-seropositivity: p=0.007;
aGVHD: p=0.024; Table 6 and Figure 2). Cumulative incidence curves for time to aGVHD
showed no effect of recipient CMV serostatus on probability of developing aGVHD by day
100 post-transplant. After univariate analysis CMV reactivation also affected TRM. This
effect disappeared after multivariate analysis, which is logical given the strong effect of a
positive CMV serostatus. TRM at 1 year for all MUD recipients was 37% (CI 95%: 23-51%).
In CMV-seropositive recipients one year TRM was 58% (CI 95%: 38-78%) and in CMV-
seronegative recipients 17% (CI 95%: 2-32%).
Discussion
Our data show that recipient and/or donor CMV-seropositivity was not predictive for OS
and TRM in patients treated with partial T cell depleted bone marrow transplantation from
matched related donors, receiving low-dose short-term pre-emptive and prophylactic treat-
ment with ganciclovir. In contrast, in MUD recipients, patient (but not donor) CMV-seropos-
itivity had a great impact on overall survival. In our institution CMV reactivation was
monitored by the CMV pp65 antigenemia assay and pre-emptive therapy with ganciclovir
was given when antigenemia was demonstrated. Prophylactic therapy was given when CMV-
seropositive patients had to be treated with high-dose steroids for aGVHD grade II-IV. A pre-
vious study of our group showed that none of the 41 CMV seropositive MRD patients,
monitored and treated similar as described above, developed CMV disease10. Now we found
that 3 of 205 MRD patients (1.5%) and 3 of 48 MUD recipients (6%) developed CMV dis-
ease.
Several studies have been published analysing the impact of CMV-seropositivity on OS and
TRM in recipients of non-TCD grafts. In three of them outcome was not significantly influ-
enced by patient and/or donor seropositivity18-20, although in the study of Nichols et al20 a
borderline significant decreased survival was observed in the R-/D+ group compared to the
R-/D- group. In MUD recipients only, patient CMV-seropositivity was an adverse risk factor
for outcome21,22, although this was not supported by a subgroup analysis by Nichols et al20.
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Two studies performed analyses among recipients of TCD grafts23,24. Broers et al23 found
patient and/or donor seropositivity to be associated with decreased survival and increased
TRM in MRD recipients. They instituted pre-emptive treatment when 4 or more cells were
positive in the antigenemia assay, used conventional dose ganciclovir, performed no T cell
add back and gave no prophylactic therapy to seropositive patients with aGVHD grade II-IV.
Results of a study among MUD recipients of TCD grafts24 were comparable to studies per-
formed among MUD patients receiving non-TCD grafts21,22. Overall, when TCD is performed
or not, CMV serostatus seems not to influence outcome in MRD recipients in the era of pre-
emptive treatment. However, CMV-seropositive MUD recipients were found to have a
decreased survival in nearly all studies. In a large EBMT mega file analysis the effect of
donor serostatus was analysed in CMV-seropositive recipients. In MRD recipients donor
serostatus did not affect outcome. In MUD recipients of non-TCD transplants outcome was
improved in those receiving seropositive grafts25. We did not observe a positive impact of
donor seropositivity in CMV-seropositive recipients, neither in MRD recipients nor in MUD
recipients. This is in concordance with the findings of the EBMT study25, since all our
patients received (partial) TCD grafts. In several reports the recovery of CMV-specific
(CMVs) immune response was associated with the infusion of bone marrow from seroposi-
tive donors26,27, probably by transfer of CMVs cytotoxic T cells. However, when TCD grafts
are infused, CMVs immune recovery is probably not influenced by donor serostatus.
Recently it was demonstrated that CMV infection inhibited maturation and antigen-present-
ing function of dendritic cells, which can have severe and multiple consequences for T and B
cell responses28 and may contribute to the immunosuppressive effect of CMV infection29. It
might be hypothesized that many CMV-seropositive transplant recipients suffer from sub
clinical CMV infection, which is not detected by the antigenemia assay. Recovery of T cells
after T cell depleted BMT is much more impaired in MUD recipients compared to MRD
recipients, probably related to the use of ATG in MUD patients30. Therefore, considering the
immunosuppressive effect of CMV infection, sub clinical CMV infection might be of more
importance in MUD recipients compared to MRD recipients. Indeed, mortality from (viral
and fungal) infections was higher in the CMV-seropositive MUD group compared to the
CMV-seronegative group (38% vs 8%; p=0.016).
In conclusion, CMV-seropositivity should not be considered an adverse risk factor for OS and
TRM in MRD recipients of partial T cell depleted grafts, when an appropriate prevention of
CMV disease is applied. In patients receiving grafts from MUDs, patient (but not donor)
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CMV-seropositivity has a high impact on overall survival, may be due to further impairment
of immune reconstitution in this already heavily immune suppressed patient population.
Approaches that will lead to a better T cell immune reconstitution after TCD stem cell trans-
plantation from unrelated donors are probably necessary to improve outcome in CMV-
seropositive MUD recipients.
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Abstract
Recently, several reports stressed the adverse impact of a positive recipient Cytomegalovirus
(CMV) serostatus on outcome in recipients of matched unrelated donor (MUD) grafts. In
this study we evaluated whether CMV-seropositive MUD recipients transplanted after 1999,
still showed inferior outcome compared to CMV-seronegative recipients. In that year two
important changes in transplantation procedure were introduced: 1) reduction of
Antithymocyteglobulin (ATG) dose (ATG was given prior to the myeloablative conditioning
regimen to prevent non-engraftment), 2) introduction of sequence based typing of HLA-
DRB1. In total 80 patients received partial T cell depleted grafts, 36 before 1999 and 44
after 1999. CMV-seropositive patients transplanted before 1999 showed a highly significant
inferior outcome compared to seronegative recipients. In contrast, in patients transplanted
after 1999 no difference in outcome was observed between the two groups.
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Introduction
Cytomegalovirus (CMV) infections in recipients of allogeneic stem cell transplants (SCT)
historically have been an important cause of morbidity and mortality, primarily due to CMV
pneumonia. This very serious complication occurred mainly in CMV-seropositive recipients,
with acute graft-versus-host disease (aGVHD) being an important risk factor1. Since the
introduction of pre-emptive treatment of CMV reactivations, a positive CMV serostatus no
longer is an adverse risk factor for outcome in recipients of matched related donor (MRD)
grafts2-5. However, in recipients of grafts from matched unrelated donors (MUD), recipient
CMV-seropositivity has a major negative impact on survival after SCT5-8. Most patients in
these studies were treated before 1999. In our transplantation centre two important changes
in transplantation procedure were introduced in that year. All patients received partial T cell
depleted (TCD) grafts and were pre-treated with Antithymocyteglobulin (ATG) prior to the
myeloablative conditioning regimen to prevent non-engraftment. In April 1999 ATG dose
was lowered from 20 mg/kg to 8 mg/kg. Furthermore, in January 1999 sequence based typ-
ing (SBT) of HLA-DRB1 was introduced. Both changes may result in an improved immune
reconstitution post-transplant. Low-dose ATG by a direct effect on T lymphocyte counts and
high resolution HLA-DRB1 typing by a decreased incidence of GVHD. Considering the
immunosuppressive effect of (latent) CMV infection9-10, this may have a positive impact on
outcome in CMV-seropositive SCT recipients, which is analysed in the present study.
Patients and methods
Patients For this study data of 80 consecutively treated patients receiving stem cells
from MUDs were analysed. Thirty-six patients were treated from July 1990 until January
1999 and 44 from January 1999 until January 2002. Patients with acute leukaemia’s (AL) in
first complete remissions (CR), chronic myeloid leukaemia (CML) in first chronic phase (CP)
and untreated severe aplastic anaemia (SAA) were considered low-risk. All patients with AL
and CML in more advanced stages and other diseases were considered high-risk. TRM was
defined as any mortality after transplantation, except relapse. Transplantations were per-
formed at the Department of Haematology of the University Medical Centre Utrecht.
131
  
 -			
Patients were treated according to clinical protocols approved by the local investigation
review board after informed consent was obtained.
Transplantation procedure The conditioning regimen consisted of cyclophos-
phamide (60 mg/kg/day for 2 days), followed by total body irradiation (600 cGy/day for 2
days) with partial shielding of the lungs (total lung dose 850 cGy). The graft was infused
after the second TBI fraction (day 0). Antithymocyteglobulin (Thymoglobulin™, Sangstat,
Amstelveen, the Netherlands) was given to MUD patients before cyclophosphamide was
infused, in a dose of 4 mg/kg/day intravenously for 5 days. Due to a change in national
treatment protocols, ATG dose was lowered to 2 mg/kg/day for 4 days from April 1999.
Post-transplant immunosuppression consisted of cyclosporin which was discontinued within
3 months after transplantation, when no active GVHD was present. Infection prevention for
all patients consisted of ciprofloxacin, fluconazole and amphotericin B given orally until
granulocyte counts exceeded 500 cells/µl. Cephalothin was given intravenously for 10 days
from day +3. Furthermore co-trimoxazole and (val)acyclovir were given orally from day +1
until 12 months post-BMT or longer in case of active GVHD, in a dose of 480 mg b.i.d. and
500 mg b.i.d., respectively.
CMV monitoring Until April 2001 CMV monitoring was pp65 based as described5.
Since then monitoring was performed using a real-time Taqman™ CMV DNA PCR. CMV
reactivation was defined as CMV pp65 antigenemia of ≥ 1 positive staining granulo-
cyte/150.000 cells or CMV DNA viral load (VL) of > 1000 copies/ml.
CMV disease Patients with symptoms of pneumonia, gastritis or enteritis underwent
bronchoscopy, gastroscopy or sigmoidoscopy, respectively. CMV pneumonia/gastritis/enteri-
tis was defined histologically by typical cytopathic effects and immunohistochemically by
immunofluorescence with use of monoclonal antibodies to immediate early CMV antigens in
biopsy specimens. When cultures of BAL fluid, saliva, urine and buffy coat were performed
in case of infectious complications, these included always CMV cultures, irrespective of CMV
serostatus.
Ganciclovir therapy CMV-seropositive patients who demonstrated CMV reactivation
or who were treated with high-dose corticosteroids for aGVHD grade II-IV received pre-emp-
tive or prophylactic therapy, respectively, with ganciclovir in a dose of 2.5 mg/kg intra-
venously twice a day for 14 days. When patients were symptomatic (unexplained fever or
symptoms compatible with CMV disease), CMV antigenemia/VL was rising or remained pos-
itive after 14 days of treatment, ganciclovir dose was doubled or foscarnet treatment was
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started instead of ganciclovir in a dose of 60 mg/kg twice a day for 14 days. CMV disease
was treated with ganciclovir 5 mg/kg twice a day for at least 14 days and continued until
symptoms resolved and antigenemia/VL became negative. In case of disease progression or
rising antigenemia/VL foscarnet treatment was started instead of ganciclovir in a dose of
60 mg/kg twice a day. Furthermore, treatment with CMV specific immunoglobulins was
added to antiviral therapy in patients with CMV pneumonia.
HLA-matching HLA-A and B matching was based on serological typing and HLA-C,
DRB1 and DQB1 matching was based on low resolution molecular typing with sequence spe-
cific primers. Since January 1999 and July 2000 SBT of HLA-DRB1 and HLA-A, B and DRB1,
respectively, was performed as well.
BMT In vitro partial TCD of the marrow was performed using the Soy Bean
Agglutinin/Sheep Red Blood Cell technique until 1997, thereafter, the immunorosette
depletion technique was used as described5. After this maximal T cell depletion procedure
the residual number of T cells was counted and nonmanipulated T cells (from a small BM
fraction that was set apart) were added to obtain the desired fixed low number of T cells (1-
5 x 105 T cells/kg recipient weight).
Statistical analysis Overall survival (OS) was estimated by the Kaplan-Meier method.
Probability of transplant related mortality (TRM) was calculated by the cumulative inci-
dence procedure, death from relapse being the competing risk. Univariate analyses were
performed using the log rank test. Variables which showed to influence OS/TRM at a level
of p<0.1 were used in a multivariate Cox regression analysis. P values from regression mod-
els were calculated with the Wald test. Pre- and post-transplant variables analysed were:
CMV serostatus of recipient (positive vs negative), CMV serostatus of donor (positive vs neg-
ative), patient age (continuous), risk status (high vs low), patient/donor sex (m/f vs other),
T cell count of the graft (< 2 x 105/kg vs ≥ 2 x 105/kg), ATG dose (high-dose vs low-dose),
aGVHD (II-IV vs other), chronic GVHD (extensive vs other), CMV reactivation (yes vs
no).The post-transplant variables ‘aGVHD’ and ‘cGVHD’, ‘CMV reactivation’ were as well
analysed as time-dependent covariates. Calculations were performed using SPSS/PC+ 10.0
(SPSS Inc, Chicago Il, USA).
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Results
Patient characteristics (Table 1). Thirty-six patients were treated before 1999 (his-
torical group) and 44 since 1999 (recent group). In both groups one patient was excluded
from analysis because of non-engraftment. Acute GVHD grade II-IV was more often diag-
nosed in the historical group compared to the recent group (40% vs 23%, respectively, ns)
as was extensive cGVHD (17% vs 7%, respectively, ns). Most important is the percentage of
CMV reactivations which was only 14% in the recent group compared to 31% in the histori-
cal group (p=0.063). Furthermore, most patients in the historical group experienced recur-
rent CMV reactivations (6 of 11 patients), compared to 1 of 6 patients in the recent group.
Two patients in the historical group showed ganciclovir related neutropenia, compared to
none in the recent group. Median follow up of survivors was 68 months (range: 45-115) in
the historical group and 20 months (range: 6-43) in the recent group.
OS and TRM Figure 1 shows OS and TRM in patients transplanted before and after
1999 according to recipient CMV serostatus. After univariate analyses, the only negative risk
factor for OS in the historical group was a positive recipient CMV serostatus (p=0.009),
while recipient CMV-seropositivity, CMV reactivation and aGVHD grade II-IV were adverse
risk factors for TRM in the historical group. However, after multivariate analysis, only recipi-
ent CMV-seropositivity adversely affected TRM (p=0.004). In the historical group 11/17
CMV-seropositive patients died from fatal viral (CMV pneumonia: n=3) and fungal infec-
tions, compared to 1/18 (CMV disease: n=0) in the recent group (p=0.005). In the histori-
cal group, survival analyses were also performed for all 4 recipient/donor CMV serostatus
combinations separately (R+/D+, R+/D-, R-/D+, R-/D-), showing no effect of donor
serostatus in the CMV-seropositive recipients. In the group treated since 1999 recipient
CMV-seropositivity did not affect outcome anymore.
When analyses were performed among CMV-seropositive patients, only ATG dose was a neg-
ative risk factor for outcome (OS: p=0.06; TRM: p=0.007).
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Discussion
This study shows that lowering ATG dose and introducing SBT of HLA- DRB1 (and later also
HLA-A and B) had an important impact on OS and TRM in CMV-seropositive MUD recipients
of partial TCD grafts. HLA-matching based on high resolution DNA typing resulted in a
decreased incidence of acute and chronic GVHD (although ns). Since ATG dose was the only
risk factor for outcome in seropositive patients and GVHD showed to have no impact, we
postulate that lowering the ATG dose has been the most important factor diminishing mor-
tality in CMV-seropositive recipients. Until April 2001 CMV monitoring was performed using
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Figure 1
Probability of OS and TRM in MUD recipients treated before and after 1999 according to CMV
serostatus.
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Table 1 Patient characteristics
Before 1999 After 1999 P
No. of patients 35 43
Age, yr (range) 31 (17-47) 33 (17-55) ns
Diagnosis (%) ns
AML 6 (17) 10 (23)
ALL 8 (23) 12 (28)
CML 10 (29) 13 (30)
SAA 7 (20) 1 (2)
Other 4 (11) 7 (16)
CMV serostatus R/D (%) ns
+/+ 6 (17) 9 (21)
+/- 11 (31) 9 (21)
-/+ 7 (20) 8 (19)
-/- 11 (31) 17 (40)
Risk status (%) ns
Low 13 (37) 9 (21)
High 22 (63) 34 (79)
aGVHD (%) ns
No-I 21 (60) 33 (77)
II-IV 14 (40) 10 (23)
cGVHD (%) ns
No-L 29 (83) 40 (93)
E 6 (17) 3 (7)
CMV reactivation (%) 0.06
Yes 11 (31) 6 (14)
No 24 (69) 37 (86)
Recurrent CMV reactivations ns
One 5 5
Two or more 6 1
Time to first reactivation ns
median days (range) 31 (20-52) 50 (11-78)
Granulocytes >500 x 106/L ns
recovery 100% 100%
median days (range) 23 (13-48) 19 (12-92)
Platelets >50 x 109/L ns
recovery 88% 95%
median days (range) 33 (17-148) 28 (12-208)
R/D = recipient/donor; L = limited; E = extensive.
the CMV pp65 antigenemia assay, thereafter monitoring was based on a real-time TaqMan™
CMV DNA PCR. This method is known to be more sensitive11-13 compared to the antigene-
mia assay, however, the incidence of CMV reactivations was still lower in the recent group
compared to the historical group. In conclusion, CMV-seropositive MUD recipients of partial
TCD grafts treated since 1999 show survival rates comparable to CMV-seronegative recipi-
ents. This effect largely resulted from a decrease in dosage of ATG, although high resolution
HLA-antigen typing may have contributed. Low-dose ATG did not result in an increase in
non-engraftment, while high-dose ATG is associated with an increase in acute toxicity.
Therefore, we recommend when ATG is used in the setting of TCD MUD transplantation, to
use the low-dose of 8 mg/kg.
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Abstract
The main risk factors for cytomegalovirus (CMV) disease in recipients of allogeneic stem cell
transplants (SCT) are recipient CMV-seropositivity and acute graft-versus-host disease.
Currently, two antiviral strategies -prophylactic or pre-emptive antiviral treatment- are used
for prevention of CMV disease, which is most favourable when short-term (14 days) pre-
emptive treatment is applied.
Several methods are available for monitoring of CMV reactivations. PCR based CMV DNA
detection assays are the most sensitive methods, however, the clinical benefit of this high
sensitivity is unclear. Even more, there is lack of clarity whether PCR tests can better be per-
formed in plasma, whole blood or peripheral blood leukocyte samples.
Recovery of a CMV-specific CD8+ cytotoxic T lymphocyte (CTL) response is necessary for
preventing CMV reactivation and disease. Reconstitution of absolute CMV-specific CTL
counts to values above 10-20 x 106 CTLs/L is associated with protection from CMV disease.
In the near future, pre-emptive therapy might be withheld in patients with CMV reactivation
who show to have adequate CMV-specific cytotoxic T cell levels.
Antiviral therapy with (val)acyclovir has only been studied as prophylactic treatment modal-
ity for prevention of CMV infection. High-dose oral valacyclovir is more effective compared
to acyclovir, when used in addition to pre-emptive treatment of CMV reactivations with gan-
ciclovir or foscarnet.
Three antiviral drugs have been tested for pre-emptive therapy of CMV reactivations and/or
treatment of CMV disease. Although intravenous ganciclovir is considered the drug of
choice, foscarnet has similar efficacy and less, especially haematologic, toxicity. Cidofovir
has not been tested extensively, so far results are disappointing. Oral valganciclovir for pre-
emptive treatment is currently studied among SCT recipients.
In addition to antiviral therapy, adoptive immunotherapy with CMV-specific cytotoxic T cells
as prophylactic or pre-emptive therapy is a very elegant strategy, however, generation of
these cells is expensive and time-consuming and therefore not available at every transplan-
tation centre. Magnetic selection of CMV-specific CD8+ T cells from peripheral blood using
HLA class I-peptide tetramers may be very promising, making this strategy more accessible.
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Introduction
In the era before introduction of ganciclovir (GCV), cytomegalovirus (CMV) infection and
pneumonia developed in 38 and 17%, respectively, of recipients of allogeneic stem cell
transplants (SCT), while mortality due to CMV pneumonia was 85%1. This very serious com-
plication occurred mainly in CMV-seropositive patients, with acute graft-versus-host disease
(aGVHD) being the most important risk factor1. Treatment of CMV pneumonia with GCV
and immunoglobulin decreased mortality to 30-50%2-3. In CMV-seronegative recipients, pri-
mary CMV infection could be prevented by a transfusion and transplantation policy making
use of either CMV-seronegative donors or leukocyte-depleted blood products/grafts4-7.
Currently, two antiviral strategies, prophylactic or pre-emptive treatment, are used for pre-
vention of CMV disease. Prophylactic treatment usually consists of antiviral therapy started
at engraftment until al least day 100 post-transplant. Pre-emptive therapy is defined as
antiviral treatment based on the detection of reactivated CMV infection by positive CMV cul-
tures, a positive antigenemia (Ag) assay or positive molecular assays.
In the present report, we review these antiviral strategies. Furthermore, several other
aspects of prevention of CMV disease are reviewed, which are: 1) methods available for
early detection of CMV reactivations, 2) monitoring of CMV-specific T cell responses, 3) the
value of several antiviral drugs and 4) adoptive immunotherapy as prophylaxis or (pre-emp-
tive) treatment of CMV reactivations/CMV disease.
Antiviral strategies: 
prophylaxis or pre-emptive treatment
In randomised trials8,9 (Table 1) among CMV-seropositive recipients, long-term (3-4
months) GCV prophylaxis initiated at engraftment showed to be effective in suppressing
early CMV disease (<100 days post-transplant). However, mortality was not influenced due
to an increased incidence of bacterial and fungal infections and late CMV disease8-12. When
studying recovery of CMV-specific cytotoxic T lymphocytes (CMVs-CTLs), it appeared that
long-term ganciclovir treatment impaired CMVs-CTL reconstitution causing the increase in
late CMV infections13.
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Many studies have been performed using pre-emptive therapy in SCT recipients to prevent
CMV disease. The paper by Schmidt et al14 was the first to evaluate this strategy, based on
positive CMV cultures of bronchoalveolar lavage (BAL) fluid. Patients underwent routine
BAL on day 35. The 40 patients with positive CMV cultures were randomised between pre-
emptive GCV treatment or observation. In the GCV group 5 of 20 patients died or had CMV
pneumonia before day 120 compared to 14 of 20 in the observation group (p=0.01), while
in the group of patients with negative CMV cultures the rate of CMV infection was 12 of 55.
Results of reports with a minimum of 30 patients and published after 1995 are summarized
in Tables 2-5, according to the CMV monitoring assay used; three of them were randomised
trials10,15,18. Pre-emptive treatment based on qualitative CMV DNA detection by PCR lowered
the incidence of CMV disease and CMV-associated mortality compared with pre-emptive
therapy instituted when positive CMV cultures were obtained (Table 5 and 2, respectively;
p=0.02)15. Boeckh et al10,11 compared two types of Ag based pre-emptive therapy (Table 4)
with prophylactic treatment. Ag based treatment was given for 28 days10 or until day 100
post-transplant11. In both the prophylactically treated group and the group receiving long-
term pre-emptive treatment late CMV disease was diagnosed more frequently, while more
invasive fungal infections were seen in the prophylactically treated group only. The inci-
dence of CMV disease at day 400 post-transplant and overall survival were similar in the
three treatment arms. Humar et al (Table 4 and 3) showed that Ag based pre-emptive treat-
ment reduced the incidence of CMV disease at day 400 post-transplant to 1.7% compared to
142
 !
Table 1 Ganciclovir prophylaxis of CMV disease
Study Rando- Donor Dose of GCV Early CMV disease Overall
mised Placebo vs GCV mortality
trial Placebo vs GCV
Goodrich8 Yes MRD/ 10 mg/kg/d (5d) 29%   vs   0% 26%   vs   30%
MUD fb 5 mg/kg/da (p<0.001) (at d 180, ns)
Winston9 Yes (P)MRD/ 6 mg/kg/db 24%   vs   10% 36%   vs   30%
(P)MUD (p=0.06) (at d 120, ns)
GCV = ganciclovir; (P)MRD = (partially) matched related donor; (P)MUD = (partially) matched unrelated donor; d =
day; fb = followed by; ns = not significant; a from engraftment until day 100; b from engraftment until day 120.
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Table 2 Pre-emptive therapy of CMV reactivation based on positive CMV cultures 
Study Rando- Donor No. Dose of GCV CMV CMV-a- Overall
mised disease mortality Survival
trial % % %
(at day) (at day) (at day)
Einsele15 Yes, see (P)MRD/ 34 5 mg/kg bid 32 15 59 
Table 5 (P)MUD (14d) fb 5 (180) (180) (180)
mg/kg/d until 
negative PCR 
Ljung- No (P)MRD/ 58 5 mg/kg bid 19 2 nda
man16 MUD (14d) (100) (100)
GCV = ganciclovir; CMV-a = CMV associated; (P)MRD = (partially) matched related donor; (P)MUD = (partially)
matched unrelated donor; bid= twice a day; d = day; fb = followed by; nd = not described; a overall survival was not
specified, however, reported as similar as observed in patients receiving PCR-based pre-emptive treatment, see Table 5. 
Table 3 Pre-emptive therapy of CMV reactivation based on CMV positive BAL  
Study Rando- Donor No. Dose of GCV CMV CMV-a- Overall
mised disease mortality Survival
trial % % %
(at day) (at day) (at day)
Reddy17 No MRD/ 55 5 mg/kg bid 11 5 57
MUD (14-28 d) fb (nd) (nd) (3yr)
maintenance 
(16 w)
Humar18 Yes, see (P)MRD/ 58 5 mg/kg bid 12.1 nd 72.4%
Table 4 MUD (14d) fb (400) (365)
maintenance
(8 w)
TCD = T cell depletion; GCV = ganciclovir; CMV-a = CMV associated; (P)MRD = (partially) matched related donor;
(P)MUD = (partially) matched unrelated donor; bid= twice a day; d = day; fb = followed by; w= weeks; nd = not
described.
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12.1% when therapy was instituted at the detection of positive CMV cultures of BAL fluid
obtained at day 35 post-transplant (p=0.022)18. Again overall survival was similar in the
two treatment arms.
Prevention of CMV disease with low CMV-associated mortality seemed to be superior in
studies using a short-term (14 days) Ag or PCR based pre-emptive GCV treat-
ment12,15,16,18,19,21,22,24,26,27. In these studies pre-emptive treatment was only extended when
CMV monitoring tests were still positive after the short-term treatment period. When ‘overall
survival’ was considered the endpoint, the varying pre-emptive treatment strategies all were
equally effective.
The introduction of pre-emptive therapy among CMV-seropositive patients receiving grafts
from matched related donors has resulted in similar transplant-related mortality and sur-
vival rates compared to CMV-seronegative recipients26,29-31. However, in CMV-seropositive
recipients of grafts from matched unrelated donors transplant-related mortality and overall
survival rates were still inferior compared to CMV-seronegative recipients, despite pre-emp-
tive antiviral treatment31-34.
Overall, the introduction of pre-emptive antiviral therapy has greatly reduced the incidence
and mortality rate of CMV disease. Prophylactic treatment has no advantage over pre-emp-
tive treatment, in fact it results in an increased incidence of bacterial and fungal infections
and late CMV disease. Pre-emptive treatment based on the Ag assay or PCR tests is superior
to culture or BAL fluid based strategies. Especially short-term (14 days) antiviral treatment
is the most favourable approach for prevention of CMV disease.
Antigenemia vs molecular monitoring
The Ag assay is widely used to monitor SCT recipients for CMV reactivations. This assay has
some drawbacks compared to molecular tests: 1) during neutropenia no monitoring can be
performed, which is similar for molecular tests performed in leucocytes, 2) the test is labori-
ous and 3) liable to intra/interobserver variability. Furthermore, a false negative Ag test
(using C10/C11 antibodies) was reported in a SCT recipient with CMV disease. Re-examina-
tion of the Ag negative samples with a different pp65 antibody pool (CINA antibodies)
revealed a high level of Ag35. Compared to Ag assays the workload per sample has been
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reduced from approximately 4 to less than 2 hours when automated DNA isolation and PCR
tests are used. The difference in workload is even more obvious when large amounts of sam-
ples are processed, since the Ag assay is not automated and every sample has to be
processed separately.
With the molecular assays a qualitative or quantitative detection of CMV DNA or RNA is per-
formed in cell-free plasma, peripheral blood leucocytes (PBL) or whole blood (WB). Technical
details of several methods for CMV monitoring have been reviewed by Boeckh et al36.
Cobas Amplicor™ CMV DNA (monitor) test The Cobas Amplicor™ CMV DNA test
is a commercially available qualitative CMV DNA PCR assay for plasma, while the quantita-
tive Cobas Amplicor™ CMV DNA monitor test can be performed in cell-free plasma, PBL or
WB. Five studies found CMV DNA PCR monitoring (qualitative or quantitative) to be more
sensitive compared to Ag, irrespective of performance in plasma, PBL or WB37-41. In only one
report leucocyte-based assays (Ag and PBL-PCR) were more sensitive compared to a plasma
PCR, showing a higher number of patients with a CMV reactivation, earlier positivity and a
more rapid decrease of viral load after the start of pre-emptive antiviral therapy42. In one
other study the gold standard to calculate sensitivity and specificity of the Ag assay and PCR
test was defined as “CMV reactivation based on positive results of the Ag assay or PCR
test”37. This method of calculation is incorrect and results in the exclusion of false positive
results, giving a specificity and positive predictive value of 100%. The value of a higher sen-
sitivity of molecular assays in a clinical setting is not clear. Solano et al40 reported 9 of 43
SCT recipients with positive plasma PCR, while Ag was negative. None of these 9 patients
progressed to CMV disease, although they did not receive pre-emptive treatment.
Furthermore, none of the patients with an initial positive Ag and PCR result who remained
PCR positive after conversion of the Ag assay to a negative result, did develop CMV disease.
The authors concluded that the Ag assay appeared to be most suitable for guiding initiation
of pre-emptive therapy and monitoring response to antiviral therapy.
Real-time automated CMV DNA PCR test using a TaqMan™ probe With the
real-time automated CMV DNA PCR assay using a TaqMan™ probe, a quantitative CMV
monitoring in plasma, WB and PBL can be performed. With this method PCR products are
detected as they accumulate during the PCR, in contrast to other quantitative PCR tech-
niques such as the Cobas Amplicor™ CMV DNA monitor test. This results in a greater linear
dynamic detection range of the real-time TaqMan™ PCR compared to the Cobas Amplicor™
CMV DNA monitor test. Analogous to the Cobas Amplicor™ tests, this assay also proved to
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be more sensitive compared to a positive Ag test. CMV DNA detection by real-time PCR
often preceded Ag and yielded more positive samples43-45.
Qualitative and quantitative in house CMV DNA PCR assay In (partly) retro-
spective studies, CMV DNA monitoring by in house PCR assays in plasma, WB or PBL yielded
similar results as described above, with higher sensitivity for molecular tests compared to
the Ag assay38,46,47. Hebart et al48 prospectively monitored CMV reactivation by Ag and in
house semiquantitative PCR in plasma and WB. WB-PCR showed the lowest sensitivity, how-
ever, overall a good correlation was seen between Ag, WB-PCR and plasma PCR. All three
assays were negative after 14 days of GCV treatment in 12 of 13 patients. In contrast, 2
studies49,50 reported the in house plasma PCR to be less sensitive compared to PBL-PCR or
Ag.
Murex™ CMV DNA Hybrid Capture assay This assay is a commercially available
solution hybridisation antibody capture assay (HCA) for the quantitative detection of CMV
DNA in leukocytes. It was less sensitive in diagnosing CMV infection compared to an in
house qualitative PCR38,51. When CMV disease was used as the gold standard for compari-
son, however, the positive predictive value of the HCA and PCR assay was 33% and 22%,
respectively51.
CMV mRNA based monitoring The qualitative determination of CMV pp67 mRNA
by nucleic acid sequence-based amplification proved to be the least sensitive technique to
assess CMV reactivation compared to DNA based assays and the Ag assay38,52,53. Detection of
immediate-early mRNA54, the beta2.7 transcript55 or spliced late CMV genes56 all were shown
to be more useful, however, these results have not been validated by other groups.
Summary In Table 6 results of studies comparing commercially available surveillance
methods with the Ag assay or in house PCR tests are summarized. Not all studies described
above are included, due to varying study designs and endpoints or lack of clinical
data37,41,42,55,56. In several papers sensitivity, specificity, positive predictive value and nega-
tive predictive value of the experimental assay(s) were calculated. In these studies the gold
standard to calculate these values was defined as CMV reactivations based on positive
results from Ag and/or PCR assays37,55,56. In our view, a surveillance method for CMV reacti-
vation should be judged on its clinical merits, the incidence of CMV disease and transplant
related mortality being the most significant endpoints.
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Overall, one can conclude that PCR based CMV DNA monitoring is more sensitive compared
to Ag based monitoring. However, the clinical benefit is unclear. Even more, there is lack of
clarity whether PCR tests can better be performed in plasma, WB or PBL samples, although
molecular monitoring in plasma has the advantage of performance irrespective of neutrope-
nia. Currently, there is no evidence that qualitative CMV detection assays have a better or
worse predictive value for the occurrence of CMV disease after SCT as compared to quantita-
tive assays. To answer this question, randomised controlled trials should be performed,
monitoring patients prospectively with either detection assay without applying pre-emptive
treatment of CMV reactivation. Such trials will never be done. Theoretically, a quantitative
method enables monitoring of response to therapy. In case of an increasing viral load after
the start of pre-emptive therapy, a dose or drug modification may be applied. This was
implemented by Mori et al28 but did not significantly change the incidence of CMV disease.
Monitoring of CMV-specific T cell responses
Studies of immune recovery after allogeneic SCT have shown a temporal delay in the recov-
ery of CMVs T cell responses and have identified a decisive role for the recovery of CD8+
CTL responses in preventing the development of CMV disease57-59. Generation of CD8+
CMVs-CTLs was associated with recovery of CD4+ CMVs T helper cells58. Li et al13 analysed
the kinetics of endogenous reconstitution of CD4+ and CD8+ CMVs T cell responses, by
lymphoproliferation and cytotoxicity assays, in 47 allogeneic SCT recipients who were ran-
domised to GCV prophylaxis or placebo after recovery of peripheral neutrophil counts.
Between day 40 and 90 post-transplant recovery of CD8+ and CD4+ CMVs T cell responses
occurred in the majority of individuals receiving placebo, but in a minority of patients
receiving GCV. Thus, long-term prophylactic GCV treatment can delay post-transplant recon-
stitution of CMVs-CTL responses. Today, several reports have been published using screen-
ing assays for CMVs T cell reconstitution to identify patients at risk of developing CMV
disease60-65. Krause et al60 performed lymphoproliferation assays, to assess CD4+ CMVs T
helper (Th) response, at regular monthly intervals. None of the patients with a CMVs T cell
proliferation on day 120 developed CMV disease after day 120. In contrast, of the patients
lacking such a response at day 120, 30.8% developed late CMV disease (after day 120).
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Hebart et al65 quantified CD8+ CMVs-CTLs and CD4+ CMVs Th cells by intracellular inter-
feron-γ staining with flow cytometry after CMV-specific stimulation. Reconstitution of both
cell types was associated with rapid clearance of CMV infection. Next to cytotoxicity and
interferon-γ staining assays, the use of HLA-peptide tetramers to quantify CMVs CD8+ T cell
reconstitution might enable prediction of the development of CMV disease61-63.
Reconstitution of absolute CMVs-CTL counts to values above 10-20 x 106/L was associated
with protection from CMV disease62,63. In contrast, Ozdemir et al64 recently reported that
frequencies and absolute numbers of CMVs CD8+ T cells were greater in subjects who expe-
rienced CMV Ag following SCT. They conclude that recovery of CMVs-CTLs, as measured by
HLA-peptide tetramer staining, is insufficient to control CMV Ag. However, it is not
described whether these patients with Ag did develop CMV disease. This might be impor-
tant, since only patients with Ag and decreased recovery of CMVs-CTLs, progressed to CMV
disease in the study of Gratama et al61. Patients with Ag who did not develop CMV disease,
demonstrated higher levels of CMVs CD8+ T cells compared to CMV-seropositive recipients
without Ag. It should be noted that most CMVs-CTL studies discussed in this review were
performed retrospectively and used tetrameric complexes of HLA A*0201 and/or B*0702
molecules. Larger prospective studies have to be performed to evaluate CMVs CD8+ T cell
reconstitution after allogeneic SCT. When the abovementioned results will be validated, pre-
emptive antiviral therapy might be withheld in patients with CMV reactivation who show to
have adequate CMVs-CTL levels. At this moment, several other HLA class I (A*0101,
A*0301, A*1101, A*2401, A*6801/2, B*3502, B*3801/2, B*44XX) restricted pp65 and
pp150 derived epitopes have been identified65,66,67 which will make tetramer based or inter-
feron-γ staining based quantification of CMVs CD8+ T cell recovery accessible for more SCT
recipients.
Antiviral therapy
Intravenous GCV is generally considered the drug of choice for pre-emptive therapy of CMV
reactivations or treatment of CMV disease68. Several other antiviral drugs have in vitro or in
vivo activity against CMV (acyclovir -ACV-, valacyclovir -VACV-, foscarnet, cidofovir -CDV-,
valganciclovir -VGCV-). (V)ACV and (V)GCV are nucleoside analogues. VACV and VGCV are
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oral prodrugs of ACV and GCV, respectively, and converted to ACV and GCV, respectively,
after cleavage of the valine moiety by the liver and intestine. The nucleosides first have to be
converted to monophosphate by a viral protein kinase (which is the gene product of UL97 in
case of CMV). Second and third phosphorylations are performed by cellular kinases. ACV or
GCV triphosphate is then incorporated in viral DNA and acts as an obligate chain
terminator69. Furthermore GCV triphosphate is a competitive inhibitor of the CMV DNA
polymerase. VGCV has a ten-fold greater bio-availability than oral GCV. Pharmacokinetic
studies of VGCV have been performed in HIV infected individuals and recipients of liver
transplants70. Among SCT recipients a randomised cross-over trial using intravenous GCV or
oral VGCV as pre-emptive treatment will be conducted at European Group for Blood and
Marrow Transplantion (EBMT) centres70. The nucleotide analogue CDV already is a
monophosphate, therefore no phosphorylation by viral enzymes is necessary. Foscarnet is a
pyrophosphate analogue forming a complex with the pyrophosphate binding site of viral
DNA polymerase. This is an essential site during incorporation of nucleotides in DNA in
which a pyrophosphate group has to be spliced from the nucleotide. Thereby, foscarnet is
inhibiting viral DNA polymerase activity.
Acyclovir/Valacyclovir (V)ACV has only been studied as prophylactic therapy for pre-
vention of CMV reactivations/disease and not as (pre-emptive) treatment. ACV has only lim-
ited activity against CMV when tested in vivo. Two studies using ACV prophylaxis were
performed in SCT recipients, however, before the strategy of pre-emptive GCV therapy
based on Ag or PCR was introduced71,72. Intravenous ACV followed by high-dose oral ACV
maintenance therapy was not effective as prevention of CMV disease, but resulted in a
decreased CMV-associated mortality and increased survival. Vusirikala et al73 compared data
of 31 SCT recipients who were prophylactically treated with VACV 1 gram 3 times a day
with a group receiving only low-dose oral ACV. Primary and secondary CMV reactivations
were observed in 3/12 and 5/19 VACV treated patients, respectively, compared to 24/31
and 16/24 in the control group, respectively. Since this was a retrospective report with small
patient numbers combining primary and secondary reactivations, it just suggested a poten-
tial benefit of VACV as prevention for CMV reactivation. In a large randomised multi-centre
study oral VACV showed to be more effective in preventing CMV viremia in SCT recipients
compared to oral ACV, although overall survival and the incidence of CMV disease did not
differ between the two groups (75% vs 76% and 5.5% vs 3.5% for the ACV and VACV
groups, respectively, ns). All patients included were initially treated with intravenous acy-
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clovir until day 28 after transplantation or until discharge74. In these two studies a PCR or
Ag based pre-emptive treatment with GCV or foscarnet was used as well73,74.
Foscarnet Intravenous foscarnet is considered second line therapy for CMV reactivations
or disease, however, for patients developing dose-limiting neutropenia or CMV strains resist-
ant to GCV it is the drug of choice68. In a survey of herpesvirus resistance to antiviral drugs,
GCV was replaced by foscarnet in 15 patients with suspected or proven GCV resistance and
this resulted in a better clinical or virological outcome in 13 of these 15 patients75.
Four non-randomised studies were published using foscarnet prophylactically76-79. In all four
studies patient numbers were very small (≤ 21), therefore, no firm conclusions can be
drawn regarding effectiveness of foscarnet prophylaxis.
Preemptive treatment consisting of foscarnet has also been reported in four studies, showing
similar efficacy of foscarnet compared to GCV80-83. Only two were randomised trials82,83, one
with a low patient number82. Reusser et al83 treated 110 patients with CMV reactivation (Ag
or PCR diagnosed) with foscarnet 60 mg/kg bid and 103 patients with GCV 5 mg/kg bid.
When test results were still positive after 14 days of treatment both drugs were continued in
a reduced dose (90 mg/kg/day:foscarnet; 6mg/kg/day:GCV) for again 2 weeks (5 days a
week). When CMV was still detectable after this second treatment period, treatment was
considered a failure, and patients were treated at the discretion of the investigator. Event
free survival and overall survival at day 180 were similar in both groups, as was the occur-
rence of CMV disease and treatment failures. No difference was observed regarding other
herpesvirus infections or major nonviral infections. Preemptive treatment with foscarnet did
not raise safety concerns (when appropriate hydration was used) and was associated with
significantly less serious haematotoxicity than GCV. In the GCV group neutropenia was more
often observed, despite the use of growth factors.
Cidofovir Ljungman et al84 performed a retrospective survey among 17 BMT centres and
enrolled 82 patients who were treated with CDV for CMV disease (n=20) or for CMV reacti-
vation (primary pre-emptive treatment n=24; secondary pre-emptive treatment in patients
who had failed or relapsed after previous pre-emptive treatment with another antiviral drug
n=38). The dosage was 1-5 mg/kg per week followed by maintenance treatment and all
patients received probenicid and prehydration. Overall 62% showed a response to CDV ther-
apy; the response being defined as disease regression without addition of other specific ther-
apy or, for pre-emptive therapy, conversion of a positive Ag or PCR test. Twenty-one
patients developed renal toxicity, which persisted after cessation of therapy in 9 patients. No
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toxicity was seen in 45 patients, while 15 developed other side effects potentially associated
with CDV therapy (nausea, vomiting, thrombocytopenia, rash, ophthalmologic and neuro-
logic toxicity). Kiehl et al85 published prospective data on 21 patients receiving first-line pre-
emptive treatment with CDV 5 mg/kg once a week for 2 weeks, thereafter fortnightly.
Treatment was Ag and/or DNA PCR based and continued until test results were negative for
at least three weeks. Only one patient showed a complete response. In 15 patients PCR
became negative, however, 2-3 weeks later a positive PCR was again observed in all 15
patients. In 5 patients CMV reactivation was not cleared. The authors stated that it might be
more effective to give CDV once a week for a longer period, which is supported by the low
toxicity rate observed in this study: only one patient developed renal toxicity. Chakrabarti et
al86 treated 4 patients pre-emptively with CDV 5 mg/kg/week for 4 weeks. Two responded
but developed severe nausea/vomitus and uveitis. Two were non responders of which one
died from CMV pneumonia and one developed CMV pneumonia eventually responding to
foscarnet. The less favourable outcome of the last two reports are in concordance with
recent prospective results from Platzbecker et al87. Here, only one of seven SCT recipients
showed a transient clearance of pp65 Ag after treatment with CDV 5 mg/kg/week for two
weeks, thereafter fortnightly. In contrast, these authors87 showed that pre-emptive treat-
ment with CDV was very successful in 10 SCT recipients treated with a non-myeloablative
conditioning regimen. Toxicity was moderate and consisted of reversible renal impairment
(n=4), proteinuria (n=1) and nausea/vomiting (n=3).
Antiviral drug resistance When prolonged (>100 days) antiviral therapy is given,
drug resistance may develop88. Data about antiviral drug resistance have largely been
obtained in AIDS patients and very little information is available about drug resistance in
the SCT setting. Resistance of CMV to GCV is associated with lack of therapeutic response
and progression of CMV disease89,90. The clinical outcome of infections caused by foscarnet
and CDV resistant CMV strains is unknown. In 1996 a survey of herpesvirus resistance to
antiviral drugs was performed in 68 bone marrow transplantation (BMT) centres. CMV
resistance to GCV was proven in 2 patients and suspected in 23 patients75. In patients with
CMV pneumonia, the virus often persists for a long time despite GCV treatment. GCV resist-
ance was determined in CMV isolates obtained from BAL fluid or from autopsy lung tissue
by DNA hybridisation. In only 1 of 12 patients a GCV resistant isolate was detected91. In a
study among 50 allogeneic SCT recipients, 10 patient exhibited sustained or recurrent anti-
genemia despite GCV treatment. Samples from these 10 patients were screened for the pres-
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ence of the most frequent CMV UL97 mutations by restriction enzyme analysis and none of
these mutations were detected92. Altogether, antiviral drug resistance has only sporadically
been reported in adult SCT recipients75,91-93. There is some evidence that it might be more
frequent in paediatric SCT recipients, especially in patients with primary immunodeficien-
cies90,94,95.
In clinical CMV strains, resistance to antiviral agents has been associated with mutations in
the viral protein kinase UL97 (for GCV only) and viral DNA polymerase UL54 (for GCV, fos-
carnet and CDV) genes89. The varying laboratory methods used for drug susceptibility test-
ing of CMV isolates have been reviewed by Erice89 and may be classified as phenotypic or
genotypic. Phenotypic methods generally are culture-based and designed to determine the
concentration of an antiviral agent that would inhibit the virus in culture. Genotypic meth-
ods are designed to determine known UL97 or UL54 mutations present in the genome of the
viruses being studied, using restriction enzyme analysis and/or sequencing, and do not
require viral cultures. A drawback of phenotypic methods is the possible in vitro selection of
specific virus isolates by several culture passages. This was recently proven by Hamprecht et
al96 who performed only one culture passage of CMV isolates before phenotypic drug sus-
ceptibility assays were performed. Virus strains isolated from these cultures were also geno-
typically analysed by UL97 restriction assays and sequencing and were compared with
primary DNA extracts of the same specimens. This resulted in the molecular proof of the in
vitro selection of one UL97 mutant strain from 3 viral variants (one wild type and two UL97
mutants) present in vivo.
Summary Overall, in the era before the introduction of pre-emptive antiviral therapy,
high-dose prophylactic ACV was shown to be effective in reducing the CMV-associated mor-
tality rate. When pre-emptive treatment with GCV or foscarnet was used, VACV proved to be
more effective as prophylaxis against CMV viremia compared to ACV, however, without sig-
nificantly affecting overall survival and the incidence of CMV disease. Currently it is not
clear whether VACV prophylaxis combined with a pre-emptive antiviral strategy is better
compared to pre-emptive therapy alone, which has to be tested in a randomised controlled
trial. Although intravenous GCV is considered the drug of choice for (pre-emptive) treat-
ment of CMV reactivations or disease, foscarnet has similar efficacy and less haematologic
toxicity. The third agent used for pre-emptive treatment, CDV, has prospectively been tested
in only a few studies all of them showing disappointing results.
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Adoptive immunotherapy with CMVs T cells
Adoptive transfer of CD8+ CMVs-CTLs for prevention of CMV reactivation/disease has been
shown effective59,97. When no CMVs Th response developed, CMVs-CTLs declined progres-
sively. However, none of the 17 patients treated with CD8+ CMVs-CTLs developed CMV
infection59,97. Einsele et al98 treated 8 patients with antiviral resistant CMV reactivation, who
had a CMV-seropositive donor, with CMVs T cells (107 CMVs T cells/m2). These cells con-
sisted of CD4+ CMVs Th cells and CD8+ CMVs-CTLs. Only patients lacking a CMVs lympho-
proliferative response in vitro, indicating a deficient CMVs Th response, were enrolled. A
response was seen in 6 of 7 evaluable patients, in which CMV reactivation was cleared. Once
CMVs T cells emerged in the peripheral blood, they persisted at numbers comparable to
those in healthy individuals. The authors hypothesize that adoptive immunotherapy is more
effective when CD4+ CMVs Th cells are given together with CD8+ CMVs-CTLs, by inducing
expansion of CD8+ CMVs-CTLs from precursors that without T cell help would not have
been activated. In this study 3 patients subsequently developed invasive aspergillosis or res-
piratory syncytial virus interstitial pneumonitis. In a commentary it is stated that more effi-
cient culture systems are needed to make this therapy more accessible. Furthermore, since
eventually 3 patients died from fungal or viral infections a more comprehensive approach to
reconstitute immunity in SCT recipients is required99. Peggs et al100 used monocyte-derived
dendritic cells to process and present CMV antigen to generate donor-derived CMVs cell
lines containing both CD4+ and CD8+ T cells with a simple and rapid 21 day culture. These
cells were administered pre-emptively to 13 allogeneic transplant recipients, of which 10
received a non-myeloablative conditioning regimen. Within 23 days following infusion
CD8+ CMVs-CTLs reached absolute counts as high as 540 x 106/L and were detectable for
up to 6 months post-transfusion. Six patients cleared CMV without antiviral drugs and no
cases of CMV disease were diagnosed. Only 1 of 12 evaluable patients showed subsequent
CMV reactivation. This patient had CMVs T cells administered at day 14 post-transplant,
when Campath-1H (the IgG1 humanized monoclonal antibody against CD52) probably was
still circulating, which might have induced lysis of these T cells.
Adoptive immunotherapy with CMV-specific cytotoxic T cells as pre-emptive therapy is a
very elegant strategy, however, generation of these cells is expensive and time-consuming
and therefore not available at every transplantation centre. Magnetic selection of CMVs
CD8+ T cells from peripheral blood of CMV-seropositive donors using HLA class I-peptide
158
 !
tetramers as decribed by Keenan et al101 may be very promising, making adoptive
immunotherapy more accessible.
Conclusion
This review focused on prevention of CMV disease in recipients of allogeneic SCT. The intro-
duction of pre-emptive antiviral therapy has greatly reduced the incidence and mortality
rate of CMV disease, especially when Ag or PCR based CMV monitoring is performed. A lot
of questions still remain to be answered. We currently do not know whether the increased
sensitivity of PCR based CMV DNA assays has any clinical benefit. Furthermore, it is not
clear whether PCR tests can better be performed in plasma, whole blood or peripheral blood
leukocyte samples. At which viral load or Ag level should antiviral therapy be instituted and
for how long should it be continued? The current conclusion is that prevention of CMV dis-
ease with low CMV-associated mortality seems to be superior in studies using a short-term
(14 days) Ag or PCR based pre-emptive treatment. In these studies pre-emptive treatment
was only extended when CMV monitoring tests were still positive after the short-term treat-
ment period. When overall survival was considered the endpoint, the varying pre-emptive
treatment strategies all were equally effective.
In the near future, monitoring CMVs T cell recovery may change our current pre-emptive
treatment strategy. The presence of CMVs T cells in patients with a documented CMV reacti-
vation, might protect these patients from developing CMV disease. Prospective studies are
needed to confirm the results derived from retrospectively performed analyses.
Lastly, efforts should focus on immune reconstitution. Once adoptive immunotherapy will
become more accessible, controlled trials should be designed to study the effectivity of
immunotherapy regarding prevention of CMV disease.
159
 	
References
1 Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J
Infect Dis 1986; 153: 478-488.
2 Emanuel D, Cunningham I, Jules-Elysee K et al. Cytomegalovirus pneumonia after bone marrow transplantation success-
fully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109:
777-782.
3 Reed EC, Bowden RA, Dandliker PS et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous
cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783-788.
4 Bowden RA, Slichter SJ, Sayers MH et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood
cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246-250.
5 Verdonck LF, de Graan-Hentzen YCE, Dekker AW et al. Cytomegalovirus seronegative platelets and leukocyte-poor red
blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone
Marrow Transplant 1987; 2: 73-78.
6 van Prooyen HC, Visser JJ, van Oostendorp WR et al. Prevention of primary transfusion-associated cytomegalovirus infec-
tion in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
Br J Haematol 1994; 87: 144-147.
7 de Gast GC, Boland GJ, Vlieger AM et al. Abortive human cytomegalovirus infection in patients after allogeneic bone mar-
row transplantation. Bone Marrow Transplant 1992; 9: 221-225.
8 Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic mar-
row transplant. Ann Intern Med 1993; 118: 173-178.
9 Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection in allogeneic bone marrow
transplant recipients. Ann Intern Med 1993; 118: 179-184.
10 Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir at
engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
11 Boeckh M, Bowden RA, Gooley TA, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treat-
ment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999; 93: 1781-
1782.
12 Einsele H, Hebart H, Kauffman-Schneider C et al. Risk factors for treatment failures in patients receiving PCR-based pre-
emptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763.
13 Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CVM)-specific T-cell responses after
allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83:
1971-1979.
14 Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganci-
clovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-
Stanford-Syntex CMV Study Group. N Engl J Med 1991; 324: 1005-1011.
15 Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus dis-
ease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
16 Ljungman P, Lore K, Aschan J, Klaesson S, Lewensohn-Fuchs I, Lonnqvist B, Ringden O, Winiarski J, Ehrnst A. Use of a
semiquantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow
transplant recipients. Bone Marrow Transplant 1996; 17: 583-587.
160
 !
17 Reddy V, Hao Y, Lipton J, Meharchand J, Minden M, Mazzulli T, Chan C, Messner HA. Management of allogeneic bone
marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-
emptive ganciclovir therapy. J Clin Virol 1999;13 : 149-159.
18 Humar A, Lipton J, Welsh S, Moussa G, Messner H, Mazzulli T. A randomised trial comparing cytomegalovirus antigene-
mia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and
peripheral blood stem cell transplant recipients. Bone Marrow Transplant 2001; 28: 485-490.
19 Verdonck LF, Dekker AW, Rozenberg-Arska M, van den Hoek MR. A risk adapted approach with a short course of ganci-
clovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplan-
tation. Clin Infect Dis 1997; 24: 901-907.
20 Manteiga R, Martino R, Sureda A, Labeaga R, Brunet S, Sierra J, Rabella N. Cytomegalovirus pp65 antigenemia-guided
pre-emptive treatment with ganciclovir after allogeneic stem cell transplantation: a single-center experience. Bone Marrow
Transplant 1998; 22: 899-904.
21 Machado CM, Dulley FL, Vilas Boas LS, Castelli JB, Macedo MCA, Silva RL, Pallota R, Saboya RS, Pannuti CS. CMV pneu-
monia in allogeneic recipients undergoing early treatment or pre-emptive ganciclovir therapy. Bone Marrow Transplant
2000; 26: 413-417.
22 Machado CM, Menezes RX, Macedo MCA, Mendes AVA, Vilas Boas LS, Castelli JB, Dulley FL, Pannuti CS. Extended anti-
genemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant 2001; 28: 1053-
1059.
23 Mori T, Okamoto S, Matsuoka S et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergo-
ing allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 765-769.
24 Kanda Y, Mineishi S, Saito T et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigene-
mia assay after allogeneic hematopoietic stem cell transplantation: a single center experience in Japan. Bone Marrow
Transplant 2001; 27: 437-444.
25. Small TN, Papadopoulos EP, Boulad F, Kiehn T, Stiles J, Sepkowitz K, O’Reilly RJ. Outcome of pre-emptive or prophylactic
anti-viral therapy to prevent CMV disease following T cell depleted related or unrelated BMT. Blood 2001; 98: S394a.
Abstract 1659.
26 Peggs KS, Preiser W, Kottaridis PD et al. Extended routine polymerase chain reaction surveillance and pre-emptive antivi-
ral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000; 111: 782-790.
27 Hebart H, Brugger W, Grigoleit U et al. Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-
based pre-emptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood
2001; 97: 2183-2185. Letter.
28 Mori T, Okamoto S, Watanabe R, Yajima T, Iwao Y, Yamazaki R, Nakazato T, Sato N, Iguchi T, Nagayama H, Takayama N,
Hibi T, Ikeda Y. Dose-adjusted pre-emptive therapy for cytomegalovirus disease based on real-time polymerase chain reac-
tion after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 777-782.
29 Humar A, Wood S, Lipton J et al. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allo-
geneic bone marrow transplants. Clin Infect Dis 1998; 26: 606-610.
30 Nichols WG, Corey L, Gooley T et al. High risk of death due to bacterial and fungal infection among cytomegalovirus
(CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary
CMV infection. J Infect Dis 2002; 185: 273-282.
31 Meijer E, Dekker AW, Rozenberg-Arska M, Weersink AJL, Verdonck LF. Influence of Cytomegalovirus-seropositivity on out-
come after T cell depleted bone marrow transplantation: contrasting results between recipients of grafts from related and
unrelated donors. Clin Infect Dis 2002; 35: 703-712.
161
 	
32 Craddock C, Szydlo RM, Dazzi F et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unre-
lated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophy-
laxis. Br J Haematol 2001; 112: 228-236.
33 Kröger N, Zabelina T, Krüger W et al. Patient cytomegalovirus seropositivity with or without reactivation is the most
important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors
using pretransplant in vivo T-cell depletion with antithymocyte globulin. Br J Haematol 2001; 113: 1060-1071.
34 Castro-Malaspina H, Harris RE, Gajewski J et al. Unrelated marrow transplantation for myelodysplastic syndromes: out-
come analysis in 510 transplants facilitated by the national marrow donor program. Blood 2002; 99: 1943-1951.
35 Seropian S, Ferguson D, Salloum E, Cooper D, Landry ML. Lack of reactivity to CMV pp65 antigenemia testing in a patient
with CMV disease following allogeneic bone marrow transplant. Bone Marrow Transplant 1998; 22: 507-509.
36 Boekch M, Boivan G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev
1998; 11: 533-554.
37 Hiyoshi M, Tagawa S, Takubo T et al. Evaluation of the Amplicor CMV test for direct detection of cytomegalovirus in
plasma specimens. J Clin Microbiol 1997; 10: 2692-2694.
38 Preiser W, Brauninger S, Schwerdtfeger R, Ayliffe U, Garson JA, Brink NS, Franck S, Doerr HW, Rabenau HF. Evaluation
of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. J Clin Virol
2001; 20: 59-70.
39 Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F, Mitterbauer M, Kalhs P. CMV monitoring
after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Bone Marrow
Transplant 2001; 28: 765-768.
40 Solano C, Munoz I, Gutierrez A, Farga A, Prosper F, Garcia-Conde J, Navarro D, Gimeno C. Qualitative plasma PCR assay
(Amplicor CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding pre-emptive gan-
ciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 2001; 39: 3938-3941.
41 Flexman J, Kay I, Fonte R, Herrmann R, Gabbay E, Palladino S. Differences between the quantitative antigenemia assay
and the Cobas Amplicor monitor quantitative PCR assay for detecting CMV viremia in bone marrow and solid organ recipi-
ents. J Med Virol 2001; 64: 275-282.
42. Boivin G, Belanger R, Delage R, Beliveau C, Demers C, Goyette N, Roy J. Quantitative analysis of cytomegalovirus (CMV)
viremia using the pp65 antigenemia assay and the Cobas Amplicor CMV monitor test after blood and marrow allogeneic
transplantation. J Clin Microbiol 2002; 38: 4356-4360.
43 Machida U, Kami M, Fukui T et al. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infec-
tion after bone marrow transplantation. J Clin Microbiol 2000; 38: 2536-2542.
44 Griscelli F, Barrois M, Chauvin S, Lastere S, Bellet D, Bourhis JH. Quantification of human cytomegalovirus DNA in bone
marrow transplant recipients by real-time PCR. J Clin Microbiol 2001; 39: 4362-4369.
45 Yakushiji K, Gondo H, Kamezaki K et al. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplanta-
tion: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplant
2002; 29: 599-606.
46 Gerna G, Furione M, Baldanti F, Percivalle E, Comoli P, Locatelli F. Quantitation of human cytomegalovirus DNA in bone
marrow transplant recipients. Br J Haematol 1995; 91: 674-683.
47 Kanda Y, Chiba S, Suzuki T, Kami M, Yazaki Y, Hirai H. Time course analysis of semi-quantitative PCR and antigenemia
assay for prevention of cytomegalovirus disease after bone marrow transplantation. Br J Haematol 1998; 100: 222-225.
162
 !
48. Hebart H, Muller C, Loffler J, Jahn G, Einsele H. Monitoring of CMV infection: a comparison of PCR from whole blood,
plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant
1996; 17: 861-868.
49 Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA. Plasma polymerase chain reaction for cytomegalovirus
DNA after allogeneic marrow transplantation. Transplantation 1997; 64: 108-113.
50 Matsunaga T, Sakamaki S, Ishigaki S et al. Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation
in bone marrow transplant recipients. Int J Hematol 1999; 69: 105-111.
51 Hebart H, Gamer D, Loeffler J et al. Evaluation of Murex CMV DNA hybrid capture assay for detection and quantitation of
cytomegalovirus infection in patients following allogeneic stem cell transplantation. J Clin Microbiol 1998; 36: 1333-337.
52 Gerna G, Baldanti F, Middeldorp JM, Furione M, Zavattoni M, Lilleri D, Revello MG. Clinical significance of expression of
human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by
nucleic acid sequence-based amplification. J Clin Microbiol 1999; 37: 902-911.
53 Hebart H, Rudolph T, Loeffler J, Middeldorp J, Ljubicic T, Jahn G, Einsele H. Evaluation of the NucliSens CMV pp67 assay
for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow
Transplant 2002; 30: 181-187.
54 Gerna G, Baldanti F, Lilleri D et al. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-
based amplification as a new parameter for pre-emptive therapy in bone marrow transplant recipients. J Clin Microbiol
2000; 38: 1845-1853.
55 Aono T, Kondo K, Miyoshi H, Tanaka-Taya K, Kondo M, Osugi Y, Hara J, Okada S, Yamanishi K. Monitoring of human
cytomegalovirus infections in pediatric bone marrow transplant recipients by nucleic acid sequence-based amplification. J
Infect Dis 1998; 178: 1244-1249.
56 Boriskin YS, Fuller K, Powles RL, Vipond IB, Rice PS, Booth JC, Caul EO, Butcher PD. Early detection of cytomegalovirus
(CMV) infection in bone marrow transplant patients by reverse transcription-PCR for CMV spliced late gene UL21.5: a two
site evaluation. J Clin Virol 2002; 24: 13-23.
57 Quinnan GV, Kirmani N, Rook AH et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and
Non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant
recipients. N Engl J Med 1982; 307: 6-13.
58 Reusser P, Riddell S, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allo-
geneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.
Blood 1991; 78: 1373-1380.
59 Riddell ST, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient
humans by the adoptive transfer of T cell clones. Science 1992; 257: 238-241.
60 Krause H, Hebart H, Jahn G, Muller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at
risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19: 1111-1116.
61 Gratama JW, van Esser JWJ, Lamers CHJ, Tournay C, Lowenberg B, Bolhuis RLH, Cornelissen JJ. Tetramer-based quantifi-
cation of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell depleted stem cell grafts and after transplantation
may identify patients at risk for progressive CMV infection. Blood 2001; 98: 1358-1364.
62 Cwynarski K, Ainsworth J, Cobbold M et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allo-
geneic stem cell transplantation. Blood 2001; 97: 1232-1240.
63 Aubert G, Hassan-Walker AF, Madrigal JA et al. Cytomegalovirus-specific cellular immune responses and viremia in recipi-
ents of allogeneic stem cell transplants. J Infect Dis 2001; 184: 955-963.
163
 	
64 Ozdemir E, St. John LS, Gillespie G et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is
associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002; 100: 3690-3697.
65 Hebart H, Daginik S, Stevanovic S et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lym-
phocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and
in patients after allogeneic stem cell transplantation. Blood 2002; 99: 3830-3837.
66 Longmate J, York J, La Rosa C, Krishan R, Zhang M, Senitzer D, Diamond DJ. Population coverage by HLA class-I
restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001; 52: 165-173.
67 Lim JB, Provenzano M, Bettinotti M, Stroncek DF. Identification of a new candidate HLA-A3 restricted CMV epitope as a
target antigen to induce specific CMV cytotoxic lymphocytes. Blood 2001; 98: S780a. Abstract 3244.
68 Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol 2000; 16: 25-40.
69 Ljungman P. Prophylaxis against herpesvirus infections in transplant recipients. Drugs 2001; 61: 187-196.
70 Reusser P. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompro-
mised hosts. Expert Opin Investig Drugs 2001; 10: 1745-1753.
71 Meyers JD, Reed EC, Shepp DH et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic
marrow transplantation. N Engl J Med 1988; 318: 70-75.
72 Prentice HG, Gluckman E, Powles RL et al. Long-term survival in allogeneic bone marrow transplant recipients following
acyclovir prophylaxis for CMV infection. Bone Marrow Transplant 1997; 19: 129-133.
73 Vusirikala M, Wolff SN, Stein RS, Brandt SJ, Morgan DS, Greer JP, Schuening FG, Dummer JS, Goodman SA. Valacyclovir
for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective
cohort analysis. Bone Marrow Transplant 2001; 28: 265-270.
74 Ljungman P, de la Camara R, Milpied N, Volin L, Russell CA, Crisp A, Webster A. Randomized study of valacyclovir as pro-
phylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99: 3050-
3056.
75 Reusser P, Cordonnier C, Einsele H, Engelhard D, Link H, Locasciulli A, Ljungman P. European survey of herpesvirus resist-
ance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 813-817.
76 Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection
in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166: 473-479.
77 Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipi-
ents at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-788.
78 Bregante S, Bertilson S, Tedone E et al. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allo-
geneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant 2000; 26: 23-29.
79 Ordemann R, Naumann R, Geissler G, Kroschinsky F, Bornhauser M, Schwerdtfeger R, Ehninger G. Foscarnet-an alterna-
tive for cytomegalovirus prophylaxis after allogeneic stem cell transplantation. Ann Hemat 2000; 79: 432-436.
80 Bacigalupo A, Van Lint MT, Tedone E et al. Early treatment of CMV infections in allogeneic bone marrow transplant recip-
ients with foscarnet or ganciclovir. Bone Marrow Transplant 1994; 13: 753-758.
81 Ljungman P, Oberg G, Aschan J, Ehrnst A, Lonnqvist B, Pauksen K, Sulila P. Foscarnet for pre-emptive therapy of CMV
infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow
Transplant 1996; 18: 565-568.
82 Moretti S, Zikos P, Van Lint MT et al. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic
hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 1998; 22: 175-180.
164
 !
83 Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, Finke J, Cordonnier C, Link H, Ljungman P. Randomized mul-
ticenter trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell
transplantation. Blood 2002; 99: 1159-1164.
84 Ljungman P, Lambertenghi Deliliers G, Platzbecker U et al. Cidofovir for cytomegalovirus infection and disease in allo-
geneic stem cell transplant recipients. Blood 2001; 97: 388-392.
85 Kiehl MG, Basara N. Cidofovir for cytomegalovirus pre-emptive therapy in stem cell transplant recipients. Blood 2001; 98:
1626. Letter.
86 Chakrabarti S, Collingham KE, Osman H, Fegan CD, Milligan DW. Cidofovir as primary pre-emptive therapy for post-trans-
plant cytomegalovirus infections. Bone Marrow Transplant 2001; 28: 879-881.
87 Platzbecker U, Bandt D, Thiede C et al. Successful pre-emptive cidofovir treatment for CMV antigenemia after dose-
reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 2001; 71: 880-885.
88 Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl
Acad Sci U S A. 2000; 97: 8039-8044.
89 Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999; 12: 286-297.
90 Wolf DG, Yaniv L, Honigman A, Kassis L, Schonfeld T, Ashkenazi S. Early emergence of ganciclovir-resistant human
cytomegalovirus strains in children with primary combined immunodeficiency. J Infect Dis 1998; 178: 535-538.
91 Slavin MA, Bindra RR, Gleaves CA, Pettinger MB, Bowden RA. Ganciclovir sensitivity of cytomegalovirus at diagnosis and
during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 1993; 37:
1360-1363.
92 Gilbert C, Roy J, Belanger R, Delage R, Beliveau C, Demers C, Boivin G. Lack of emergence of cytomegalovirus UL97 muta-
tions conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipi-
ents. Antimicrob Agents Chemother 2001; 45: 3669-3671.
93 Erice A, Borrell N, Li W, Miller WJ, Balfour HH. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus
(CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis 1998; 178: 531-
534.
94 Eckle T, Prix L, Jahn G, Klingebiel T, Handgretinger R, Selle B, Hamprecht K. Drug-resistant human cytomegalovirus infec-
tion in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000; 96: 3286-
3289.
95 Prix L, Hamprecht K, Holzhuter B, Handgretinger R, Klingebiel T, Jahn J. Comprehensive restriction analysis of the UL97
region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. J Infect
Dis 1999; 180: 491-495.
96 Hamprecht K, Eckle T, Prix L, Faul C, Einsele H, Jahn G. Ganciclovir-resistant cytomegalovirus disease after allogeneic
stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis 2002;
187: 139-143.
97 Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity
against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med
1995; 333: 1038-1044.
98 Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection
not responding to antiviral chemotherapy. Blood 2002;99:3916-3922.
99 June CH. CD4 T cells to kiss off chemotherapy-resistant CMV? Blood 2002; 99: 3883. Editorial.
165
 	
100 Peggs K, Verfuerth S, Pizzey A, Khan N, Moss P, Mackinnon S. Cytomegalovirus-specific adoptive cellular therapy results in
massive and persistent expansions of CMV-specific T-cells and significantly reduces the incidence of CMV reactivation fol-
lowing allogeneic transplantation. Blood 2001; 98: S779a. Abstract 3240.
101 Keenan RD, Ainsworth J, Khan N, Bruton R, Cobbold M, Assenmacher M, Milligan DW, Moss PA. Purification of
cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br J Haematol 2001; 115: 428-
434.
166
 !
Chapter 11
Summary
Recipients of stem cell transplants (SCT) are severely immunocompromised at least during
the first 6 months post-transplant. In the introduction (chapter 1) this immunodeficiency is
further described. During the neutropenic period patients are at risk for developing bacterial
and fungal infections. Once neutropenia has recovered, opportunistic viral infections are a
major threat. Both the Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) are herpes
viruses and share the phenomenon that primary infection is followed by latent infection. In
immunocompetent individuals latent infection of these viruses is controlled by T cell immu-
nity. However, in immunocompromised patients herpes viruses frequently show reactiva-
tions, regularly resulting in herpes virus related disease. In this thesis, T cell
immunodeficiency and EBV and CMV infections after allogeneic SCT are studied.
The extent of the immunodeficiency is determined by several factors such as patient age,
development of graft-versus-host disease (GVHD) and the institution of immunosuppressive
therapy. Furthermore, ex vivo T cell depletion (TCD) of grafts, the use of alternative donors
(partially matched related donors or matched unrelated donors) and the source of stem cells
may play a role as well, although their contribution is less clear. Antithymocyteglobulin
(ATG) is generally used in recipients of TCD grafts from unrelated donors to prevent graft
failure. In chapter 2 the effect of ATG on quantitative immune recovery and GVHD was
analysed in recipients of MRD grafts compared to MUD recipients. Apart from ATG infusion
in MUD recipients treatment of both patient groups was similar. Recovery of T cell subsets,
NK cells and B cells was determined at 2, 3, 6 and 8 months post-transplant. In the MRD
group markedly higher T cell and subset values were measured during this period. MRD
recipients received significantly less T cells and suffered more acute and chronic GVHD com-
pared to MUD recipients. These data suggest that ATG is an important negative factor in the
reconstitution of T cells and their subsets in MUD recipients. On the other hand, ATG results
in a lower incidence and severity of GVHD.
In chapter 3 the effect of 3 different ATG doses (8 mg/kg, 6 mg/kg and 4 mg/kg) on graft
failure and incidence of GVHD was evaluated. Lowering ATG dose from 8 mg/kg to 6 mg/kg
did not influence the occurrence of graft failure nor the incidence of GVHD. However, when
ATG dose was decreased to 4 mg/kg the incidence of severe acute GVHD grade III-IV and
extensive chronic GVHD rose dramatically, without affecting the occurrence of graft failure.
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EBV reactivations or primo/re-infections in severely immunocompromised patients may
result in the development of EBV-associated lymphoproliferative disorders (EBV-LPD). In
MUD recipients of TCD grafts reactivation of EBV is a frequent event, which is described in
chapter 4. In this study it was shown that plasma EBV DNA quantitatively predicted EBV-
LPD. The negative and positive predictive values of a viral load of 1000 c/ml were 100% and
39%, respectively. EBV-LPD was not diagnosed in recipients of non-TCD grafts, although
EBV reactivations did occur in these patients. The use of ATG in MUD recipients, was an
important risk factor for the occurrence of EBV reactivations.
Until now it is not known whether EBV reactivations result from a true reactivation of the
endogenous patient strain or a re-infection with exogenous strains. In chapter 5 preliminary
data are presented of EBV strain typing in six patients in pre-transplant collected mouth-
washes and post-transplant collected plasma samples, peripheral blood mononuclear cells
(PBMCs) and mouth washes. Furthermore, prospective data of EBV DNA monitoring per-
formed in PBMC as well as cell free plasma are given. In 3 of 6 patients the post-transplant
EBV sequence pattern differed from the pre-transplant pattern, indicating a re-infection
post-transplant with an exogenous strain instead of a reactivation of the original endoge-
nous EBV strain. In one MRD patient it was not possible to differentiate since pre-transplant,
post-transplant and donor sequence patterns were identical. In a MUD recipient pre- and
post-transplant sequence patterns were identical too, which makes a reactivation of the
endogenous EBV strain likely in this patient, although a re-infection is not excluded. Post-
transplant EBV strains of the sixth patient differed by only one nucleotide from the pre-
transplant strain. This might have been the result of a point mutation acquired during viral
replication, making it more likely this patient suffered a reactivation instead of a re-infec-
tion.
In 17 patients double EBV DNA monitoring was performed in PBMCs and plasma. Only 4 of
17 (23%) patients showed a reactivation in plasma samples compared to 15 of 17 (88%) in
PBMC samples (p<0.001). None of the patients with a reactivation in PBMCs only pro-
gressed to EBV-LPD, compared to 18% of patients with EBV reactivation in plasma.
Therefore, it can be concluded that monitoring in PBMC samples is less specific for predict-
ing EBV-LPD compared to plasma samples.
The risk for EBV-LPD varies according to the techniques used for T cell depletion, being low-
est (<2%) when methods are used which remove both T and B cells. In chapter 6 the inci-
dence of EBV-LPD among MRD and MUD recipients of TCD grafts is presented. All MUD
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recipients were treated with ATG. When grafts from MUDs were both T and B cell depleted,
4 out of 31 patients (13%) developed EBV-LPD compared to 5 of 7 patients (71%) when no
B cell depletion was performed. A T/B cell ratio in the graft of ≥ 0.25 seemed sufficient to
significantly reduce the incidence of EBV-LPD after TCD SCT from MUDs. In contrast,
among recipients of grafts from an HLA-identical sibling donor the incidence of EBV-LPD
was not influenced by B cell depletion in addition to TCD (5% in T and B cell depleted
group; 4% in TCD group).
In chapter 7 an overview is given of the prevention and treatment of EBV-LPD in recipients
of stem cell and solid organ transplants. Several risk factors for the development of EBV-LPD
after solid organ transplantation (SOT) and SCT, respectively, have been identified: 1) pri-
mary EBV infection in EBV-seronegative patients, 2) type of transplanted allograft, 3) CMV
serostatus mismatch (seronegative recipient/seropositive donor), 4) CMV disease 5) use of T
cell antibodies in SOT recipients and 1) TCD of grafts, 2) use of unrelated or ≥ 2 HLA anti-
gen mismatched related donors, 3) use of ATG or 4) anti CD3 monoclonal antibodies in SCT
recipients. Guidelines for monitoring of EBV viral load are given (which patients should be
monitored, at what frequency, for how long). Furthermore, the varying treatment modalities
are reviewed and treatment recommendations are given.
Due to the high mortality rate of CMV disease, latent CMV infection has long been consid-
ered a negative risk factor for overall survival (OS) and TRM. In chapter 8 the effect of CMV
serostatus on OS and TRM in 253 consecutively treated patients receiving partial TCD stem
cells from either matched related donors (n=205) or matched unrelated donors (n=48) was
analysed. Transplantations were performed between July 1990 and May 2000. All patients
were given leukocyte-depleted blood products. CMV monitoring was performed using the
pp65 antigenemia assay. Pre-emptive therapy consisted of short-course (2 weeks) low-dose
(2.5 mg/kg intravenously b.i.d.) ganciclovir treatment as soon as a positive antigenemia
assay was obtained (≥ 1 positive staining granulocyte/150.000 cells). Ganciclovir prophy-
laxis, identical to pre-emptive therapy, was given to CMV-seropositive patients with acute
GVHD grade II-IV who were treated with high-dose corticosteroids. This analysis showed
that CMV-seropositivity was not an adverse risk factor for OS and TRM in MRD recipients of
partial TCD SCT. However, in MUD recipients, patient CMV-seropositivity still had a high
impact on OS and TRM.
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The effect of CMV-seropositivity on outcome in MUD recipients is mostly studied in patients
treated before 1999. In chapter 9 it is evaluated whether CMV-seropositive MUD recipients
transplanted after 1999, still showed inferior outcome compared to CMV-seronegative recip-
ients. In our transplantation centre two important changes in transplantation procedure
were introduced in that year. In April 1999 ATG dose was lowered from 20 mg/kg to 8
mg/kg. Furthermore, in January 1999 sequence based typing (SBT) of HLA-DRB1 was intro-
duced. Both changes may result in an improved immune reconstitution post-transplant.
Low-dose ATG by a direct effect on T lymphocyte counts and high resolution HLA-DRB1 typ-
ing by a decreased incidence of GVHD. Considering the immunosuppressive effect of
(latent) CMV infection this may have a positive impact on outcome in CMV-seropositive SCT
recipients. In total 80 patients received a partial TCD graft, 36 before 1999 and 44 after
1999. CMV-seropositive patients transplanted before 1999 showed a highly significant infe-
rior outcome compared to seronegative recipients (see also chapter 8). In contrast, in
patients transplanted after 1999 no difference in outcome was observed between the two
groups.
In chapter 10 the prevention of CMV disease in recipients of allogeneic stem cell transplants
is reviewed. Before the introduction of ganciclovir, CMV infection and pneumonia developed
in 38 and 17%, respectively, of SCT recipients, while mortality due to CMV pneumonia was
85 %. Currently, two antiviral strategies, prophylactic or pre-emptive treatment, are used for
prevention of CMV disease in seropositive recipients. Prophylactic treatment usually consists
of antiviral therapy started at engraftment until at least day 100 post-transplant. Pre-emp-
tive therapy is defined as antiviral treatment based on the detection of reactivated CMV
infection by positive CMV cultures, a positive antigenemia assay or positive molecular
assays. In this chapter these antiviral strategies are reviewed and recommendations for pre-
vention of CMV disease are given. Furthermore, several other aspects of prevention of CMV
disease are reviewed, which are: 1) methods available for early detection of CMV reactiva-
tions, 2) monitoring of CMV-specific T cell responses, 3) the value of several antiviral drugs
and 4) adoptive immunotherapy as prophylaxis or (pre-emptive) treatment of CMV reactiva-
tions/CMV disease.
In conclusion, recipients of stem cell transplants are severely immunocompromised at least
during the first 6 months post-transplant. This is even more true for recipients of grafts from
matched unrelated donors. However, several important changes in transplantation proce-
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dure have resulted in a more favourable outcome among MUD recipients. B cell depletion -
in addition to TCD- of grafts, a reduced dosage of ATG and high resolution DNA typing of
HLA-antigens all have contributed to this better outcome. The reduced ATG dose and
sequence based typing of HLA-antigens may have improved immune recovery in MUD recip-
ients, thereby eliminating CMV-seropositivity as an adverse risk factor for overall survival
and transplant related mortality. In MRD recipients pre-emptive treatment of CMV reactiva-
tions alone was sufficient to eliminate CMV-seropositivity as an adverse risk factor for out-
come. The optimal dose of ATG is unknown, however, considering the immunosuppressive
and direct toxic effects of ATG, the lowest possible dose should be used. In the setting of
SCT with (partially) TCD grafts from MUDs, using limited post-transplant immunosuppres-
sion with cyclosporine A, a total dose of 6-8 mg/kg is recommended. A further decrease
greatly increases the risk of severe GVHD. The future aim is to further improve immune
reconstitution post-transplant and to implement new methods for monitoring, prevention
and treatment of opportunistic infections. With respect to prevention of EBV-LPDs, it is
important to know the most frequent transmission route of EBV re-infections. Further stud-
ies using LMP-1 fingerprinting for strain identification of patient, donor and partner samples
are necessary.
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Samenvatting voor niet-ingewijden
Bij diverse kwaadaardige en enkele niet-kwaadaardige hematologische ziektebeelden biedt
een allogene stamceltransplantatie met stamcellen van een donor (allogene SCT) de enige
kans op genezing. Een SCT is een zware behandeling met diverse mogelijke complicaties.
Eén van die complicaties betreft het optreden van opportunistiche infecties, dit zijn infecties
die je bij mensen met een normale afweer vrijwel niet ziet. De toegenomen vatbaarheid voor
infecties is het gevolg van een sterk verminderde afweer (immuundeficiëntie) tijdens de
post-transplantatie fase. Geleidelijk herstelt de afweer (immuniteit) zich, maar met name
gedurende de eerste 6 maanden post-transplantatie is deze sterk gestoord. In de introductie
(Hoofdstuk 1) wordt deze immuundeficiëntie beschreven. Kort na de SCT is juist de vat-
baarheid voor bacteriële en schimmel infecties verhoogd, terwijl na enige weken vooral
virus infecties een belangrijke bedreiging vormen. Zowel het Epstein-Barr virus (EBV) als
het Cytomegalovirus (CMV) behoort tot de groep van herpes virussen. Herpes virussen blij-
ven na een eerste ofwel primo-infectie latent in het lichaam aanwezig. Het merendeel van
de mensen raakt tijdens de kinderjaren met deze virussen geïnfecteerd. Bij gezonde mensen
worden die virussen onder controle gehouden door specifieke afweer cellen (cytotoxische T
cellen). Dit is niet het geval bij immuundeficiënte mensen, zoals patiënten die een SCT heb-
ben ondergaan. Bij deze patiënten vertonen herpes virussen frequent een reactivatie, het-
geen kan leiden tot ernstige en vaak fatale ziektebeelden. In dit proefschrift worden diverse
aspecten van de T cel immuundeficiëntie en EBV en CMV infecties na allogene SCT bestu-
deerd.
De mate van immuundeficiëntie in de post-transplantatie fase wordt door verschillende fac-
toren bepaald, zoals de leeftijd van de patiënt, de ontwikkeling van een omgekeerde afsto-
tingsreactie (“graft-versus-host disease”, GVHD) en het gebruik van afweeronderdrukkende
medicijnen (immuunsuppressiva). GVHD is een complicatie die veroorzaakt wordt door
afweercellen van de donor in het transplantaat (de “graft”). Deze donor cellen herkennen de
patiënt (de “host”) als vreemd en gaan daar een afweerreactie tegen ontwikkelen. Bij het
zoeken naar een potentiële donor worden specifieke weefselkenmerken van zowel patiënt
als donor in kaart gebracht (HLA-typering). De beoogde donor moet een gelijke HLA-type-
ring hebben als de patiënt. De kans op GVHD is groter als gebruik gemaakt wordt van niet
verwante donoren of van familiedonoren die niet volledig passend zijn. Patiënten die een
allogene SCT hebben ondergaan, krijgen immuunsuppressiva om de GVHD te voorkomen of
te beperken. In sommige instituten worden de transplantaten (gedeeltelijk) ontdaan van T
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cellen (T cel depletie) om de kans op het optreden van de omgekeerde afstotingsreactie te
verminderen. Deze T cel depletie is mogelijk ook een factor die bijdraagt aan de ernst van de
immuundeficiëntie, tezamen met het gebruik van niet verwante donoren of gedeeltelijk pas-
sende familiedonoren en met de bron van stam cellen (bloed of beenmerg). 
Bij ontvangers van een T cel gedepleteerd transplantaat van een onverwante donor bestaat
een verhoogde kans op afstoting van het transplantaat (graft failure). Deze afstoting wordt
veroorzaakt door resterende T cellen van de patiënt. Antithymocytenglobuline (ATG) is een
middel dat een T cel depletie in het lichaam bewerkstelligt. Toediening van het middel ver-
mindert de kans op afstoting van het transplantaat en tevens vermindert het ook de kans op
het optreden van GVHD. In Hoofdstuk 2 wordt het effect van ATG op het herstel van de
immuniteit en op het optreden van GVHD bestudeerd in ontvangers van een T cel gedeple-
teerd transplantaat van onverwante donoren en vergeleken met ontvangers van een familie-
transplantaat. Het kwantitatieve herstel van specifieke afweercellen (T cellen, NK cellen en
B cellen) werd bepaald 2, 3, 6 en 8 maanden na transplantatie. Bij de ontvangers van een
familietransplantaat (“matched related donor”, MRD groep) werden significant hogere T cel
waarden gemeten, terwijl zij minder T cellen via het transplantaat toegediend kregen en fre-
quenter zowel acute als chronische GVHD ontwikkelden vergeleken met ontvangers van een
transplantaat van onverwante donoren (“matched unrelated donor”, MUD groep). Deze
gegevens suggereren dat ATG een belangrijke beperkende factor is met betrekking tot het
herstel van T cel aantallen in MUD patiënten. Echter, ATG resulteert tevens in een lagere
incidentie en ernst van GVHD.
In Hoofdstuk 3 wordt het effect van 3 verschillende ATG doseringen (8 mg/kg, 6 mg/kg en
4 mg/kg) op de incidentie van graft failure en GVHD geëvalueerd.  Het optreden van graft
failure en GVHD werd niet beïnvloed door een dosisverlaging van 8 mg/kg naar 6 mg/kg.
Echter, bij een verlaging naar 4 mg/kg nam de incidentie van ernstige acute GVHD (graad
III-IV) en uitgebreide chronische GVHD dramatisch toe, zonder het optreden van graft fai-
lure te beïnvloeden.
EBV reactivaties of primo/re-infecties kunnen, wanneer ze optreden bij immuundeficiënte
personen, leiden tot een ernstig ziektebeeld: een EBV-geassociëerde lymfoproliferatie (EBV-
LPD). Dit betreft een woekering van specifieke afweercellen, B cellen, onder invloed van het
EBV virus, wat bij SCT patiënten binnen enkele dagen een fatale afloop kan hebben. Het
EBV virus heeft zich na een primo-infectie in latente vorm in B cellen verstopt. Zonder ade-
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quate T cel immuniteit kan het virus gaan groeien. Een EBV reactivatie, primo/re-infectie of
chronisch actieve infectie kan aangetoond worden middels een EBV DNA bepaling in bloed
of plasma. Het totale EBV DNA in bloed is de resultante van een latente infectie en een
actieve infectie, terwijl EBV DNA in plasma specifiek een actieve infectie weergeeft. In
Hoofdstuk 4 wordt beschreven dat EBV reactivaties met name frequent voorkomen bij MUD
patiënten die een T cel gedepleteerd transplantaat ontvangen en met ATG worden behan-
deld. In deze studie wordt tevens getoond dat EBV DNA in plasma een voorspellende
waarde heeft met betrekking tot het optreden van een EBV-LPD.  De negatief en positief
voorspellende waarde van een virale load van 1000 copieën (c)/ml was 100% en 39%, res-
pectievelijk. Bij ontvangers van een niet-T cel gedepleteerd transplantaat werd geen EBV-
LPD vastgesteld, wel werden EBV reactivaties gezien in deze groep. Het gebruik van ATG
was een belangrijke risicofactor voor het optreden van EBV reactivaties.
Tot op heden is niet bekend of een EBV reactivatie werkelijk een reactivatie van de endo-
geen aanwezige patiënten stam is of dat er een re-infectie met een exogene stam  heeft
plaatsgevonden. Er zijn aanwijzingen dat de voorbehandeling voor de transplantatie in staat
is de eigen stam te vernietigen. In Hoofdstuk 5 worden preliminaire data gepresenteerd
betreffende de EBV stam identificatie in 6 patiënten. Ook tijdens een latente infectie wordt
het EBV in mondspeeksel uitgescheiden. Mondspeeksel is daardoor de belangrijkste trans-
missiebron van het virus. Dit verklaart waarom een primo-infectie met EBV (“Pfeiffer”) ook
wel de “kissing-disease” wordt genoemd. Mondspeeksel is bij latent geïnfecteerde personen
de belangrijkste bron voor virusisolatie. We hebben aldus bij alle patiënten en, indien moge-
lijk, bij donoren voorafgaande aan de transplantatie mondspoelingen verzameld om het EBV
virus te isoleren en te karakteriseren. Na de transplantatie werd het virus geïsoleerd uit
plasma, bloedcellen en opnieuw mondspoelingen. Bij 3 van de 6 patiënten verschilde de
post-transplantatie stam van de pre-transplantatie stam. Dit geeft aan dat bij deze personen
een re-infectie heeft plaatsgevonden in plaats van een reactivatie. Bij één MRD patiënt  kon
geen onderscheid gemaakt worden, daar de pre-transplantatie, post-transplantatie en donor
stammen identiek waren (hetgeen niet ongebruikelijk is binnen families). Bij de laatste twee
patiënten is er meest waarschijnlijk sprake geweest van een reactivatie, hoewel een re-infec-
tie bij deze twee niet met 100% zekerheid was uit te sluiten.
De kans een EBV-LPD te ontwikkelen wordt mede bepaald door de techniek die gebruikt
wordt om de T cel depletie van het transplantaat te verrichten.  In Hoofdstuk 6 wordt het
effect van verschillende T cel depletie technieken geanalyseerd met betrekking tot de inci-
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dentie van EBV-LPD in MRD en MUD ontvangers. De MUD patiënten werden tevens behan-
deld met ATG. Als de MUD transplantaten  zowel van T als B cellen ontdaan werden, ont-
wikkelde 13% (4/31) van de patiënten een EBV-LPD vergeleken met 71% (5/7) van de
patiënten indien geen B cel depletie verricht werd. Een T/B cel ratio in het transplantaat van
≥ 0.25 lijkt voldoende om de incidentie van EBV-LPD bij MUD patiënten in belangrijke mate
te verminderen. Bij ontvangers van familietransplantaten werd de incidentie van EBV-LPD
niet beïnvloed door B cel depletie (5% in de groep waarbij B en T cel depletie werd verricht;
4 % als alleen T cel depletie werd verricht). Dit kan goed verklaard worden door het gebruik
van ATG in de MUD ontvangers, leidende tot een nog sterker gestoorde disbalans tussen
geïnfecteerde B cellen en beschermende T cellen. Het feit dat B cel depletie van het trans-
plantaat beschermt tegen EBV-LPD, pleit tevens voor de hypothese dat een EBV reactivatie
niet werkelijk een reactivatie is, maar eerder een re-infectie vanuit donor B cellen (zie
Hoofdstuk 5).
Ter afsluiting van het onderdeel EBV infecties wordt in Hoofdstuk 7 een overzicht gegeven
van de preventie en behandeling van EBV-LPD in ontvangers van SCT en van solide orgaan
transplantaties (bijvoorbeeld nier-, hart-, lever- en darmtransplantaties). De risicofactoren
voor het ontwikkelen van een EBV-LPD worden beschreven alsook richtlijnen voor het moni-
toren van de EBV DNA virale load.  Tevens worden de verschillende behandelingsmodalitei-
ten samengevat en aanbevelingen gegeven met betrekking tot behandeling.
Een reactivatie van het CMV virus kan leiden tot CMV ziekte. Deze CMV ziekte uit zich in de
vorm van een longontsteking, maag/darm/leverontsteking of netvliesontsteking. De meest
ernstige vorm van CMV ziekte is de longontsteking die zonder behandeling bij 80% van de
patiënten een fataal beloop heeft. Tegenwoordig zijn er antivirale middelen beschikbaar,
echter ook met het gebruik hiervan overlijdt 30-50% van de mensen met CMV longontste-
king. Ook CMV reactivaties kunnen in het bloed aangetoond worden middels diverse tech-
nieken. Veel centra maken hier gebruik van en starten met antivirale therapie op het
moment dat het CMV in bloed aantoonbaar is (pre-emptieve behandeling). Dit heeft geresul-
teerd in een enorme afname van het optreden van CMV ziekte en overlijden hieraan.
Sommige centra kiezen voor een andere optie, namelijk het constante gebruik van antivirale
medicatie tot een zeker tijdsstip (profylactische behandeling). In tegenstelling tot het EBV
virus, geeft het CMV virus bij SCT patiënten zelden primo- of re-infecties, mits de juiste
voorzorgsmaatregelen genomen worden. Dus alleen de CMV-seropositieve patiënten, die
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patiënten die in het verleden een CMV infectie hebben doorgemaakt en waarbij het virus nu
latent aanwezig is, hebben kans op een reactivatie. Ondanks de pre-emptieve behandelstra-
tegie beschouwen veel transplantatie centra CMV-seropositiviteit nog steeds als een nega-
tieve risicofactor voor  het overleven na een SCT. 
In Hoofdstuk 8 wordt het effect van de CMV serostatus op de overleving en transplantatie
gerelateerde mortaliteit geanalyseerd in MRD patiënten (n=205) en MUD patiënten (n=48)
die tussen Juli 1990 en Mei 2000 in het UMCU werden getransplanteerd. Daar CMV overge-
dragen kan worden via witte bloedcellen (leucocyten), kregen alle patiënten leucocyten-
arme bloedprodukten. Er werd een pre-emptieve behandelstrategie gevoerd bij CMV
reactivaties. Tevens werd een kortdurende profylactische antivirale behandeling gegeven
aan CMV-seropositieve patiënten met een acute GVHD die met prednison in hoge dosering
behandeld moesten worden. Deze patiëntengroep heeft een vergroot risico op CMV reactiva-
ties. Bij de MRD patiënten bleek CMV-seropositiviteit geen  negatieve risicofactor voor de
overleving post-transplantatie te zijn. Bij MUD patiënten, daarentegen, was de overleving
van CMV-seropositieve patiënten sterk verlaagd ten opzichte van CMV-seronegatieve patiën-
ten, grotendeels veroorzaakt door fatale infecties.
Deze bevinding in MUD patiënten is ook door anderen gerapporteerd. Echter, het merendeel
van de studies is verricht onder patiënten die voor het jaar 1999 behandeld werden. In
Hoofdstuk 9 wordt onderzocht of de overleving van MUD patiënten die getransplanteerd
zijn sinds 1999 nog steeds beïnvloed wordt door de CMV serostatus. In ons transplantatie-
centrum werden in 1999 twee belangrijke wijzigingen in het transplantatie regime doorge-
voerd. Ten eerste werd de ATG dosering verlaagd van 20 mg/kg naar 8 mg/kg. Ten tweede
werd een veel gevoeliger techniek voor HLA typering ingevoerd (sequence based typing van
HLA-DRB1). Beide veranderingen zouden een beter immuunherstel in de post-transplantatie
fase tot gevolg kunnen hebben. De dosis verlaging van ATG door een direct effect op het
aantal T cellen en de verbeterde weefseltypering middels een betere donor keuze door een
verlaagde incidentie van GVHD. Gezien het immuunsuppressieve effect van (latente) CMV
infecties, zouden deze wijzigingen de overleving van CMV-seropositieve MUD patiënten
positief kunnen beïnvloeden. In totaal 80 patiënten ontvingen een gedeeltelijk T cel gede-
pleteerd  transplantaat, 36 voor 1999 en 44 na 1999. Bij CMV-seropositieve patiënten die
voor 1999 getransplanteerd werden, werd een sterk verlaagde overleving gezien vergeleken
met CMV-seronegatieve patiënten (zie ook Hoofdstuk 8). Bij patiënten die na 1999 getrans-
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planteerd werden, echter, was geen verschil waarneembaar tussen de twee groepen wat
betreft overleving en transplantatie gerelateerde mortaliteit.
Ter afsluiting van het onderdeel CMV infecties wordt in Hoofdstuk 10 een overzicht gege-
ven van de preventie van CMV ziekte bij ontvangers van allogene SCT. De twee eerder
genoemde antivirale strategieën (pre-emptief en profylactisch) worden besproken en aanbe-
velingen met betrekking tot de preventie van CMV ziekte worden gegeven. Tevens worden
enige andere aspecten van de preventie van CMV ziekte samengevat: 1) beschikbare metho-
den voor de monitoring van CMV reactivaties, 2) monitoring van CMV-specifieke T cel
immuniteit, 3) de waarde van verschillende antivirale middelen en 4) van immunotherapie
als profylactische of pre-emptieve behandeling van CMV reactivaties/CMV ziekte.
Concluderend kan gesteld worden dat ontvangers van allogene SCT ernstig immuungecom-
promiteerd zijn gedurende tenminste de eerste 6 maanden post-transplantatie. Dit geldt
vooral voor ontvangers van transplantaten van onverwante donoren.  Echter, enkele belang-
rijke veranderingen in het transplantatie programma hebben de transplantatie gerelateerde
mortaliteit onder MUD patiënten in sterke mate doen afnemen. B cel depletie van de trans-
plantaten (naast de T cel depletie), de dosis verlaging van ATG en de verbeterde weefselty-
pering (sequence based typing van HLA-DRB1) hebben allemaal bijgedragen aan deze
verminderde mortaliteit. De dosis verlaging van ATG en de sequence based typing van HLA-
DRB1 hebben mogelijk geleid tot een minder ernstige immuundeficiëntie, waardoor het
effect van de CMV-seropositiviteit niet meer klinisch relevant is. In MRD patiënten bleek dat
met het toepassen van een pre-emptieve behandelstrategie van CMV reactivaties, CMV-sero-
positiviteit geen risicofactor is voor slechtere overleving danwel toegenomen transplantatie
gerelateerde mortaliteit. De optimale ATG dosering is niet bekend, echter, gezien de
immuunsuppressieve en direct toxische effecten van ATG moet de laagst mogelijke dosis
gebruikt worden. Bij SCT met (gedeeltelijk) T cel gedepleteerde transplantaten van onver-
wante donoren, waarbij post-transplantatie slechts een beperkte immuunsuppressie toege-
past wordt bestaande uit cyclosporine, wordt een totale dosis van 6-8 mg/kg aanbevolen.
Een verdere dosisreductie heeft geleid tot een sterk verhoogde incidentie van ernstige
(graad III-IV) acute GVHD.
In de toekomst moet gewerkt worden aan een verdere verbetering van het immunologische
herstel tijdens de post-transplantatie fase. Nieuwe methoden moeten ontwikkeld en geïm-
plementeerd worden betreffende de monitoring, preventie en behandeling van opportunisti-
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sche infecties. Voor de specifieke preventie van EBV-LPD is het noodzakelijk meer inzicht te
verkrijgen in de origine van de EBV infecties in de post-transplantatie fase. 
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